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ABSTRACT 
 
A RETROSPECTIVE DATA ANALYSIS IN VETERANS WITH INFLAMMATORY 
BOWEL DISEASE: USING WAGNER’S CHRONIC CARE MODEL  
TO EXPLORE MEDICATION ADHERENCE 
 
 
 
 
By 
Lori K. Rizzo 
August 2014 
 
Dissertation supervised by Dr. Alison M. Colbert  
Background 
Medication adherence in inflammatory bowel disease (IBD) ranges between  
7-72%. Increased healthcare utilization has been associated with non-adherence in IBD. 
Wagner’s Chronic Care Model (CCM) posits that care coordination between primary and 
gastroenterology (GI) specialty care could improve adherence and healthcare utilization.  
Methods 
Guided by the CCM, a retrospective analysis was conducted in veterans with IBD to: 
describe medication adherence rates; describe healthcare utilization measured by ER visits and 
  
 v 
inpatient admissions; and describe care coordination measured by primary care and GI specialty 
care use.  A secondary study aim was to explore the relationships between those key outcome 
variables and select demographic/health history characteristics. 
A local Veteran’s Affairs database was used to extract a cohort of individuals with 
Crohn’s disease and ulcerative colitis for fiscal year (FY) 2011. Medical utilization and IBD 
medication refills were collected. A dichotomized medication possession ratio (MPR .80) was 
used in logistic regression to identify factors affecting medication adherence.  Logistic regression 
was also used to examine factors affecting ER visits, inpatient utilization, and care coordination. 
Results 
The cohort consisted of 165 White male veterans 75 with Crohn’s disease and 89 with 
ulcerative colitis. The overall rate of adherence was 50.9% with a median MPR of .82. 
Regression models did not render any statistically significant predictors of adherence.  ER 
utilization was significantly associated with adherence (OR=.314, 95%CI=.111-.886, p=.029) 
and care coordination (OR=45.73,95%CI=9.053-231,p=.001) in multivariate analysis. Inpatient 
admission was associated with: younger age (OR=.108,95%CI:.019-.609,p=.012), adherence 
(OR=.113,95%CI=.014-.939,p=.044), IBD diagnosis (OR=.117,95%CI=.017-.784,p=.027), and 
care coordination (OR=11.89,95%CI=1.228-115,p=.033). Logistic regression identified 
statistically significance associations with care coordinated between primary and GI specialty 
care and the following factors: taking both a 5-ASA and immunomodulating medication 
(OR=5.122,95%CI=1.874-14.00, p=.001), younger age (OR=.905,95%CI=.871-.940,p=.001), 
and having a comorbidity (OR=2.643,95%=1.171-5.965,p=.027).   
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Conclusions  
No predictors of medication adherence emerged. However, the CCM element of care 
coordination provided additional insight into the healthcare utilization of veterans with IBD as 
statistically significant associations between care ER visits and hospitalization were identified. 
Further inquiry into the influences of medication adherence and healthcare utilization in this 
population is warranted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
key words: adherence to medication, Wagner’s chronic care model, coordination of care,    
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Chapter 1 
Introduction 
Chapter 1 provides an overview for this dissertation study. This chapter includes study 
background, purpose, aims, as well as operational definition of variables. Additionally, the 
chapter encompasses study assumptions and limitations. Finally, this chapter concludes with 
study significance to nursing. 
1.1 Background of the Study  
Chronic illness affects nearly one-half of those residing in the United States including 
those who suffer with inflammatory bowel disease (IBD), a set of chronic inflammatory diseases 
of the GI tract with symptoms that exacerbate and ameliorate (Robert Wood Johnson 
Foundation, 2013). IBD affects 1.5 million Americans (Kappleman, Moore, Allen, & Cook, 
2013) , approximately 45,000 of whom are veterans who utilize Veterans Affairs (VA) for 
chronic illness care of this disease (Hou, Kramer, Richardson, Mei, & El-Serag, 2013).  
Medication Adherence 
Long-term medication administration is required in IBD for disease control that is 
tenuous (Peppercorn, 2012). There are no allowable gaps in treatment, making strict medication 
adherence critical to successful disease control (Regueiro, 2012a). A systematic review 
demonstrated that medication adherence in IBD is problematic and in the range of 7-72% 
corresponding to rates in other chronic disease (C. A. Jackson, Clatworther, Robinson, & Horne, 
2010; Krueger, Berger, & Felkey, 2005).  However, little is known about medication adherence 
rates for veterans with IBD who access healthcare through the VA. This gap in scientific 
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knowledge supported the primary line of inquiry for this study exploring the rates of medication 
adherence in this cohort. 
Over 50 years of medication adherence research exists. However, the topic only came to 
the forefront in IBD in the last 20 years and remains inconsequential in the minds of clinicians 
who fail to recognize the need for assessment of medication adherence as part of routine chronic 
illness care in this population (Trindade, Morisky, Ehrlich, Tinsley, & Ullman, 2011).  
Furthermore, a review of the literature conducted for this study, demonstrated that those who do 
conduct an assessment, utilize non-validated tools, calling into question the reliability of the 
results from this type of inquiry. Therefore, adherence science in IBD continues to stymie. 
 The majority of adherence research in IBD has taken place in the last five years, using 
cross-sectional design, conducted in small samples of specialty IBD clinic patients throughout 
the world. Modifying factors affecting medication adherence in IBD are not distinctive, existing 
in many chronic diseases and include lack of knowledge regarding illness and treatment, 
discordance in the physician-patient relationship, low health literacy, pill burden, and depression 
(C. A. Jackson et al., 2010). Several noteworthy, unique, condition specific factors found to 
affect adherence included disease duration, remission status, disease type (CD versus UC), new 
patient status, timing of last colonoscopy, and taking immunosuppressants (C. A. Jackson et al., 
2010) .  The literature presents conflicting data for non-modifiable risk factors for non-adherence 
in most diseases, including IBD, such as age, gender, and race, supporting closer examination of 
these demographics in this study.  
Over a decade ago, the international community (National Council on Patient Information 
and Education, 2007; National Institutes of Health, ; World Health Organization, 2003) 
recognized medication adherence in chronic disease as a healthcare crisis that today, continues to 
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consume scarce healthcare resources (Lachaine, Yen, Beauchemin, & Hodgkins, 2013) . Despite 
international recognition, scientific stalemate persists because uncertainty remains about how 
best to define and measure medication adherence. After years of intensive review, the 
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) announced a call 
to action to standardize both the definition and measurement of medication adherence. These 
efforts were aimed at improving the quality of adherence research so that results could be 
compared across studies to move science forward (Cramer et al., 2008). While no “gold 
standard” to measure adherence exists, IBD experts deemed use of pharmacy refill data as the 
criterion measure in this cohort, specifically the calculation of the Medication Possession Ratio 
(MPR) (S. Kane et al., 2012). This recommendation is corroborated by ISPOR (Peterson et al., 
2007)  and supports the retrospective research design chosen for this study.  
Chronic Care Model 
Initially, the patient was at the center of non-adherence research. However, as 
understanding of the concept evolved, the complexity of treatment adherence emerged, 
demonstrating that healthcare systems providing services were not meeting the treatments needs 
of those with chronic disease (Wagner, 1998). As a result, adherence research began to change 
its focus from individual behaviors to examination of healthcare systems as a whole. Treatment 
deficiencies were the genesis for the Chronic Care Model (CCM) that provides a framework for 
chronic illness care based on best practices that accounts for intricate systematic influences on 
the delivery of healthcare (Wagner, Austin, & Von Korff, 1996).  
Additionally, as acknowledged by global adherence experts, congruent with the CCM, 
the impact of healthcare systems outside the U.S. on medication adherence in IBD cannot be 
understated (World Health Organization, 2003). A study conducted by (Robinson, 2001) 
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demonstrated the potential influences of the health system on adherence in IBD in a study 
conducted to examine the rates of non-adherence in European countries. Reported rates of non-
adherence varied widely between countries: France 13%, Italy 25%, UK 33%, and Germany 
46%. That said, at least 50% of adherence research in IBD has occurred outside the U.S. with 
virtually no investigations conducted in the U.S. evaluating systematic effects. Therefore, a 
discrepancy in the literature exists regarding not only the effects of healthcare delivery in the 
U.S. on adherence in IBD, but also the effects of a closed system such as the VA has on 
medication adherence in this population. This supports the use of the systems based framework 
chosen for this study. The results of this investigation aid in rectifying informational inequality 
existing in IBD adherence research.  
Moreover, in 2003, (World Health Organization, 2003)  acknowledged that little research 
on the effects of healthcare teams and system-related factors on adherence exists, which, a 
decade later, remains true in patients with IBD, supporting further study in this arena (Shah, 
Tinsley, & Ullman, 2011) . Therefore, the CCM provides the framework for this study exploring 
the influences of the Veterans Affairs (VA) healthcare system in veterans with IBD.  
Specifically, the effects of primary and specialty care in this population.  
Primary care is at the Model’s center since this is the origin of chronic care in this 
country, including in the VA, because primary care acts as a gatekeeper to access VA specialty 
care (Kizer, 1996). Moreover, with the advent of evidence based medicine and the development 
of clinical practice guidelines, primary care is at the forefront of preventing and treating chronic 
illness (Starfield, Shi, & Macinko, 2005) . However, experts in chronic disease management 
propose coordination of care between primary and specialty care as a mechanism to attain 
optimal health (Shi & Singh, 2012).  
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For this study, gastroenterology was the specialty of focus, consulted through primary 
care, for the management of IBD. The literature suggests that organizational variables such as 
number of visits to primary and specialty care, as well as continuity of care, may have far greater 
impacts on treatment adherence than any other intervention (Albaz, 1997). One of the main 
functions of primary care is the coordination of care between primary and specialty care service 
lines (Shi & Singh, 2012) . Coordination of care between these two departments was the CCM 
element of interest in this study as it relates to medication adherence and healthcare utilization in 
this population, as the role of care coordination is requisite to improve adherence in chronic 
disease and was not formally explored in IBD.  (MacColl Institute for Healthcare Innovation, 
2010; World Health Organization, 2003) . 
Care coordination is integral to delivery of chronic illness care in the Veterans Health 
Administration (VHA), a multifaceted agency governing the largest integrated benefits system in 
the world, the VA, providing services to honorably discharged members of the U.S. Armed 
Services (Kizer & Dudley, 2009) . VHA adopted the CCM in the late 1990s as a vehicle for 
transformation of this closed healthcare system (Perlin, J. B, Kolodner, R. M., & Roswell, R. H., 
2004). Care coordination, a priority in VHA, occurs through the “medical home” model that 
consists of an interdisciplinary team of health professionals housed in primary care with requisite 
consultation to specialists as warranted (Shi & Singh, 2012) . VA efforts are consistent with the 
plan for coordination of care set forth by the (MacColl Institute for Healthcare Innovation, 2010)  
from which the CCM originates. 
Intuitively, coordination of primary and specialty care should equate with improved 
health outcomes. However, the results from a recent Cochrane review (S. M. Smith, Allwright, & 
O'Dowd, 2009) conducted to assess the effectiveness of care coordination between primary and 
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specialty care in chronic disease management, were conflicting. Overall, no consistent 
improvement in outcomes across disease states materialized with the exception of medication 
adherence that indicated significant benefit with care coordination in this realm, supporting the 
need for further inquiry into the effects of care coordination on medication adherence for which 
no data exists in veterans with IBD (Neugaard, Priest, Burch, Cantrell, & Foulis, 2011). 
This study builds on existing research by conducting the first medication adherence 
assessment of veterans to offer a critical evaluation of systematic influences of the VA on 
coordination of care, medication adherence, and healthcare utilization in patients with IBD. The 
results of this study may inform clinical practice as well as national health policy on the manner 
in which chronic illness care occurs in veterans with IBD.  
Healthcare Utilization 
Evidence suggests that when chronic illness is sub optimally treated, complications may 
worsen leading to increased consumption of healthcare resources such as ER services, inpatient 
admissions, as well as office visits (N. H. Miller, 1997), suggesting that higher levels of 
medication adherence may reduce healthcare costs, assuming the medication was appropriately 
prescribed (Sokol, McGuigan, Verbrugge, & Epstein, 2005). Repeatedly, research has 
demonstrated that those with IBD who do not follow prescribed medication regimes are at 
increased risk for disease relapse, up to five times that compared to those who adhere (Bhatt, 
Patil, Joshi, Abraham, & Desai, 2009; S. V. Kane & Hanauer, 2000; S. Kane, Huo, & Magnanti, 
2003) .  A disease flare, perhaps compelled by non-adherence to therapy, could influence the 
need for health services. Direct healthcare costs estimates are $3.1 billion for CD and $2.1 billion 
for UC (Kappleman et al., 2011). 
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World adherence experts (World Health Organization, 2003) provide support for 
examination of healthcare utilization concurrently with medication adherence rates as this data 
works synergistically to accurately inform health outcomes and future interventions. Additional 
support for this study emanates from two recently published papers from IBD experts 
(Kappelman, Palmer, Boyle, & Rubin, 2010; Shah et al., 2011) that identified gaps in the 
literature regarding patterns of healthcare utilization in this cohort for which a dearth of 
information exists due to the decentralized nature of the healthcare system in the U.S. 
(Kappleman et al., 2011). Therefore, this study began to explore the relationship between 
medication adherence and healthcare utilization in veterans with IBD as the consequence of 
these relationships are unknown.  
1.2 Purpose of Study 
 The purpose of this descriptive, retrospective data analysis was to convey medication 
adherence rates of veterans with IBD and to examine the relationships between care 
coordination, medication adherence, and healthcare utilization. 
1.3 Specific Aims 
The primary aim for this study was as follows: 
1. Described medication adherence, healthcare utilization, and care coordination of 
veterans with inflammatory bowel disease (IBD) who employ Veterans Affairs 
(VA) healthcare at one Veterans Affairs Medication Center (VAMC).  
Secondary study aims were as follows: 
 1.  Examined the association between medication adherence adjusted for  
care coordination, age, IBD diagnosis, comorbidity, and IBD medication in 
veterans with IBD who employ VA healthcare. 
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2. Explored the relationship between healthcare utilization adjusted for medication 
adherence, age, IBD diagnosis, IBD medication, coordination of care and 
comorbidities in veterans with IBD who employ VA for healthcare. 
1.4 Definition of Terms 
Inflammatory Bowel Disease 
Inflammatory bowel disease (IBD) is a set of conditions including, ulcerative colitis (UC) 
and Crohn's disease (CD), that cause chronic inflammation of the GI tract (Peppercorn, 2012). 
The ICD-9 code of 555.x for CD and 556.x for UC identified subjects with said disease in this 
study (Thirumurthi, Chowdhruy, Richardson, & Abraham, 2010). 
Medication Adherence 
Researchers have posited many definitions of medication adherence. This study used the 
definition of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 
that defines medication adherence as the "extent to which a patient acts in accordance with the 
prescribed interval, dose, and dosing regimen (Cramer et al., 2008, p.46). Adherence is reported 
as a percentage of total number of doses taken (if prospectively measured) or therapy-days 
available (if retrospectively measured), in relation to the time period of observation during which 
compliance is measured" (Burrell, Wong, & Ollendorf, 2005, p.194). Medication adherence was 
assessed using VA pharmacy refill data to calculate a rate of adherence using the medication 
possession ratio (MPR) defined as: “the sum of the days’ supply of medication divided by the 
number of days between the first fill and the last refill plus the days’ supply of the last refill” 
(Sikka, Xia, & Aubert, 2005, p. 449). The terms "adherence" and "compliance" are 
indistinguishable in the literature. For this study, the two terms were synonymous.  
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Healthcare Utilization 
Healthcare utilization was the “use of healthcare resources” (Bernstein et al., 2003, p.1). 
For this investigation, the following healthcare services represented healthcare utilization: 
emergency department visits and inpatient admissions 
Emergency Department Visit 
Emergency department (ED) visit was defined as the “direct personal exchange between 
a patient and a physician or other healthcare provider working under the physician’s supervision, 
for the purpose of seeking care and receiving personal health services” (Bernstein et al., 2003, 
p.129). For this study, the total number of ED visits in FY 2011 represented healthcare utilization 
of ED services as measured by clinic stop code 77 for any diagnosis.  
Inpatient Admission 
An inpatient admission was “an admission to an inpatient service of a hospital for 
observation, care, diagnosis, or treatment” (Bernstein et al., 2003, p.130).  Inpatient admissions 
were measured as the total number of inpatient admissions for FY 2011.  
Outpatient Department Visit 
An outpatient department (OPD) visit was “the direct, personal exchange between an 
ambulatory patient seeking care and a physician or other healthcare provider to render personal 
health services within a hospital facility” (Bernstein et al., 2003, p.130). OPD visit measurement 
consisted of clinic stop codes for primary and specialty (Gastroenterology) care. 
 Primary Care 
Primary care was defined as the provision of "integrated, accessible healthcare services 
by clinicians who are accountable for addressing a large majority of personal healthcare needs, 
developing a sustained partnership with patients, and practicing in the context of family and 
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community" (Vaneslow, Donaldson, & Yordy, 1995, p.192).  Identification of healthcare 
utilization occurred using a clinic stop code, “a required field in the VA OPC Hospital Location 
file that assigns a number representing a type of care or Service/treating Specialty” (Zivin et al., 
2010) . The clinic stop codes of 323, 301, 322, 348, 350, 170, 634, and 172 represented primary 
care for this study. 
Specialty Care 
Specialty care was the "delivery of care to individuals based on a certain physiological 
system or clinical condition or based principally on the age of patients" (S. M. Smith et al., 2009, 
p.3). Specialty care referred to Gastroenterology as measured by clinic stop code 151.  
Care Coordination  
Care coordination was the “deliberate organization of patient care activities between two 
or more participants (including the patient) involved in a patient’s care to facilitate the 
appropriate delivery of healthcare services. Organizing care involves the marshaling of personnel 
and other resources needed to carry out all required patient care activities, and is often managed 
by the exchange of information among participants responsible different aspects of care” 
(McDonald et al., 2007, p.41). The literature characterizes the term “shared care” as tantamount 
with coordination of care, as was the case for this study (Starfield, 2003). The stop codes for 
primary care (323, 301, 322, 348, 350, 170, 634, 172) and gastroenterology (specialty care, 151) 
represented care coordination. Coordination of care was assumed when the patient had clinic 
stop codes for both primary and specialty care.  
Comorbidity 
Comorbidity was the "presence of additional diseases in relation to an index disease in 
one individual"  (Valderas, Starfield, Sibbald, Salisbury, & Roland, 2009, p.359) measured by 
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ICD-9 code as reported by (Deyo, Cherkin, & Ciol, 1992), originating from (Charlson, Pompei, 
Ales, & MacKenzie, 1987). The index disease in this study was IBD. Therefore, measurement of 
this construct provided information regarding the influences of diseases additional to IBD on 
healthcare utilization in the population of interest.  
Demographic Variables 
Demographic variables included age, gender, and race/ethnicity. VA administrative 
databases provided this information.  
1.5 Assumptions  
The assumptions for this study were as follows: 
1. Patients who obtained prescriptions for IBD medications consumed the 
medication starting the first day of the fill, used the drug as prescribed, and 
consumed all medications obtained.  Patients were not stock piling medication, 
skipping doses, or giving their medications away. 
2.  When measuring adherence by drug class or by condition, patients were adherent 
as long as they received medication from a drug class for a specific condition, 
regardless of dose titration, switching, as well as adding or dropping medications.  
3.  Medications prescribed for IBD were appropriate for treating the intended 
condition. 
 4.  The diagnosis of IBD, as documented by ICD-9 code, was accurate. 
 5.  Patients used VA for healthcare services only.  
 6. Patients received the correct number of tablets equating to the days’ supply 
   of fill per dosing instructions.  
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7.  Patients were assumed to have care coordinated if both primary and specialty GI 
clinic stop codes were present. 
1.6 Limitations 
The limitations of this study were as follows: 
1.  Because the study was limited to veterans who utilized the VA for healthcare, the 
findings may not be generalizable to veterans who do not use the VA for 
healthcare or to the civilian population.  
 2.  Patients may have filled prescriptions for IBD medications outside the VA  
                        pharmacy. 
3.  Observations made about adherence in this study were not sufficient to 
characterize the patients' adherence to all medications in his/her regime. 
Calculated adherence only applied to those medications taken for IBD.  
4.  Since data extraction occurred from administrative data sets, information captured 
may be incomplete and data of unknown quality. 
 5.  Patients may have accessed healthcare services outside the VA Healthcare  
                        System.  
6.  Feasibility did not allow a multi-method approach to data collection that included 
both a self-report and an objective measure, as considered state-of-the-art in 
measuring adherence behavior (World Health Organization, 2003).  
7. Local VA databases did not contain the Sig for medications. Therefore, the 
researcher was unable to compare the number of tablets dispensed against the 
dosing instructions to ensure accuracy of prescription refills.   
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1.7 Significance to Nursing 
Non-adherence to medication is an international healthcare crisis resulting in increased 
morbidity and mortality in many chronic illnesses including IBD (World Health Organization, 
2003). Current understanding of medication adherence acknowledges this construct as 
multifaceted requiring a multidisciplinary team approach to disease management. Yet, who the 
members of such a team should be, and the definitions of their roles, are not evident. Much of the 
published literature regarding coordination of care in patients with IBD hales from the position 
of specialty care synchronization.  Little knowledge exists concerning the outcomes of shared 
care across the primary/specialty care continuum in patients with IBD, particularly rates of 
medication adherence and healthcare utilization patterns in this cohort.  
A recent synthesis of the literature suggested that nurses are the crucial link between 
primary care and specialty care coordination in the chronic disease management of IBD 
(Hernandez-Sampelayo et al., 2010). Support of this notion came from a case study conducted in 
the VA that explored the role of the nurse in coordinated shared medical appointments between 
primary and specialty care using the CCM as a guiding framework (Watts, Hynes, & Kopp, 
2003). Furthermore, the American Academy of Nurse Practitioners and the White House also 
recognized the unique, integral role nurses play in chronic illness care by endorsing the expanded 
role of nurse practitioners in chronic disease treatment of our Nation’s veterans in a collaborative 
effort known as Joining Forces (American Academy of Nurse Practitioners, 2012).  
This study began to describe the impact of coordination of care on medication adherence 
and healthcare utilization in patients with IBD.  Armed with knowledge regarding the effects of 
coordination of primary and specialty care on medication taking behavior and resource 
utilization, nurses are poised to make significant impacts on patient care and to advocate 
  
 14 
allocation of scare healthcare resources. Nurses contribute to the chronic illness care in IBD by 
generating effective interventions and changing health policy in this population about which, 
currently, little information exists. 
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Chapter 2 
REVIEW OF LITERATURE 
2.1 Introduction 
This chapter presents the theoretical foundation for this study as well as the current state 
of knowledge of the disease state under consideration, along with a comprehensive discussion 
surrounding the nomenclature and measurement of adherence as it relates to the population of 
interest. A summary show casing the gaps in the literature rounds out this chapter. 
2.2 Conceptual Framework: The Chronic Care Model 
Chronic illness affects more than 133 million individuals in this country with 
approximately half of these individuals experiencing more than one chronic illness 
(Bodenheimer, Chen, & Bennett, 2009). Research suggests that system(s) in which individuals 
obtain care for chronic illness are not conducive to meeting care needs of this vast group and 
result in deficient management of the most common chronic illnesses (Bodenheimer et al., 2009).  
In response to these deficiencies, (Wagner et al., 1996) generated a model to improved care for 
chronic conditions, the Chronic Care Model (CCM).   
In broadest terms, the CCM seeks to encompass systems change by examining the 
interactive relationship between three key areas of influence on chronic illness care: the 
community, the healthcare system, and the provider organization. Primary care is the principal 
location of chronic illness care and is therefore, the focus of the Model.  
The CCM places a self-motivated patient at the center of chronic care delivery as a method to 
improve disease management and to prevent complications. However, primary care collaboration 
between the patient, healthcare provider, and the healthcare system provides the underpinning for 
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the Model that posits resultant mutual goals, requisite skills for self-management, and improved 
chronic illness outcomes.  
In 1998, the initial CCM contained six key elements that work in tandem to produce high 
quality outcomes: community; the health system; self-management support; delivery system 
design; decision support; and clinical information systems as depicted in Figure 2.1. The 
MacColl Center expanded the CCM into its current format in 2003, to include the previous six 
domains as well as five new elements. Expanded Model elements include patient safety (in 
health system), cultural competency (in delivery system design), care coordination (in health 
system and clinical information systems), community policies (in community resources and 
policies), and case management (in delivery system design) as illustrated in Figure 2.2. 
The Community 
The element of Community involves the mobilization of community resources to meet 
patient needs. By accessing existing assets, healthcare systems expand the depth and breadth of 
services provided. Ultimately, healthcare institutions, in collaboration with local, state, and 
national agencies, would act as advocates for patients with chronic disease to affect policy.  
Self-Management Support  
The self-management component of the CCM consists of patient engagement in: 1) 
activities that promote health; 2) interactions with healthcare providers and adhering to advised 
treatment recommendations; 3) ongoing self-assessment with resultant medical decision making; 
and 4) managing the effects of disease to participate in activities of daily living (Von Korff, 
Gruman, Schaefer, Curry, & Wagner, 1997). The self-management support plan of care is 
revised through a collaborative team process (MacColl Center & 1996-2013, 2013) (MacColl 
Center, 2013). 
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Figure 2.1. Representation of the Chronic Care Model.  Reprinted from "Chronic Disease 
Management: What Will It Take to Improve Care for Chronic Illness?" by E. H. Wagner, 
August/September 1998, Effective Clinical Practice, 1, p. 4.  Copyright 1998 by the American 
College of Physicians. Reprinted with permission.  
 
The Health System 
The Health System in the CCM represents an organization that has identified chronic 
illness care as a priority and views improvement of this care as a fluid process that will continue 
to evolve. The organization recognizes that comprehensive institutional change provides the 
foundation for effective care delivery and has origins at all staff levels with support from senior 
leadership. Collaboration across the institution is fundamental.  
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Figure 2.2. Expanded Representation of the CCM. Copyright 1996-2012 .The MacColl Center.  
The Improving Chronic Illness Care program is supported by The Robert Wood Johnson 
Foundation, with direction and technical assistance provided by Group Health's MacColl Center 
for Health Care Innovation. Reprinted with permission. 
 
Delivery System Design 
The configuration of healthcare delivery in the CCM necessitates creation of prepared, 
proactive practice teams. The system providing treatment becomes proactive by providing 
evidenced based care that shifts the focus from acute to chronic illness care. Multidisciplinary 
practice teams communicate regularly about the care of a defined group of patients and often 
consult professionals outside of a single practice (Starfield et al., 2005).  
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Decision Support 
The decision support component of the CCM necessitates an educational foundation for 
members of the practice team to allow for the appropriate development of a treatment plan. 
Clinical reminders and standing orders support implementation of practice standards in medical 
decision-making. Evidenced based guidelines drive treatment decisions, serve to reduce 
inconsistencies in clinical practice, and provide standards for optimal chronic care.  By sharing 
practice guidelines, healthcare providers encouraged patients to participate in disease 
management and treatment adherence. Patients are educated about disease process by employing 
methods that have demonstrated effectiveness. Decision support also incorporates access to 
medical specialty expertise.  
Clinical Information Systems 
Comprehensive clinical information systems are an essential attribute to effective disease 
management. A critical component of clinical information systems, patient registries generated 
from an electronic medical record (EMR) allow tracking of individuals with particular chronic 
disease states.  Once the registry is establish, clinical reminders permit practice teams to address 
condition specific needs. In turn, the EMR can track performance of the team regarding the 
accomplishment of clinical goals. Additionally, the EMR coordinates care between services 
across a healthcare system as well as sharing information with patients.  
                                                             Summary 
 Successful disease management relies on relations between individuals, healthcare 
providers, systems, and adherence to recommended protocols. Evidence suggests that clinical 
outcomes for individuals with chronic disease are suboptimal, due to interactions focused on 
urgent treatment needs rather than on long-term disease and symptom control, attributed to 
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widespread deviation from standard medical practice and lack of patient self-management skills. 
 The CCM imparts a template for healthcare organizations to achieve high quality chronic illness 
care. Core changes to primary care, the location most frequently providing chronic disease 
management, are required to attain optimal disease management. 
The Model has identified characteristics that are common among successful disease 
treatment programs in the literature. These characteristics are synergistic and include consistently 
planned follow-up, systematic assessments, acquisition of self-management proficiency, access 
to disease expertise, and supportive information systems. Implementation of all Model elements 
results in productive interactions between a prepared, proactive practice team and an informed, 
activated patient. Preparation of the clinical team incorporates chronic disease expertise as well 
as the resources to manage conditions effectively. An informed patient is one who possesses the 
knowledge and self-efficacy to capitalize on exchanges with clinical team members. Productive 
interactions involve the generation of a patient-centered, collaborative plan of care utilizing 
effective clinical treatments. Ultimately, use of CCM elements, renders coordinated services that 
are patient-centered, timely and efficient, as well as evidence based and safe.  An application of 
the Model to this study follows.  
2.3 Application of Theory to Study 
The literature contains five decades of extensive medication adherence inquiry. When 
research in the field began, the patient was the center cause for deviation from prescribed 
treatment regimes. As such, initial theoretical models explained the construct from the 
perspective of changing individual behaviors. Models such as the Health Belief Model and 
Transtheoretical Model, as well as the Theory of Reasoned Action, self-efficacy, and the Theory 
of Planned Behavior pervade the literature in attempts to predict behavior leading to non-
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adherence based on individual functioning. However, as the discipline evolved, the complexity 
of medication adherence became apparent, such that examining individual actions was not 
sufficient to address the magnitude of this problem, even with the use of intricate conceptual 
frameworks. 
 
 
  Figure 2.3.  Application of Wagner’s Chronic Care Model in Veterans with IBD 
 
Therefore, corresponding with the current state of knowledge, a comprehensive system 
model, the CCM, was the guiding framework for this study. This multidimensional Model 
addressed how elements of chronic illness care organization within a healthcare system produce 
improved outcomes. In this study, only one element of chronic illness care was reviewed, the 
prescribing of medications for veterans with IBD, coordinated between primary care and 
specialty care. The outcome variable was medication adherence. Congruent with the CCM, 
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prescribing IBD medication, coordinated between primary and specialty care, may improve 
medication adherence as well as healthcare utilization as depicted in Figure 2.3.  
The CCM provides healthcare systems with salient mechanisms to address the challenges 
of chronic illness care as evidenced by extensive testing of the Model throughout the world that 
have yielded promising results (Coleman, Austin, Brach, & Wagner, 2009). Further support of 
the Model was generated by a meta-analysis performed by (Tsai, Morton, Mangione, & Keeler, 
2005) which demonstrated that interventions containing one component of the CCM improved 
clinical outcomes and processes of care. However, the literature does not present a clear picture 
of the impact individual Model elements contribute to effective chronic care. Influenced by the 
disease considered and the characteristics of both the organization under study and the 
population the organization serves, the effect of single Model elements may fluctuate (Sperl-
Hillen et al., 2004) .  This supports research examining just one element of the CCM, in this 
case, coordination of care between primary and specialty care in the VA healthcare system in 
veterans with IBD. This was the first study to use the CCM in veterans with IBD to explore the 
relationships between medication adherence, healthcare utilization, and coordination of care in 
the VA system. The significance of this study was in identifying potential points of intervention 
in the chronic illness care of this population.  
2.4  Inflammatory Bowel Disease 
Inflammatory bowel disease is comprised of two major disorders: Crohn's disease (CD) 
and ulcerative colitis (UC). These disorders have both distinct and overlapping characteristics. 
However, the pathogenesis of these disorders remains poorly understood. Theories of 
environmental exposure, genetic influence and autoimmune dysregulation subsist. 
  
 23 
Both CD and UC are chronic inflammatory conditions of the GI tract typified by 
relapsing and remitting symptoms. Representations of CD include transmural inflammation with 
skip lesions that can occur anywhere from the oral pharynx to the anus which often lead to 
scarring and obstruction. Whereas, the inflammation found in UC is contiguous, superficial, 
usually involves the rectum, and is limited only to the mucosal layer of the colon, thereby unable 
to cause fibrosis of colonic tissue.  
Epidemiology 
In North America, the incidence rates for ulcerative colitis range from 2.2 to 19.2 cases 
per 100,000 with a prevalence of 238 per 100,000 (Molodecky et al., 2012).The incidence rates 
of Crohn's disease range from 3.1 to 20.2 cases per 100,000 with a prevalence of 201 per 
100,000. This equates to approximately 1.2 million with IBD in the U.S. (Kappleman et al., 
2013). 
In North America the prevalence rates of IBD in Hispanics is 4.1% per 100,000 and in 
Asians 5.6% per 100,000. These rates are much lower when compared to the rates for White 
individuals of 43.6% per 100,000 and African American individuals at 29.8% per 100,000 
(Baumgart & Carding, 2007). Additionally, both CD and UC are more common in Jews than 
non-Jews  (Acheson, 1960).  
Current statistics demonstrate that IBD accounts for approximately 45,000 veterans who 
access VA healthcare services for the chronic illness care of this disease (Hou et al., 2013).  This 
study reported the prevalence of IBD in a national VA sample from 1998-2009 the results of 
which demonstrated an IBD occurrence primarily in men (>90%) with 50% of this cohort falling 
between the ages of 55 to 74.  
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Smoking effects both CD and UC in dichotomous ways. The risk of developing CD is 
twice as likely in smokers versus nonsmokers (Silverstein, Lashner, Hanauer, Evans, & Kirsner, 
1989). While current smokers have a 40% lower risk of developing UC than nonsmokers. 
Interestingly, former smokers are 1.7 times more likely to develop UC when compared to those 
who have never smoked (Boyko, Koepsell, Perera, & Inui, 1987). Smoking cessation in UC has 
been associated with an increase in disease activity as well as hospitalization. 
Other risk factors implicated in the occurrence of IBD include diets high in processed, 
fried, and sugary foods, obesity, GI infections, breast feeding, antibiotic usage, anti-
inflammatory medication, oral contraceptives, Isotretinoin, and having an  appendectomy 
(Peppercorn, 2012).  
Clinical Manifestation 
A comparison of the clinical manifestations of CD and UC are found in Table 1.The 
clinical manifestations of CD are more variable compared to those with UC and consist primarily 
of prolonged diarrhea, with or without gross bleeding, fever, weight loss and crampy abdominal 
pain. While UC typically presents with intermittent rectal bleeding in patients with mild disease 
confined to the rectum (proctitis). In moderate UC, inflammation extends to the splenic flexure 
(left-sided colitis) and the patient experiences frequent bloody diarrhea (up to 10x daily), mild 
anemia, abdominal pain, and fever.  
In patients with severe disease, often inflammation extends the entire length of the colon 
to the cecum (pancolitis), bloody bowel movements number > 10 per day, and the patient may 
require a blood transfusion. Additionally, rapid weight loss leading to poor nutritional status may 
result in severe cases. If the inflammation in UC is severe enough, the process may extend 
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beyond the mucosa to involve the muscle layers of the colon causing impaired colonic motility 
and possible perforation (Peppercorn, 2012).  
A recent review article was published by (Peyrin-Biroulet, Loftus, Colombel, & 
Sandborn, 2010) who examined the natural history of adult CD from 1935 through 2008. The 
results showed that while the disease remained stable over time with approximately 10% of the 
cohort experiencing prolonged periods of remission, half of all patients had intestinal 
complications within 20 years of diagnosis. The annual incidence of hospitalization was 20%. 
Additionally, half of the patients required surgery within 10 years of diagnosis with a 
postoperative risk of recurrence in the 44-55% range 10 years out.  
Diagnosis 
The diagnosis of CD is established with endoscopic findings and/or imaging studies in 
patients with a history consistent with the disease. Colonoscopy, with intubation of the terminal 
ileum, establishes the diagnosis of ileocolonic CD. Inflammation occurs in patches with normal 
colonic mucosa between lesions. Usually, the rectum is not affected. Colonic biopsies confirm 
the diagnosis with inflammation found on the small bowel biopsy. Imaging studies are typically 
done to assess for small bowel activity not evaluated by colonoscopy and include an upper GI 
with small bowel follow through, Ct, Ct enterography, MRI, and MR enterography.  
Initially, flexible sigmoidoscopy establishes the diagnosis of UC (Peppercorn, 2012). 
Inflammation is in a contiguous pattern with rectal involvement. Biopsy confirms the diagnosis. 
Colonoscopy is usually not the first line exam in the severely ill patient due to risk for 
megacolon or perforation. In this country, diagnosis of UC does not depend on imaging studies. 
However, in Europe, ultrasonography provides information regarding the extent of colitis 
(Peppercorn, 2012) . 
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Table 1 
 
Comparison of Crohn’s Disease and Ulcerative Colitis 
 
Crohn’s Disease Ulcerative Colitis 
 
Inflammation may occur anywhere in the 
digestive tract and is in patches, the 
rectum is spared 
 
Inflammation only occurs in the large 
intestine, is continuous, and typically 
affects the rectum 
 
Ulcers in digestive track are deep and may 
extend into all layers of the bowel wall 
 
Mucus lining of large intestine may have 
ulcers, but they do not extend beyond the 
inner lining 
 
Bleeding from the rectum during bowel 
movements is not common 
 
Bleeding from the rectum during bowel 
movements is common 
 
Symptoms 
 
Diarrhea Bloody Diarrhea 
Weight Loss Weight Loss 
Joint Pain Joint Pain 
Anemia Anemia from severe rectal bleeding 
 
 
Treatment  
The goal of treatment is to induce remission, assessed by a variety of methods that 
include patient subjective report of convalescence in symptoms, blood studies, as well as 
improvement on colonoscopic exam. However, treatment for IBD is convoluted requiring 
individualized application of current therapies due to disease heterogeneity. IBD typically has a 
relapsing, remitting path that requires continuous, particularized, therapy adjustment. Some 
individuals will have a quiescent disease course, while others have much more aggressive 
disease. Treatment considerations include the extent of disease, cost of therapy, patient 
compliance, and risk for toxicity. Because of disease and treatment complexity, there is no 
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consensus among discipline experts about how best to treat these patients. Many guidelines 
subsist with no one platform universally adopted. Therefore, the most current evidenced based 
practice recommendations provided guidance for the following discussion.  
Treatment of CD 
Generally, two approaches for the treatment of mild to moderate Crohn’s disease: step-up 
therapy and top-down therapy are widely recognized as illustrated in Figure 2.4 (Farrell & 
Peppercorn, 2012). The most favored approach is step-up therapy that involves using 
medications that are the least potent, with fewer side effects, first. Medications with more toxic 
side effects follow, if initial therapy fails. Conversely, top-down therapy starts with potent 
therapies early on in disease course. Outpatient treatment with oral medication is appropriate for 
most individuals with mild to moderately active Crohn’s disease. However, inpatient 
management is usually required for those with severely active disease.   
Administration of oral medication depends upon the site of disease. Gastroduodenal 
disease occurs in less than 5% of CD patients, the treatment for which is prednisone. The ileum 
is the site most commonly involved in CD, the initially treatment for which is a 3-4 week course 
of an oral 5-aminosalicylate (5-ASA) medication such as mesalamine or sulfasalazine (Farrell & 
Peppercorn, 2012). Using a 5-ASA as an initial treatment in CD is controversial as studies 
evaluating its efficacy in this population are mixed.  
If patients do not respond to the 5-ASA trial, treatment with either metronidazole alone or 
in combination with ciprofloxacin is next advised (Sartor, 2012). The mechanism of action of 
antimicrobials in IBD is not transparent with theories of intestinal bacterial overgrowth or 
possible microperforation speculated. Four weeks of tapering, oral steroid therapy follows a 
failed course of antibiotics to treat recalcitrant symptoms.  
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For intractable cases of CD, treatment consists of immune modulating medication such as 
azathioprine, 6-mercaptopurine (6MP), or methotrexate that has a response rate of 60-70% in 
small bowel and colonic disease (Farrell & Peppercorn, 2012). Reaction to these medications 
typically takes three to six months during such time the patient may need concomitant therapy 
with oral steroids. These medications have been associated with malignancy, bone marrow 
suppression, and hepatotoxicity. Therefore, close monitoring of biochemical parameters is 
required. 
 
 
Step-up Versus Top-Down Therapy
Step-up Therapy
Anti
TNF
Immune 
Modulator
5-ASA
Top-down Therapy
5-ASA
Immune
Modulator
Anti
TNF
 
      Figure 2.4 Step-up versus Top-down Therapy for Treatment of Crohn’s Disease 
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In a step-up approach, use of anti-TNF agents, also known as biologics, such as 
infliximab, adalimumab, and certolizumab represent the top tier of treatment and are not 
recommended as first line therapy but rather to be used in refractory cases and are often used in 
conjunction with immune modulating medications (Farrell & Peppercorn, 2012) . Due to 
immunocompromise with these medications, screening for hepatitis B and C as well as for TB, is 
advisable prior to initiation of therapy. Many possible serious side effects from anti-TNF 
medications are possible that include heart failure, malignancy, and demyelinating disease 
(Stone, 2012). As a recent systematic review demonstrated, it is unclear whether exposure to 
both immunomodulators and biologics simultaneously exponentially increases cancer risk 
(Kotlyar et al., 2011).  
Approximately 10 to 20 percent of patients experience a prolonged remission after initial 
diagnosis (Solberg et al., 2007). Additionally, a recent review of the literature (Lichtenstein, 
Hanauer, Sandborn, & Practice Parameters Committee of American College of 
Gastroenterology, 2009) provided insight into the state of knowledge regarding treatment 
outcomes in this population. Important treatment statistics generated from the study analysis 
included:  
 patients in remission for one year have an 80% chance of maintaining remission in 
subsequent years 
  patients with active disease in the past year have a 70% chance of remaining active 
in the next year 
 13% of patients will have a period from relapse, while 20% have annual relapses, 
and 67% have a combination of years of relapse and remission with less than 5% of 
patients having a continuously active disease course.  
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Treatment of UC. 
Similar to CD, treatment for UC focuses on the location of the inflammation. For example, 
treatment of proctitis, a disease limited to the distal 10 to 15cm of the colon, present in 
approximately 30% of patients, consists of a topical 5-ASA or steroid suppository (Farrell & 
Peppercorn, 2012). Treatment for disease extending into the left side of the colon consists of 5-
ASA or steroid enema at bedtime, with response seen in four to six weeks (Farrell & Peppercorn, 
2012). Treatment for non-responders consists of a second morning enema. Finally, therapy for 
non-responders to the aforementioned treatments consists of oral 5-ASA preparations that take 
three to six weeks to exert maximal benefit.  
Deployment of tapering oral prednisone occurs for those with severe UC. However, 
chronic oral steroid use is not beneficial due to multiple deleterious effects such as weight gain, 
osteoporosis, diabetes, hypertension, cataract development, and mood swings. Additionally, 
there is no evidence that oral steroids maintain remission. Therefore, immune modulating 
medication as described, are added for those unable to wean off steroid. If no response occurs 
with immune modulating medication and/or the patient is unable to tolerate steroid wean, the 
final drug choices used to treat severe UC, prior to considering colectomy, include IV 
cyclosporine and Infliximab.  However, the role of these medications in treating complicated 
cases of UC remains contentious.  
Complications 
CD and UC share a number of extraintestinal manifestations that correlate with the 
amount of inflammatory activity present. For example, arthritis such as ankylosing spondylitis 
that affects large joints, occurs in approximately 20% of patients and is the most common 
extraintestinal complication (Peppercorn, 2012). Eye involvement that exhibits as uveitis or iritis 
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occurs in 5% of patients (Peppercorn, 2012). Similarly, primary sclerosing cholangitis, also 
present in 5% of patients, is a consideration when alkaline phosphatase and gamma glutamyl 
traspeptidase (GGT) are elevated. Erythema nodosum and pyoderma gangrenosum, two common 
skin conditions, arise in 10% of patients (Peppercorn, 2012).  
Several vitamin deficiencies plague patients with IBD, who experience impaired vitamin 
D and calcium absorption that may result in bone loss related to steroid use. Additionally, 
pernicious anemia can result from severe ileal inflammation since vitamin B12 is absorbed in the 
distal 50-60cm of ileum (Peppercorn, 2012).  
IBD patients are at risk for renal stones. Calcium oxalate and uric acid kidney stones can 
result from steatorrhea and diarrhea (Obialo et al., 1991). Uric acid stones also result from 
dehydration and metabolic acidosis. Although rare, an additional renal complication includes 
secondary amyloidosis.  
Pulmonary complications, although less likely, also exist in this population related to 
underlying inflammation but may be influenced by the medications used to treat the disease 
(Black, Mendoza, & Murin, 2007). Lung manifestations include pulmonary embolism, 
sarcoidosis, and interstitial lung disease.  
Individuals with both CD and UC are at increased risk for colorectal cancer when 
compared to the general population. However, the data in this regard are disparate with much 
more known about this risk in UC and with no consensus regarding the timing of surveillance 
colonoscopy declared. Furthermore, a reduction in mortality due to colonoscopic surveillance 
has not materialized (Peppercorn & Odze, 2012) . Despite this, the general recommendation is to 
perform annual colonoscopy after eight years of disease duration in those with disease that 
extends beyond the hepatic flexure and after 12 years for those with left sided colitis (Peppercorn 
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& Odze, 2012). These surveillance exams do not preclude interim colonoscopic evaluations to 
assess disease extent as warranted. 
Because IBD is an illness that tends to onset during the child bearing years, pregnancy 
and infertility are concerns that need addressed. Overall, decreased rates of fertility occur for 
both men and women with IBD (Walsh, Mabee, & Trivedi, 2011). For men, changes in fertility 
are associated with medication, methotrexate and 6MP, which resolved with cessation of the 
medication. Similarly, women experience decreased rates of fertility while taking methotrexate 
as well. Men and women should be counseled about the abortifacient and teratogenic effects of 
methotrexate and be advised to use two type of birth control while taking this medication (Walsh 
et al., 2011). While IBD improves during pregnancy, an individualized plan of care coordinated 
by an experienced gastroenterologist is critical for successful birth outcomes.  
Summary 
Inflammatory bowel disease is comprised of a set of conditions that cause chronic 
inflammation in the GI tract for 1.5 million Americans including approximately 45,000 veterans 
who access VA for healthcare services. The symptoms of IBD and the medications used to treat 
the disease can be debilitating and are a drain on scarce healthcare resources. 
Two recently published papers (Shah et al., 2011) and (Kappleman et al., 2011) raise 
concerns about the quality of treatment for IBD noting significant variations in clinical practice 
that contribute to a misappropriation of therapy. Authors of both articles identified gaps in the 
literature regarding comprehensive evaluation of chronic illness care for this population that 
includes variations in prescribing practices as well as patterns of healthcare utilization. Not only 
did the results of these review articles support the need for additional research in medication 
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adherence and healthcare utilization in this cohort, the authors advise using a framework such as 
the CCM to do so which provided strong support for this study. 
2.5 Medication Adherence 
Chronic illness that requires prolonged treatment with medications affects more than 40% 
of individuals in this country and is the principal variable affecting treatment outcomes 
(Hoffman, C., & Schwartz, K., 2008).  A meta-analysis demonstrated that rates of medication 
adherence in chronic disease varies and is in the range of 4.6% to 76% (DiMatteo, 2004).   
While adherence to long-term therapies for chronic illness has been extensively 
deliberated for the last 50 years, a consistent profile of factors affecting adherence, or a single 
strategy that guarantees compliance, has not materialized. Furthermore, how to best define and 
measure this construct remains elusive.  A discussion in this regard follows.   
Defining Medication Adherence 
Terminology and definitions of medication adherence used in research vary. The most 
common terms used are adherence, compliance, concordance, and persistence. The connotation 
of medication-taking language is widely debated (Osterberg & Blaschke, 2005; Steiner & 
Earnest, 2000).  However, there is no consensus in the literature about how best to define this 
concept. Without homogeneity in construct description, it is problematic to compare research 
findings. Thus, advancement of knowledge in this field stymies. 
In 2008, a paper presented standardization of the terms and definitions used when 
referring to medication-taking behavior. This publication was based on three years of 
international appraisal of this topic conducted by the International Society for 
Pharmacoeconomics and Outcomes Research (ISPOR) (Cramer et al., 2008) in which 
investigations conducted over the last half-century were considered. In an effort to comply with 
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standardization, the definitions generated from this report will serve to characterize adherence 
for this study.   
The term compliance is purported to be offensive to patients when compared to the term 
adherence. However, after extensive review of this consideration, the authors concluded that no 
scientific support for the assumption that the term adherence is a less disparaging term or 
preferred by patients exists. Therefore, medication adherence was synonymous with compliance 
and was defined as “the extent to which a patient acts in accordance with the prescribed interval 
and dose of a dosing regime” (Cramer et al., 2008).  
Measuring Medication Adherence 
Similar to defining medication adherence, no “gold standard” for measuring this 
conception exists in scientific publication (S. Kane et al., 2012). Methods for measuring 
medication adherence are direct and indirect. Each measure elucidates a different aspect of this 
construct, making choice of the appropriate mechanism for research dependent upon study 
methodology and research questions.  
This section presents a discussion of the advantages and disadvantages of the most 
frequently used methods of direct measures to include: observed therapy, measurement of 
medicine metabolite, and measurement of serology biologic marker, and indirect measures of: 
patient self-report, pill counts, pharmacy refill records, and electronic medication monitoring 
(Osterberg & Blaschke, 2005). Each of these methods, when used in isolation, often yields 
inaccurate and unreliable data (MacLaughlin et al., 2005). For this reason, use of a subjective 
and an objective measure to corroborate research findings are advised (Turner & Hecht, 2001).  
Because of limited resources, deployment of a corroborating source did not occur for this study.  
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Direct Measures 
Directly Observed Therapy 
Randomized control trials most often use the method of directly observing a patient 
receive medication where this type of intensive intervention warrants. However, its applicability 
in routine clinical settings is limited due to the expensive, labor-intensive nature of this data 
collection method.  Although considered the most accurate means of measuring medication 
adherence, this method is not full proof as the patient could feign swallowing medication and 
then remove it from their mouths once the observation period had ceased.  
Measurement of Medicine Metabolite 
Biologic fluids can identify medication use during a stipulated period. However, presence 
or absence of a drug metabolite cannot fully substantiate adherence. Serum and urine drug levels 
do not explain medication consumption. For example, consider “white-coat compliance”, a 
phenomenon where by the patient may exhibit adherence that corresponds with a clinic visit 
(Feinstein, 1990). Further complicating the use of this measure, are the variations that exist in 
individual’s absorption, metabolism, and excretion that affect drug levels.  
Measurement of Serology Biologic Marker 
Biologic markers are compounds added to target or placebo medications used in clinical 
trials and extend similar inadequacies as medicine metabolites. Isotopes, phenobarbital, digoxin, 
and phenol red are examples of markers that have been used (Farmer, 1999) . 
Indirect Measures 
Patient Self-Report 
Soliciting input from individuals via self-report is crucial to understanding adherence 
because patients ultimately decide whether to comply with treatment protocols. Self-report 
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measures are the most common, cost effective, convenient method of assessing medication 
adherence and include patient diaries, patient interviews, and validated adherence questionnaires 
(Sakthong, Chabunthom, & Charoenvisuthiwongs, 2009).  The basic premise of this measure is 
simply asking the patient if they have been adherent to a drug regime. A caveat to this is that 
patients often times overestimate their adherence (Wang et al., 2004). Similarly, clinicians 
generate inaccurate assessments of patient compliance as well (Osterberg & Blaschke, 2005).  
Confirmation of findings in studies of medication adherence using a self-report method is 
advised (Morisky, Green, & Levine, 1986). Despite this recommendation, there are few studies 
available in the literature that compare self-report to objective criteria such as electronic 
monitoring (Wang et al., 2004).  
Self-report methods have been widely used throughout the last several decades to 
measure adherence in a variety of chronic illness. However, due to the number of methods used 
to interview and retrieve information from patients, as well as the lack of psychometric 
properties of such tools, comparing results across studies can be arduous.  
Pill Counts 
Second only to self-report, pill counting is the most common method to measure 
medication adherence that involves counting the number of dosage units 
(tablets/capsules/drops/puffs) the patient has not taken by the scheduled appointment.  A 
comparison of returned units with the number of units received by the patient in the most recent 
prescription and the length of time since the medication was dispensed takes place (Farmer, 
1999). Calculation of medication adherence occurs by subtracting the number of units returned 
from the number of units issued which calculates the amount of medication used by the patient 
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during the observation period that can then multiplied by 100 to determine the percentage of 
adherence.  
Once thought to be a viable mechanism for measuring medication adherence due to ease 
of use and cost effectiveness, pill counting has fallen out of favor due to overestimation of 
compliance (Cramer et al., 2008).  This method of measuring medication adherence gives no 
insight of ingestion of medication by the patient.  Patients can easily manipulate the results of the 
data collection. A phenomena known as "pill dumping" may occurs whereby patients ingest large 
amounts of medication immediately preceding a clinic visit (Rudd et al., 1989).  Additionally, 
patients may not return all residual medications in an attempt to hide their behavior. Even when 
assessments are accurate, pill counts cannot explain reasons for non-adherence.  
Pharmacy Refill Records 
Use of prescription refill records to assess medication adherence has become the most 
common measure of this construct in the last decade (Ho, Bryson, & Rumsfeld, 2009). The 
advent of the electronic medical record has provided opportunity to access pharmacy data for 
research purposes. Because this was the chosen data collection method for this study, a detailed 
discussion occurs further on in this review. 
The accuracy of this measure depends in large part if patients are filling prescriptions 
within a closed pharmacy system (i.e. patients are obtaining medication from a single pharmacy) 
such as VA (Osterberg & Blaschke, 2005). Measuring medication adherence using electronic 
claims can be problematic if patients obtain prescriptions from multiple sources. Additionally, 
pharmacy records do not provide any information about medication consumption. Patients may 
order refills of medications as scheduled and stockpile them.  
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Electronic Medication Monitoring 
The last four decades have witnessed use of electronic monitors to record the time and 
date when patients open a prescription container (Osterberg & Blaschke, 2005).  The most 
commonly used device is the Medication Event Monitoring System (MEMS) which costs 
approximately $100 per monitor, inhibiting its use in routine clinical practice and large studies 
(Balkrishnan, 2005).  When the device communicates to the appropriate computer software, it 
has the ability to identify non-adherent behaviors such as drug holidays, pill dumping, and white 
coat compliance (MacLaughlin et al., 2005). However, electronic monitoring cannot document 
whether the patient actually ingested the medication after opening the container.  Despite this 
fact, electronic monitoring is considered to provide the most reliable adherence data (Osterberg 
& Blaschke, 2005).  
Measuring Medication Adherence Using Administrative Databases 
Administrative data are data files assembled for billing of healthcare services (Hess, 
Raebel, Conner, & Malone, 2006).  VA has been keeping such records related to medication 
refills for over the last twenty years. About the time of electronic medical record development, 
researchers at VA facilities proposed a method of measuring medication adherence using 
pharmacy refill records. This method was borne from frustration with the limitations of other 
methods that were available at that time. The VA, as a closed pharmacy system (i.e. the 
assumption that patients only receive medications from one pharmacy), provided the ideal 
laboratory for this type of data collection method.  
In 1980, (Inui, Carter, Pecoraro, Pearlman, & Dohan, 1980) used VA pharmacy data to 
assess for correlations between refill data and mean diastolic blood pressure in a group of 
patients taking hydrochlorothiazide as well as the resting pulse in patients taking propranolol  
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(N = 419). The results indicated that hydrochlorothiazide compliance significantly correlated 
with mean diastolic blood pressure (r = -.63, p<0.05). The results further suggested a correlation 
between resting pulse and compliance with propranolol (r = -.41, p <0.05).   
Subsequently, while the use of administrative data to measure medication adherence was 
evolving as a viable data collection method, substantive growth was not recognized in this field 
until the sentinel paper was published in 1988 which introduced a variety of new concepts into 
the literature that have expanded considerably over the years (Steiner, Koepsell, Fihn, & Inui, 
1988). Following, will be a discussion of the history of this method year to date.  Table 2 
contains simulated data generated to provide a reference for the various mathematical 
calculations.  
MED-INT/MED-TOTAL/MED-OUT/REG-TOTAL/REG-OUT 
In 1988, (Steiner et al., 1988) introduced the concepts of: Medication-Interval (MED-
OUT); Medication-Total (MED-TOTAL); Medication-Out (MED-OUT); Regimen-Total (REG-
TOTAL);and Regime-Out (REG-OUT) in a study that sought to validate a data collection 
method  using VA refill data that incorporated changes in drugs or dosages, variable refill 
intervals, as well as regimens of multiple medications. The investigation examined compliance to 
long-term medications used to treat hypertension and seizure disorder.  
MED-INT is the ratio of the days' supply obtained at the beginning of a specific time 
interval to the days lapsed before the next fill. Days' supply, the equation numerator, is 
calculated, as the number of pills dispensed divided by the number of pills prescribed per day.   
For example, Patient B taking Sulfasalazine for UC 500mg, two tablets three times daily, who 
obtains a thirty day supply of medication for the 4th refill during the observation period, the 
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quantity of pills dispensed would be 180, divided by 6 for number doses in a day, and finally 
dividing by 30, the number of days in a refill interval: 
 (Quantify of pills dispensed 180) / (pills per dose 2 x doses per day 3) 
Days in refill interval (30) 
the Medication Interval in this example is 1.  The applicability of this equation in clinical 
practice has limited use since it only provides adherence information for one refill which cannot 
then be extrapolated to draw conclusions about the patient's overall adherence to a drug regime.   
For a series of refills, the MED-TOTAL equation provides a method to calculate an overall 
measure of compliance. The MED-TOTAL calculation is the total supply of pills  
dispensed divided by the total number of days in the refill period. Expanding on the example 
above, to examine a six-month refill period for both Patients A and B, the equation would 
resemble the following: 
Sum of days' supply dispensed (180 days x 6 months) 
Sum of days in all refill intervals (180 days x 6 months)             
The MED-TOTAL is 1, indicating perfect adherence during the six month observation period. 
This example reveals the limitations of this calculation. Both Patients A and B receive a score 
that represents perfect adherence.  However, Patient A has a gap in treatment because instead of 
the patient filling the medication after 90 days had elapsed, the patient fills the medication 100 
days after the previous refill, signifying a 10-day gap when the patient was without medication. 
The third concept presented by (Steiner et al., 1988) is that of MED-OUT that represents the total 
number of days without medications divided by the total days of observation. As discussed 
above, in the example of Patient A taking Sulfasalazine, the 2nd refill  
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Table 2 
Simulated Pharmacy Refill Data 
Patient A  
 
    
Drug Quantity Days Supplied Date Days Elapsed 
 
Sulfasalazine 500mg 540 90 10/01/2010 0 
Sulfasalazine 500mg 540 90 04/06/2011 100 
Sulfasalazine 500mg 540 90 07/01/2011 185 
Sulfasalazine 500mg 540 90 09/30/2011 275 
Patient B  
 
    
Drug Quantity Days Supplied Date Days Elapsed 
 
Sulfasalazine 500mg 540 90 10/01/2010 0 
Sulfasalazine 500mg 540 90 12/29/2010 90 
Sulfasalazine 500mg 540 90 04/28/2011 210 
Sulfasalazine 500mg 180 30 07/27/2011 300 
Sulfasalazine 500mg 180 30 08/26/2011 330 
Sulfasalazine 500mg 180 30 09/25/2011 360 
Fairman, K. & Motheral, B. (2000). Evaluating medication adherence: Which measure is right 
for your program? Journal of Managed Pharmacy. 6(6). 499-504. Reprinted with permission.   
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demonstrates that the patient went 10days without medication. To calculate MED-OUT for this 
individual: 
(Sum of days without medication)  10 
(Sum of days in the observation period) 180 
or 0.05. For the individual who never runs out of medication before obtaining a refill, MED-
OUT will equal zero.   
This calculation is not sensitive to changes in doses that would alter the supply of drug on 
hand. Such that, if this patient were instructed to increase the medication interval from three 
times daily to four times daily, this reason for the patient to be out of medication would not be 
readily apparent by performing this calculation.  
The final two concepts put forth by (Steiner et al., 1988), REG-TOTAL and REG-OUT 
mirror MED-TOTAL and MED-OUT. While the latter equations represents medication 
adherence as it relates to one drug, the former can be used to examine compliance as it relates to 
an entire regime since it is recognized that patients may adhere to varying degrees with different 
medications in the same treatment regime. 
 To obtain  REG-TOTAL and REG-OUT , the MED-TOTAL and MED-OUT are 
calculated for each drug in the individuals regime respectively, summed and then divided by the 
total number of observation days for each drug.  
The authors validated MED-TOTAL and MED-OUT by demonstrating a correlation 
between the measures and Dilantin serum levels, correspondingly, (r = 0.31, p = 0.03, 95% CI 
0.04 to 0.54) and (r = -0.40, p = 0.004, 95% CI -0.14 to -0.61).  Expectedly, the MED-OUT 
correlation was negative because serum Dilantin levels decrease if the patient is without 
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medication. The investigators attempted to validate REG-TOTAL and REG-OUT by examining 
all hypertensive medications each individual in the study was taking and comparing these 
calculations to diastolic blood pressure. There was a correlation found between compliance and 
diastolic blood pressure for both REG-TOTAL and REG-OUT. However, neither reached a 
statistically significant level, (r = -0.14, p = 0.23, 95% -0.35 to 0.09) and (r = 0.17, p = 0.15, 95% 
CI -0.06 to 0.39) respectively.  
CSA,CSG,CMA,CMG,DSA,DSG,DMA,DMG 
Research of medication adherence using pharmacy refill data continued to grow 
throughout the 1980s and 1990s.  (Steiner & Prochazka, 1997) expanded on their 1988 work by 
performing a systematic review of the literature from 1969 through 1994 to examine the state of 
knowledge regarding the use of administrative databases to measure compliance. In all, the 
authors examined 41 studies from the U.S., UK, Australia, and Finland that employed refill 
compliance measures. Twelve of the 41 studies reviewed occurred in VAMCs that meant that 
VA pharmacy data informed these studies.  
The researchers created a new typology that introduced three new categories into the 
literature to describe refill measures. The categories included: 1) the distribution of the adherence 
variable was continuous (C) versus dichotomous (D); 2) the number of refill intervals was either 
single (S) or multiple (M); and  3) the measure either assessed the time period over which drugs 
were available to the patient (A) or the time intervals during which gaps in medication 
possession occurred (G).  From this review, the authors generated new classifications by 
grouping studies by typology.   
The first category presented by (Steiner & Prochazka, 1997) is that of continuous, single-
interval measures of medication availability (CSA).  Similar to MED-INT that provides minimal 
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information on a patient's overall adherence to a drug regime, CSA is of limited clinical 
usefulness, as it too, gives little insight into adherence.  None of the studies in this review 
utilized CSA as a measure for compliance. 
The second typology offered by the authors is continuous, single-interval measures of 
medication gaps, CSG. This calculation provides information about gaps in adherence for 1 refill 
only, typically 30, 60, or 90 days. For example, if a patient fills a medication for 30 days and the 
observation period is for a total of 90 days, this leaves a gap in the treatment of 60 days. CSG is 
calculated: 60/90 = 0.67. When no gaps in treatment occur, CSG will be zero.  Analogous to both 
CSA and MED-INT, CSG will have limited pertinence in medication adherence research due to 
its confined scope of measurement. The data presented by (Steiner & Prochazka, 1997) did not 
include any studies that utilized this equation. 
The third classification generated is CMA that is a continuous, multiple-interval measure 
of medication availability. This measure is comparable to MED-TOTAL and provides 
information on mean adherence over all refill intervals. Dividing the sum of the days' supply 
obtained over a series of refill intervals by the total days from the beginning to end of the 
observation period provides the calculation for CMA.  For the patient taking Sulfasalazine who 
refills this medication every 30 days for 6 months, the CMA would be 1 (180/180), which 
demonstrates perfect adherence. Any number > 1 constitutes an oversupply of medication. 
Over 50% (23) of the studies in this review used CMA as a measure of adherence.  Of these, 11 
collected data using VA administrative databases to examine a large variety of medications with 
4 of the 11 studies observing adherence for 6months and the remaining studies reviewing data 
for 12 months or more. The mean CMA for the 11 studies was .87 indicating a high level of 
compliance. 
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The fourth concept in this review is the continuous, multiple-interval measure of 
medication gaps (CMG). This corresponds with MED-OUT and documents the amount of time a 
patient is without medication.  CMG calculation consists of dividing the total number of days in 
treatment gaps by the duration, in days, of the observation period. The denominator in this 
equation can be a specific date at the end of the observation period or the date of the last 
medication fill. If the former is used, all gaps are "embedded" within a series of refills. If the 
latter is used, a "terminal gap" is present after the last fill. This measure assumes that gaps in 
treatment correspond to a lack of adherence rather than a temporary or permanent dose change 
made by the provider.  
Eight studies in this review examined medication adherence using CMG, the majority of 
which were studies conducted in the VA.  The mean CMG for these studies was 0.17 indicating 
small gaps in treatment, i.e. higher levels of adherence. The remaining four equations, DSA, 
DSG, DMA, DMG, are simply dichotomous measures generated from their continuous 
counterparts, CSA, CSG, CMA, and CMG. 
Dichotomous cutoffs were used to differentiate between complaint versus partially 
compliant or complaint versus noncompliant individuals. The investigations in this review did 
not offer clinical or pharmacological justification for the choice of a threshold value. Often the 
cutoff of .80 represents the ceiling (Esposti et al., 2004). Therefore, those with a calculated 
adherence of .80 and above are adherent. Whereas those with a score < .80, would be categorized 
as partially compliant or non-compliant.  
Medication Possession Ratio 
Included in the review conducted by (Steiner & Prochazka, 1997), however not explicitly 
addressed, was the construct of Medication Possession Ratio (MPR). (Sclar et al., 1991) 
  
 46 
introduced the MPR into the literature and defined it as the number of days’ supply obtained by 
the patient during an observation period. The ultimate outcome is a ratio of 1:1 representing 
perfect adherence. This equation provides comparable data to MED-TOTAL and CMA in that it 
provides information about adherence to a drug regime over time.   
Considerable research was generated from the preliminary (Sclar et al., 1991)  
investigation during the next 15 years utilizing the MPR as a method for measuring medication 
adherence. Consequently, while many adherence measures that used pharmacy refill data exist in 
the literature during this period, the MPR sustained and gained popularity. The definition of 
MPR had expanded from what has previously been described into the following: “the sum of the 
days’ supply of medication divided by the number of days between the first fill and the last refill 
plus the days’ supply of the last refill” (Sikka et al., 2005).  
MPR was the measure of medication adherence used in a recent study conducted by   
(Lockwood, Steinke, & Botts, 2009) that examined this concept and readmission rates in the 12 
months following discharge, in a sample (N = 82) of Veterans with Posttraumatic Stress Disorder 
(PTSD), released from an inpatient psychiatric stay for such. Local pharmacy data was used to 
measure adherence to psychiatric medication regimes, as calculate by the MPR, with adherence 
defined as a ratio of at least 0.8.  The majority of patients (66%), were not adherent to 
medication during the 12 months following discharge and 20.7% were readmitted for 
symptomatic PTSD. However, non-adherence was not significantly associated with relapse 
(p=0.91).  
Additionally, the authors reported that the larger the total number of drugs prescribed for 
a Veteran, the higher the level of adherence (p=0.014). Age, substance abuse, combat service, 
and service connection were not associated with medication adherence.    
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Table 3 contains a summary of adherence and persistency measures found in the 
literature which demonstrated a distinct difference between adherence and persistence. Whereby 
the MPR calculates adherence through assessing medication availability over multiple refill 
cycles, persistency denotes the duration of time a patient remains on chronic medication for a 
specified surveillance interval. Therefore, MPR in isolation may not impart information on the 
consistency of refilling behavior, i.e. persistency.  
Persistency as a function of the MPR 
As previously discussed, MPR is a measurement of adherence based on the patient's 
possession of a medication.  A comparable concept, proportion of days covered (PDC), is also 
found in the literature and is as frequently chosen as the MPR to measure both compliance and 
persistency (Ho et al., 2009). MED-TOTAL and CMA can also be relegated to this category. The 
selection of a threshold of .80 to indicate adherence is arbitrary. In the paper written by (Sikka et 
al., 2005), it was argued that a patient could be considered persistent with an MPR of .80 because 
it would be reasonable to assume that individuals with this score were continuously refilling 
medication over a defined time period. (Vink, Klungel, Stolk, & Denig, 2009) conducted a study 
using automated databases to calculate both MPR and a gap measure of persistence for 3,877 
patients. The findings illustrated that both equations yielded similar products.  
(Sikka et al., 2005) stressed the importance of using the same measurement endpoints for 
all subjects to ensure accurate results. Such that, patients with shorter observation periods could 
generate an MPR that is higher than it actually is when compared to other patients with longer 
surveillance intervals. 
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Persistency as a function of medication availability at a fixed point in time 
Persistency as a function of medication availability at a fixed point in time measures the 
availability of medication on hand or the presence of a medication refill on a fixed date after 
filling the initial prescription. This measure is insensitive as it regards persistent based on one 
refill and is comparable to MED-INT and CSA where persistent occurs at 2 years if a patient has 
a single day's supply of medication or a refill available at the end-point of 2 years. This measure 
is applicable in very short periods of observation since this would improve its accuracy. 
However, this measure does not reflect changes in refill behavior that occur over multiple refills.  
The Anniversary Model is another example of a persistence measure calculated based on a fixed 
point in time (Caetano, Lam, & Morgan, 2006). In the Anniversary Model, a patient is persistent 
at 1 year if a prescription fill occurs within a specified interval surrounding the anniversary of the 
first fill (i.e. 30 days). This is a dichotomous measure. 
The Minimum-Refills Model is also a measure of persistence based on a fixed point in 
time, 1 year. Such that, a patient is considered to be persistent at 1 year if a minimum number of 
refills are dispensed during the year (Caetano et al., 2006). This too is a dichotomous measure. 
Persistency as a function of gaps between fills 
The most broadly used method for assessing persistency is a tool that examines gaps in 
treatment.  This calculation contains an allowable grace period in which patients can refill 
medications and is equivalent to MED-OUT and CMG. The Refill-Sequence Model represents 
another persistency measure that takes into account gaps between refills (Caetano et al., 2006). 
The Model calculation uses the time between the date of the first fill and the point at which an 
undesirable gap between refills occurs. Whereby, non-persistence results if the prescription refill  
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Table 3 
Summary of Refill Adherence/Persistency Measures 
 
Definition Analogous Concepts Formula Calculations 
  
Medication-Interval 
MED-INT 
 
(# of pills dispensed)  /  (Pills dose X doses per 
day)/Days in refill interval 
Single Interval 
Medication 
Availability 
Continuous, Single-interval 
measures of medication 
Availability 
CSA 
 
Anniversary Model 
Days' supply obtained  per interval  / Total days 
in interval 
 
 
Dichotomous measure in which a patient is 
deemed persistent for 1 year if a prescription is 
filled within a defined anniversary date of the 1st 
fill (i.e. 30 days) 
 
 Medication Total 
MED-TOTAL 
 
Continuous Measure of 
Medication Acquisition 
CMA 
 
Medication Possession Ratio 
MPR 
 
Sum of days’ supply dispensed / Sum of days in 
all refills 
 
Cumulative days' supply obtained  / Total days 
from beginning to end of time period 
 
Sum of days’ supply / Number of days between 
first and last fill   +  Days’ supply of last fill 
 
Medication 
Possession Over 
the Entire 
Surveillance 
Period 
 
 
 
 
 
 
Medication Possession Ratio 
Modified 
MPRm 
 
Medication Refill Adherence 
MRA 
 
Proportion of Days Covered 
PDC 
 
Compliance Rate 
CR 
 
 
Refill Compliance Rate 
RCR 
 
Minimum-Refills Model 
 
Total days’ supply / Sum of number of days 
from first fill up to, but not including, the date of 
last fill + Days’ supply obtained at last fill X 100 
 
Total days’ supply / Number of days of study 
participation X 100 
 
Number of days patient has medication / Total 
days in dispensing period 
 
Sum of days’ supply – Days’ supply at last fill / 
Number of days from first up to, but not 
including, last fill 
 
Total days’ supply X 100 / Number of days from 
first to last fill 
 
A patient is considered to be persistent at 1 year 
if a minimum number of refills are dispensed 
during the year   
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Table 3 (continued) 
Summary of Refill Adherence/Persistency Measures 
 
  
Medication-Out 
MED-OUT 
 
Sum of days without medication/Sum of days in all 
refills 
 Continuous Multiple Interval 
Measure of Oversupply  
CMOS 
Total number of days' surplus 
Days of study participation 
 
Gaps in Treatment Continuous, Single-Interval 
Measures of medication Gaps 
CSG 
Days in interval – Days' supply obtained/Total days 
in interval 
 
 
 Days Between Fills 
Adherence Rate 
DBR 
1 - (Day between fills – Today days’ supply) X 100 
Number of days between fills 
 
 
 Refill-Sequence Model 
 
Continuous Measure of 
Medication Gaps  
CMG 
Is calculated as the interval between the date of the 
first refill and the point at which an unacceptable 
gap between refills occurs. 
 
Total number of days in treatment gaps/Duration of 
the observation period 
 
 
does not occur within a predetermined number of days. This Model generally recognizes 
switching of medication as an indication of persistence. 
The principal challenge encountered when calculating persistency based upon gaps in 
treatment is to define the permissible gap that specifies length of the grace period between refills. 
The researcher decides the appropriate length of a grace period by considering a variety of 
factors that may include the following influences: medication half-life, dosage titration, and 
number of days in a refill period (i.e. 30, 60, or 90 days).  For example, the permissible gap may 
be one-half the number of days in the previous prescription supply. Such that, a patient who 
refills a medication for 30 days would be given a 15 day grace period in which to obtain the next 
fill. Therefore, non-persistence does not occur until day 46.  
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Innumerable methods for measuring gaps between refills exist in the literature reported 
dichotomously, persistent versus non-persistent (Vink et al., 2009). The most frequently cited 
permissible gap in the literature is 30 days. Ultimately, sound clinical validation informs the 
choice for the permissible gap threshold. However, the rationale for choice of persistency 
calculation is rarely transparent in published papers. Few studies examine multiple methods of 
persistency in the same investigation (Vink et al., 2009).  
Conversely, a study conducted by (Hudson, Rahme, Richard, & Pilote, 2007) examined 
refill records of over 20,000 patients who were administered a statin.  The authors calculated 
persistence using three different measures for each patient: (1) MPR, (2) persistency as a 
function of medication availability based on a fixed point in time, and (3) persistency as a 
function of gaps between fills. The rates of persistency were variable in the range of 5-94% 
depending on the calculation used. Kaplan Meier analysis illustrated rates of persistency as a 
function of a wide variety of gaps between fills, from one to 120 days. As hypothesized, the 
results demonstrated that longer grace periods increased the level of persistency. Results 
emphasize the importance of defining a consistent allowable gap for all patients in a study that is 
scientifically sound. The findings of a study conducted by (Van Wijk, Klungel, Heerdink, & de 
Boer, )  provided further corroboration of the results from the (Hudson et al., 2007) investigation.  
Additional Measurement Considerations 
About the same time, (Andrade, 2006) also completed a comprehensive review of the 
literature to examine methods of measuring adherence and persistence using automated 
databases which included appraisal of 136 articles. The results of this evaluation identified 
methods previously presented.  In addition, this assessment revealed several other considerations 
when working with pharmacy refill data that includes switching, retentiveness, and turbulence.   
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Switching 
This review included 34 studies that took into consideration a change to a different drug 
within the same class during the observation period, i.e. switching. The literature contains a 
myriad of definitions of switching, for example, (Chan, Walker, & Yood, 1993) defined 
switching as dispensing of a different drug within the same class within 120 days following the 
initial fill of the drug. Whereas, (Walker, Chan, & Yood, 1992) defined switching as 
administration of a different drug within the same class within 60 days of the initial fill.   
The deliberation of switching when examining treatment compliance has been encouraged. 
However, it should be noted that unless the requisite administrative database utilized for the 
study makes a specific provision for noting the reason why switching occurred, it would be 
difficult to discern the reason for a medication switch outside of a reported adverse drug event. 
Alternatively, a manual chart review may clarify the rationale for the switch. This approach 
would likely prove too labor intensive in large studies.  
Retentiveness 
Retentiveness is an additional concept of consideration when switching has indeed 
occurred. Retentiveness has been defined as "the number of repeat pairs for that drug divided by 
all the pairs in which the drug was the first one dispensed” (Walker et al., 1992). Retentiveness 
accounts for the repeat dispensing of the same medication, though not necessarily at the same 
dose, within the identified timeframe.   
Turbulence 
Turbulence generates a calculation based on the total number of changes that occur 
during an observation interval.  (Caro, Speckman, Salas, Raggio, & Jackson, 1999) defined 
turbulence as "the number of changes (i.e. addition of a new drug, dropping of 1 or more drugs, 
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or a switch to 1 or more other drugs) occurring in 6-month intervals from the time of index 
prescription” p. 44.  Patients noted to have turbulence are less likely to be persistent with 
prescribed drug regimes.  The usefulness of this calculation will depend on the goals of the 
study.  
Standardization of Measurement 
A call to action occurred in 2008 for uniformity of medication compliance calculations 
using administrative data. By this juncture, uncertainty over what constituted compliance versus 
persistence had emerged from scientific consideration since MPR creates the same discordance 
as MED-TOTAL and CMA. Whereby Patient A and B can have the same calculated compliance 
score and yet the rate of continuous refilling (persistence) is not the same for these two patients. 
Therefore, making it difficult to conclude that Patient A and B are adherent to a drug regime in a 
similar fashion.  Hindrance of scholarship in the field occurred from an inability to compare 
results across studies.  
In an attempt to advance the knowledge of this methodology by generating  
standardization, the International Society for Pharmacoeconomics and Outcomes Research 
(ISPOR) published a paper in this regard (Cramer et al., 2008). A discussion of these 
developments follows.  
The work produced by ISPOR was conducted over a three year period and involved a 
review of the literature that spanned nearly four decades, from 1966-2005. The goal of the 
workgroup was to provide uniform definition and operationalization of the constructs 
compliance, adherence, and persistence relating these terms to measurement using administrative 
databases.   
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The authors concluded that the terms compliance and adherence can be utilized 
synonymously and may be defined as follows: “the extent to which a patient acts in accordance 
with the prescribed interval and dose of a dosing regime” (Cramer et al., 2008). A further 
detailed definition of the concept generated from the ISPOR report will inform the definition of 
adherence for this study found in Chapter 1.  
The ISPOR paper operationalized compliance using the MPR as defined by retrospective 
assessment of the number of doses dispensed in relation to the dispensing period. Refill of 
medication equates with compliance. MPR is calculated with the following formula: 
                               Number of days supplied   X   100  
                                    Days of observation 
 
The lack of daily dosing detail using this equation is a limitation of this method.  
Persistence is acknowledged by ISPOR as a construct distinct from compliance that considered 
the consistency with which a medication is taken during a given surveillance period.  In this 
review, persistence was defined as “the duration of time from initiation to discontinuation of 
therapy”  (Cramer et al., 2008).  
Persistence is operationalized by counting the number days of medication availability 
from initiation of the prescription, or a define point in time during chronic treatment, to the end 
of the observation period. This calculation must define the permissible gap allowed between 
refills based on the pharmacodynamics of the medication under consideration (Cramer et al., 
2008).  Such that, the maximum amount of time a patient could go without taking the medication 
and not encounter adverse consequences is distinguished.  However, currently, no allowable gaps 
exist for any prescribed medications (Andrade, 2006). The literature contains reports of 
persistence as both a continuous and a dichotomous variable.  
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In a separate document, ISPOR presented a systematic approach to study methodology 
when using pharmacy refill data to assess compliance (Peterson et al., 2007).   This paper 
represents an international consensus on the standardization of study design created to improve 
the quality of research conducted in the field. The following is a brief overview of these 
proceedings meant to function as a guideline for research process in this study. The paper should 
address the suitability of data sources to answer specific research questions as well as the 
reliability and validity of the source. Procedures for protection of personal health information 
exist. Conversion of continuous data to categorical data is discouraged and a discussion of the 
limitations of retrospective data occurs.  
There are several inconsistencies in the two papers provided by ISPOR.  Both the 
(Peterson et al., 2007) report as well as the  (Cramer et al., 2008) paper advise that a persistence 
analysis be contained in the methodology as separate from compliance and must include a gap 
determination. However, there are inconsistencies in the definitions of various adherence 
constructs found in both works. Therefore, misrepresentation of the terms persistence and 
compliance continues. Furthermore, the (Peterson et al., 2007) article, also produced by ISPOR, 
does not specifically endorse the use of a defined allowable gap as a requisite when measuring 
persistence.  Additionally, the authors assert that very few medications have a defined 
permissible gap in which patients could safely forego taking a prescribed medication and not 
experience adverse events. Therefore, calculation of tolerable gaps using retrospective pharmacy 
data remains a challenge. This is the case with all medications prescribed for IBD. For patients 
with IBD in remission, a scientifically established “drug holiday” that would avoid disease 
reactivation, has not been ascertained (Regueiro, 2012c).  In an effort to achieve remission in 
IBD patients with active disease, no advisable gap in treatment exists making calculation of 
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persistence using a permissible gap in this cohort impossible with the state of knowledge that 
currently exists. 
Summary 
It is appreciated that medication adherence has a substantial bearing on clinical outcomes 
and utilization of healthcare resources. As a result, much discourse exists regarding the 
establishment of the appropriate mechanism for assessing this variable. While many methods for 
measuring adherence in chronic illness subsist, all have inherent benefits as well as 
shortcomings. After decades of research, no consensus on how best to measure this construct has 
been forthcoming. The purpose of the investigation should be the driving force behind the choice 
of a data collection method in medication adherence research.  
Medication Adherence in Patients with IBD 
Medication is a key component to controlling disease in IBD. Non-adherence to 
treatment regimens should be the first issue suspected in patients who are not responding to 
therapy as poor adherence is the primary reason for suboptimal clinical outcomes (World Health 
Organization, 2003).  
Universally, regardless of disease type or severity, medication adherence is problematic 
in all situations requiring self-administration of treatment, as is the case in IBD. Despite the 
availability of effective medication to control the condition, adherence remains a challenge since 
IBD is an illness at high risk for poor adherence due to onset at a younger age, relapsing and 
remitting disease course, as well as prescribed difficult to follow therapies (Lopez San Roman, 
Bermejo, Carrera, Perez-Abad, & Boixeda, 2005a) Rates of non-adherence in IBD mirror those 
found in other chronic diseases. Adherence to long-term medication treatments in the most 
common chronic illnesses are in the range of 17% to 80%  (Krueger et al., 2005) 
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Correspondingly, a recent systematic literature review revealed rates of non-adherence in IBD to 
be between 7% and 72%  (C. A. Jackson et al., 2010). 
Earliest published reports to improve adherence in gastrointestinal diseases recognized 
the complex nature of this construct and encourage healthcare provider assessment of patient 
participation in treatment (Levy & Feld, 1999). This widely referenced paper, published about 
the time of CCM promulgation, weighed in well before the majority of adherence research in 
IBD was completed. Thus, chronic diseases other than IBD provided a benchmark to create 
discipline recommendations.  
Although not explicated stated,  (Levy & Feld, 1999) ascribed most of the CCM 
elements, such as proactive healthcare teams, informed activated patients, self-management 
support, the health system, and decision support as strategies to expand adherence. Papers of an 
editorial nature by (Kappleman et al., 2011) and (Shah et al., 2011), provided additional support 
for examining these CCM components in patients with IBD within the context of the health 
system and the quality of care delivery in this population.  
Therefore, in accordance with the CCM, interpretation of IBD adherence results occurs 
from the perspective of the health system in which data collection takes place, because at least 
one-half of all investigations transpire outside the U.S. in countries that have socialized 
medicine. A study conducted by (Robinson, 2001) demonstrated the potential influences of the 
health system on adherence in IBD in a study conducted to examine the rates of non-adherence 
in European countries. Reported rates of non-adherence varied widely between countries: France 
13%, Italy 25%, UK 33%, and Germany 46%. Similar variations in adherence rates exist in other 
countries and disease states (Bovet, Burnier, Madeleine, Baeber, & Paccaud, 2002; Reid, 
Abramson, Raven, & Walters, 2000). The large disparities in levels of non-adherence in 
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countries with government-sponsored healthcare, as noted in above studies, supports the need for 
further research examining the effects of other government operated healthcare systems, such as 
the VA, on medication adherence in patients with IBD. Without assessment of systematic 
influences on adherence and resource utilization, engendered population health outcomes are in 
danger of failure (World Health Organization, 2003). 
Despite this, clinical inertia exists regarding assessment of medication adherence in 
patients with IBD since research in the discipline did not begin until the early 1980s, while 
adherence research began decades earlier in many other chronic disease states. Furthermore, 
authorities in the specialty, generating IBD clinical guidelines, fail to propose formal 
recommendations to screen for medication adherence, inclusive of comprehensive chronic illness 
care in this population (Kornbluth & Sachar, 2010). 
Yet, a study survey of Gastroenterologists (n = 395) in the U.S. who care for patients 
with IBD demonstrated a large portion of those surveyed (77%) screen for adherence to 
medication but only 19% used a valid method to do so (Trindade, Ehrlich, Kornbluth, & Ullman, 
2011)  This may be prejudiced by the fact that only one validated medication adherence survey 
for use in patients with IBD currently exists, the Morisky Medication Adherence Scale -8 
(MMAS-8) (Trindade et al., 2011). Nevertheless, 95% of the physicians in the aforementioned 
study recognized the importance of determining a patient's level of medication adherence to 
guide treatment.   
Furthermore, the gastroenterology discipline as a whole comprehends the importance of 
medication adherence in this population as the literature contains five review articles, published 
in the last five years, regarding rates and factors associated with non-adherence in patients with 
IBD. Four of the reviews were non-systematic in nature and served to examine the current state 
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of relevant publications in this regard and to initiate discussion about research methodologies 
and study findings  (Hawthorne, Rubin, & Ghosh, 2008; S. Kane, 2006; Lakatos, 2009; 
Robinson, 2008) .  
One review, the most recent (C. A. Jackson et al., 2010), was the only review that used 
systematic criteria both in searching for and in evaluating articles, thereby providing a critical 
assessment of the status of knowledge in this arena. The results of which are addressed below.  
In all, the paper included 17 studies, 76% of which were cross-sectional, with a total sample of 
4,322 subjects over the age of 18, recruited principally from IBD specialty clinics (92%). None 
of the reviewed studies used a power calculator to estimate sample size and only one study 
reported procedures for handling missing data. Europe was the country in which 65% of the 
studies originated with the remaining conducted in North America. Measurement of adherence 
occurred using an assortment of methods:  self-report (interview, questionnaire, VAS, and 
diaries), serologic and urine samples, as well as administrative pharmacy data and was reported 
in the range of 7-72%. The highest rates of non-adherence (30-43%) appear with use of self-
report tools.  
While no variables consistently demonstrated an associated with non-adherence, the 
following primary factors related to non-adherence were identified: younger age, employment, 
single status, shorter disease duration, active disease, patients in remission, poly-pharmacy, pill 
burden, immune modulator medication, lack of confidence in physician, and psychological 
distress. Intriguingly, non-adherence was not associated with the number of primary care visits, 
time since last outpatient visit, and time since last colonoscopy.   
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Further discussion of IBD medication adherence research ensues. The passages that 
follow provide further detail regarding rates and factors of adherence as well as methods used to 
measure adherence.  
Rates and Predictors of Adherence in IBD 
(Linderberg, C. S., Solorzano, R. M., Vilaro, F. M., and Westbrook, L. O., 2001) argued 
that the initial step in building science is qualitative inquiry. Remarkably, the two qualitative 
adherence studies conducted in patients with IBD occurred simultaneous to the discipline’s 
quantitative work. 
(A. Hall & Porrett, 2006)  interviewed six patients from an IBD specialty clinic in the 
United Kingdom, in a study designed to explore factors affecting medication adherence in 
patients with IBD. The authors discovered ten categories encapsulating the experiences of 
patients regarding factors that affected compliance. These included beliefs regarding medication, 
side effects, length of time and experiences since diagnosis, social support, medication regimen 
and routine, practicality of the administration of medication, costs of prescription and 
communication regarding a change in medication, supportive medical staff, access to healthcare 
services, and information resources. The findings of this study mirror results of quantitative work 
simultaneously performed by the researchers of the discipline. The authors conceded that factors 
influencing medication adherence in this cohort are multifactorial, contemporaneous, and fluid.  
(Moshkovska, Stone, Baker, & Mayberry, 2008) directed the only other qualitative study 
to examine medication adherence in IBD. The authors used grounded theory approach to 
explored patients’ experiences and rationale for medication taking behavior in 17 ulcerative 
colitis patients from specialty clinics in the UK. Analogous with quantitative findings, this study 
demonstrated the impact of patient information on medication adherence as reflected by two key 
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determinants: patient beliefs about medication and the quality of the doctor-patient relationship. 
Lack of perceived benefit and paucity of disease information were barriers to adherence. Factors 
identified as associated with an increased risk for non-adherence included: complicated dosing 
regimens, less active disease, younger age, new patient status, forgetfulness, and inadequate 
information from healthcare providers. All of which have been identified as risk factors for non-
adherence by quantitative measure.  
Researchers considering findings from quantitative investigations examining IBD 
medication adherence need to consider the origin of the rates and factors presented, i.e. rates and 
factors associated with adherence versus non-adherence, as there is no consistency in reporting 
across studies. Additionally, IBD adherence researchers will report adherence rates as complete 
or partial, creating further complexity when interpreting results across studies.  Because 
ultimately, accurately identifying barriers to adherence, influences creation of intervention(s) to 
improve rates targeted to the appropriate audience.  
The literature suggests that generation of effective adherence interventions may have a 
greater impact on the health outcomes of a population than any improvement in medical 
treatment (Haynes, Ackloo, Sahota, McDonald, & Yao, 2008). Interventions should be tailored 
to a particular illness as well as healthcare system as no single intervention has proved effective 
across all patients, conditions, and settings (World Health Organization, 2003). In this case, 
veterans with IBD receiving care for this disease in the VA healthcare system.   
Another consideration of IBD adherence study findings is the fact that very few 
investigations report use of a power calculation to estimate required sample size. Therefore, there 
is a risk that some non-significant findings occur due to a lack of power rather than a lack of 
effect. Generalization of study conclusions due to omission of power analysis occur as well. 
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Additionally, variables mentioned in the methods segment of publications did not appear in the 
results section, making it difficult to assess if any significant findings resulted from this data 
collection.  
There were no studies in this review conducted solely to report rates of medication 
adherence in this population. Intuitively, factors associated with non-adherence provided further 
insight into the medication taking behavior of this cohort. Reports of adherence rates and factors 
associated with adherence/non-adherence make up the vast majority of medication adherence 
investigations in IBD, a summary of which is located in Table 4. As found extensively  
throughout the literature, organization of adherence factors in IBD for this review is by patient 
factors, health system factors, and condition factors. 
Patient  factors 
Patient factors regarding adherence include employment status, educational attainment, 
socio-economic status, treatment cost, race, age, social support, community service utilization, 
gender, illiteracy, patient beliefs and perceptions, knowledge of condition, marital status, 
confidence in treatment, patient/provider relationship, disease stigma, comorbidities, and 
attendance at follow up appointments (S. V. Kane, 2008). 
Race 
A decade ago, world experts in chronic disease adherence recognized race as an 
independent predictor of adherence (World Health Organization, 2003) . Conversely, a meta- 
analysis of the last 50 years of adherence research performed about that same time (DiMatteo, 
2004) reported age, gender, level of education, and socioeconomic status as having a significant 
impact on medication adherence. However, race was not acknowledged in the analysis as a  
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Table 4 
 
Summary of  Non-Adherence Rates and Factors Associated with Adherence and  
Non-adherence in IBD 
 
 
Author 
 
Year 
 
Country 
 
Sample 
Size 
 
Non-
Adherence 
Rate 
Factors Associated with  
Adherence (A) &  
Non-Adherence (NA) 
 
Baars 
 
2009 
 
Netherlands 
 
1,067 
 
13% 
 
A: shorter disease duration(< 8  
     years), older age, CD diagnosis 
 
Bermejo 2010 Spain 107 69% NA: lack of information about  
       disease, > 3x daily dosing 
 
Bernal 2006 Spain 214 43% A: complicated disease course 
 
Bhatt 2009 India 127 81% NA: taking >4 meds daily 
 
Bokemeyer 2007 Germany 65 9% NA: fear of adverse drug reaction, 
employment 
 
Cerveny(a) 2007 Prague 396 32% NA: > disease activity 
 
    Cerveny 
 
 
 
D’Inca 
2007 
 
 
 
2008        
Prague 
 
 
 
Italy                 
177 
 
 
 
485 
39% 
 
 
 
39% 
NA: higher levels of education, 
disease > 10 years, younger age, lack 
of confidence in treatment 
 
NA: younger age, employment 
 
Ediger 2007 Canada 326 25%M 
37%F 
NA Men: diagnosis of UC, full time 
employment; NA Female: younger 
age 
 
      
Horne 
 
 
 
 
Kane(a) 
 
 
Kane(b) 
2009 
 
 
 
 
2000 
 
 
2001 
UK 
 
 
 
 
U.S. 
 
 
U.S. 
1,871 
 
 
 
 
98 
 
 
94 
29% 
 
 
 
 
<25% 
 
 
60% 
NA: doubts about need for 
medication, younger age, shorter 
disease duration (<5 years), fewer 
outpatient visits (<3 a year) 
 
NA: male gender, shorter length of 
remission 
 
NA: less extensive disease, male, 
single, left sided disease, taking > 4 
medications daily 
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Table 4 (continued) 
 
 
Summary of Non-Adherence Rates and Factors Associated with Adherence and  
Non-adherence in IBD 
 
 
Author 
 
 
Year 
 
Country 
 
Sample 
Size 
 
Non-
Adherence  
Rate 
 
Factors Associated with Adherence (A) 
&  
Non-adherence (NA) in IBD 
      
Kane(c) 
 
 
Khan 
 
Lachaine 
2003 
 
 
2013 
 
2013 
U.S. 
 
 
U.S. 
 
Canada 
99 
 
 
13,062 
 
1,681 
12% 
 
 
43% 
 
72% 
NA with meds increases disease 
recurrence 
 
NA: increased risk of disease flare 
 
A: male, older age (>60yo), current 
use of steroid. 
 
Lopez san 
Roman 
2005 Spain 40 72% NA: lower quality of life scores, less 
active disease, high depression scores, 
high patient MD discordance, longer 
duration of disease, lack of treatment 
info, lack of trust in MD 
  
Mantzaris 
 
 
Mitra 
2006 
 
 
2012 
Greece 
 
 
U.S. 
28 
 
 
1,693 
64% 
 
 
72% 
NA: male gender, single status, taking > 
5 meds daily 
 
NA: increased healthcare costs 
 
Moshkovska 2009 U.K. 169 32% 
 
NA: younger age, doubts about need for 
medication, South Asian ethnicity 
 
Nahon 2011 France 1,069 10% A: older age, treatment with TNF, 
membership in support group NA: 
constraints r/t treatment, anxiety, 
smoking, and moodiness 
 
Nguyen 2009 U.S. 235 35% A: trust in MD, increasing age, lower 
QOL, white race 
 
Nigro 
 
 
Robinson  
  
Selinger 
2001 
 
 
2013  
  
2013 
Italy 
 
 
UK.  
  
UK 
85 
 
 
1,200  
  
356 
18% 
 
 
39%  
  
28.7% 
A: shorter disease duration, NA: disease 
severity and psychiatric diagnosis 
 
NA: greater risk of relapse, switching > 
risk of relapse  
NA: doubts about need for medication 
 
Sewitch 2003 Canada 153 41% NA: less active disease, shorter disease 
duration, no scheduling f/u, with MD < 1 
year 
 
Shale 2003 U.K. 98 43% NA: 3x daily dosing, full time 
employment, depression 
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variable having considerable influence on this construct. Similar opinion purveys the vast 
editorial work published on IBD adherence in the last five years and race was not purported to be 
a mediator of consequence in any of these papers (Bernick & Kane, 2010; S. V. Kane, 2008; 
Lakatos, 2009; Lichtenstein, 2008; Selinger, Robinson, & Leong, 2011).  
Meanwhile, a systematic review was done to examine racial and ethnic disparities in 
patients who utilize VA health services. (Saha et al., 2008), found inequalities in VA across 
many clinical areas and service types. Discrepancies were most prevalent for medication 
adherence, patient-provider communication, and shared decision-making suggesting that 
intervening may improve outcomes in these subjects. Results of the Saha study provided 
additional support for further study into the impact of race on non-adherence in veterans with 
IBD who use the VA to access healthcare.  
Literature promulgated by IBD experts suggested focusing efforts on modifiable 
components of adherence, such as patient/provider relationships, versus emphasizing the impact 
of a non-modifiable risk factor such as race. Consequently, there was only one study in this 
review conducted specifically to examine the effect of race on adherence in this cohort. IBD 
subjects from a specialty clinic (n = 120 Black and 115 White) were included in a cross-
sectional, prospective cohort to determine whether medication adherence differed among Black 
and White IBD patients (Nguyen, Munsell, & Harris, 2009). Overall rate of adherence in this 
study was 65%. Blacks had significantly higher rates of non-adherence than White counter-parts 
(50% versus 80%, OR 0.25, 95% CI 0.14-0.48) which persisted after adjustments for 
confounders had been made (OR 0.29, 95% CI 0.13-0.64).  
The only other study in this review that discussed race was conducted by (Moshkovska et 
al., 2009) in a sample of patients (n = 151) with ulcerative colitis from the UK. The only 
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demographic variable independently associated with non-adherence was South Asian ethnicity 
(OR 2.940, 95% CI 1.303-6.638) which made up only 19% of this sample. 
Interestingly, an additional goal of the Moshkovska study included assessment of the 
correlation between adherence and the patient/provider relationship, which was the risk factor 
concentrated on in the aforementioned editorials as having the utmost impact on improvement of 
medication taking behavior in this population. Patient trust in the physician displayed the 
strongest correlation independently associated with adherence (R = -0.30) with no observed 
differences between Blacks and Whites noted (R = -0.25 versus -0.30, p = 0.8).   
Lack of data concerning the influence of race on medication adherence in patients with 
IBD represents a gap in the literature. The literature suggests that treatment disparities based on 
race, found in other chronic disease states, may also exist in IBD but this relationship is not 
readily understood (J. F. Jackson & Kornbluth, 2007). Furthermore, research suggests that racial 
disparities exist in the VA system (Saha et al., 2008) However, little is known of how race 
influences chronic illness care in veterans with IBD.  
(Sewell, Yee, & Inadomi, 2009) provided support for further investigation of the 
influences of race on adherence in a study done to assess the trends of hospitalization among 
minority patients with IBD, which showed statistically significant increases in admissions among 
all race groups, particularly Asians, as non-adherence has been implicated in increased 
healthcare utilization. Additionally, a systematic review demonstrated a rise in the incidence rate 
of IBD among Hispanics (from 2.6 to 7.5 per 100,000 and Asians (from 0.22 to 3.62 per 
100,000). This study also showed that minorities have a more complicated disease course. Both 
of these issues provided support for further inquiry regarding the effects of race on medication 
adherence, in this growing patient population, for which little is known (Ho et al., 2009). 
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Age 
In other chronic disease states, younger age is widely accepted as a risk factor for non-
adherence (DiMatteo, 2004). This too appears to be the case in IBD as demonstrated by many 
studies in this review (Cerveny et al., 2007; D'Inca, Bertomoro, Mazzocco, Vettorato, & 
Rumiati, 2009; Ediger et al., 2007; Horne, Parham, & Robinson, 2009; Moshkovska et al., 2009; 
Sewitch et al., 2003; Shale & Riley, 2003) . Higher rates of non-adherence among younger 
individuals may be exceptionally problematic in IBD because the onset of disease most often 
occurs in the late teens and early 20s.  
Remarkably, four studies revealed older age as a significant independent predictor of 
adherence ((Lachaine et al., 2013)) (OR=1.6, CI 1.3-2.0), (Nahon et al., 2011)  (p < 0.01), 
(Nguyen, Tuskey, Dassopoulos, Harris, & Brandt, 2007)  (p = 0.01, R = -0.19), and  (Baars et al., 
2009) (p = 0.01, OR 1.57, 95% CI 1.2-2.02). However, these results are not surprising given that 
as age increases, so does adherence until the seventh decade when treatment adherence levels off 
or begins to decrease (Mehta, Moore, & Graham, 1997). This study helped fill a gap in the 
literature regarding the impact of age on medication adherence in veterans with IBD for which 
little data exists. 
Gender 
A meta-analysis conducted to analyze rates and predictors of adherence across disease 
states in the last 50 years showed a lack of correlation between gender and adherence (DiMatteo, 
2004). Additionally, international recommendations to improve adherence to long-term therapies 
(World Health Organization, 2003), a widely referenced medication adherence paper (Osterberg 
& Blaschke, 2005), as well as two recent systematic reviews (Gellad, Grenard, & Marcum, 2011) 
and (Ingersoll & Cohen, 2008) all fail to recognize gender as having significant impact on 
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medication adherence. However, a comprehensive review done to catalog barriers to medication 
adherence, demonstrated conflicting results regarding the influences of gender on adherence in a 
variety of conditions (Krueger et al., 2005). 
Similarly, the consequences of gender on adherence in IBD are mixed. Several studies 
showed no impact of any demographic variable inclusive of gender (Cerveny et al., 2007; Lopez 
San Roman, Bermejo, Carrera, Perez-Abad, & Boixeda, 2005b) . Men were more likely to be 
non-adherent in four studies ((D'Inca et al., 2009; S. Kane, Cohen, Aikens, & Hanauer, 2001; 
Lachaine et al., 2013; Mantzaris et al., 2007)). Whereas, (Waters, Jensen, & Fedorak, 2005) 
demonstrated women were more likely to be non-adherent in an interventional study.  
Noteworthy results were produced by (Ediger et al., 2007) who reported different 
predictors of low adherence for men and women. For men, predictors of low adherence included 
a diagnosis of UC (OR 4.42, 95% CI 1.66-11.75), being employed full-time (OR 11.27, 95% CI 
2.05-62.08) having high scores on obstacles to medication assessment, and having a low level of 
personality agreeableness. For women, predictors of low adherence include younger than 30 
years of age (OR 3.64, 95% CI 1.41–9.43), high scores on obstacles to medication assessment 
(OR 3.89, 95% CI 1.90–7.99) , and low level of agreeableness (OR 2.03, 95% CI 1.12–3.66). 
Research suggests that addressing the impression of non-modifiable demographic variables such 
as gender, on adherence, are not as important as concentrating on modifiable elements (Albaz, 
1997). However, a lack of clear understanding about the impact of gender on medication 
adherence in patients with IBD warrants further investigation, particularly due to the potential 
deleterious effects of non-adherence with medical therapy during pregnancy (Katz & Pore, 
2001). 
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Employment, marital status, and education 
IBD tends to onset at a younger age when decision regarding employment and education 
are considered. IBD can have a labile course interfering with fulfillment of pursuits, a course 
exacerbated by non-adherence to treatment. A review demonstrated that patients with IBD have a 
higher rate of nonparticipation in the labor force (Marfi & Buchman, 2005). This same review 
found similar levels of educational attainment among those with IBD when compared to the 
general population.  
Studies conducted by (Ediger et al., 2007) (OR 11.27, 95% CI 2.05-62.08) and (Shale & 
Riley, 2003) (OR 2.7, 95% CI 1.1-6.9) revealed full-time employment as a risk factor for non-
adherence. Whereas, (Bernal et al., 2006) demonstrated that unemployment was a risk factor for 
non-adherence but was noted to not have reached statistical significance. A weakness of the 
Bernal study was a lack of reporting of the set level of significance for the analysis.  
Only one study in the review found any correlation between non-adherence and level of 
education. Higher levels of education were associated with increased levels of non-adherence  
(p = 0.046) in a Czech Republic sample (Cerveny, Bortlik, Vlcek, Kubena, & Lukas, 2007). 
 Likewise, only one study found any correlation between marital status and non-
adherence. Single status was a predictor of non-adherence in the 2006 Mantzaris study. 
Intriguingly, being married was supportive of adherence (OR, 95% CI 0.39-0.57) (S. Kane et al., 
2001) . 
These contradictory findings across a variety of demographic factors, speaks to the 
complex nature of medication adherence in this cohort. In addition, the lack of knowledge related 
to demographic factors and medication adherence represents a gap in the literature and need for 
further study. 
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Health System Factors 
Patient/provider relationship, medication access, patient education, patient follow up, 
interventions to improve adherence, organization and coordination of healthcare services, 
utilization of healthcare resources, and healthcare costs are all examples of variables categorized 
as health systems factors in regard to medication adherence (World Health Organization, 2003). 
Each of these are discussed below. 
Patient/provider Relationship 
Two studies explored the influence of patient/provider relationships on medication 
adherence in IBD. Instinctively, lower rates of adherence occur when patient/provider 
interactions are less than ideal.  
Ten gastroenterologists and 153 of their adult IBD patients were the subjects in a 
prospective, Canadian study performed to identify determinants of non-adherence in IBD and 
assess the impact of patient-physician discordance on adherence (Sewitch et al., 2003) . 
Discordance describes physician and patient perceptions of the patient’s health status and of the 
clinic visit, as measured by a survey completed independently immediately after the office 
encounter. The outcome variable was medication adherence as measured by the validated MAS-
4. Results showed total non-adherence to be 41% or 63 of the patients. Patient-physician 
discordance (OR = 1.59, p = 0.0120), consulting a health professional and new patient status (OR 
2.80, p = 0.0239) were predictors of non-adherence.  Interestingly, patients treated by the 
physician for < 1 year had an 84% higher risk of non-adherence than those treated by the same 
physician > 1 year.  
An IBD specialty clinic in Spain was the setting for a 2005 study conducted by (Lopez 
San Roman, Bermejo, Carrera, Perez-Abad, & Boixeda, 2005a) designed to investigate the 
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degree of adherence to therapy and to identify factors affecting medication adherence in this 
cohort (n = 40). The authors also collected data on depression, patient-physician discordance, 
QOL, and disease activity. Medication adherence measurement took place using the MAS-
4.Total non-adherence was 72%. However, to keep this high rate of non-adherence in context, 
the MAS-4 does not quantify the amount of medication omitted. It merely denotes if the patient 
had ever missed a dose of medication. The results showed a higher degree of non-adherence was 
associated with patient-physician discordance scores (p = 0.01) and those who trusted their 
physicians less (p = 0.03).  
Coordination of Care 
The literature suggests that organizational variables, such as number of provider visits, 
both  to primary and specialty care, as well as continuity of care, may have a far greater impact 
on medication adherence than demographic variables (Albaz, 1997). Furthermore, coordination 
of care between primary and specialty care is requisite to improve adherence (MacColl Institute 
for Healthcare Innovation, 2010). However, the results from a Cochrane review (S. M. Smith et 
al., 2009) conducted to assess the effectiveness of care coordination between primary and 
specialty care, in chronic disease management, were conflicting. Overall, no consistent 
improvement in outcomes across disease states materialized with the exception of medication 
adherence that indicated significant benefit with coordination of care in this realm.  
(Herrinton et al., 2007) conducted a study to explore the variations in IBD practice 
patterns and outcomes over a decade (1998-2005) across medical centers in an integrated  
 healthcare plan in the U.S. in 2,892 adults with CD and 5,895 with UC. Health plan 
administrative data provided information for this study. The healthcare system under 
investigation had many similar features of the VA such as a closed pharmacy system housed 
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within multiple medical centers campuses that include inpatient care, outpatient clinics, 
laboratory, and x-ray services. Most medical centers had GI services but no specialty IBD 
clinics. No endorsement of IBD practice guidelines existed. Primary care providers had 
privileges to write for all drugs to treat IBD, save anti-TNF medications. The results showed a 
striking shift of IBD care from specialty care to primary care with GI consultation provided as 
deemed necessary.  
The notion of coordination of care is widely endorsed by the VA healthcare system (Asch 
et al., 2004; McQueen, Mittman, & Demakis, 2004). Yet, coordination of care in the VA has not 
been systematically assessed (Neugaard et al., 2011). The primary care service line in VA acts as 
a gatekeeper for access to specialty care thereby, coordinating care, such that veterans cannot 
obtain specialty care without submission of a specialty consult by the primary care provider.  
Although a multidisciplinary approach to chronic illness care in IBD is suggested 
(Hernandez-Sampelayo et al., 2010), IBD management by primary and specialty care has not 
been critically evaluated (Herrinton et al., 2007) as there were no studies in this review that 
examined this conception. This may be due in part to the fact that while the discussion of IBD 
care organization adopts the input of many disciplines, the focus remains on the contributions 
made from other specialties such as surgery, radiology, pathology, dermatology, rheumatology, 
and ophthalmology and not primary care (Mikocka-Walus et al., 2012; Ricci, Lanzarotto, & 
Lanzini, 2008). The dearth of information regarding coordination of care between primary and 
specialty care in the management of IBD in the VA system supported the need for further inquiry 
in this realm.  
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Healthcare Utilization 
Direct healthcare costs estimates are $3.1 billion for CD and $2.1 billion for UC. 
(Kappleman et al., 2008). A disease flare, perhaps compelled by non-adherence to therapy, could 
influence the need for health services.  
World adherence experts (World Health Organization, 2003) provide support for 
examination of the variables associated with healthcare utilization concurrently with medication 
adherence rates as this data works synergistically to accurately inform health outcomes and 
future interventions. Furthermore, the authors encourage exploring these constructs using a 
systems model such as the CCM as a guide. Therefore, this study began to explore the 
relationship between medication adherence and healthcare utilization in veterans with IBD who 
use the VA healthcare system. Healthcare utilization in this study included outpatient visits to 
primary and Gastroenterology (GI) specialty care, ER usage and inpatient admissions for IBD 
related illness.  
(Kappleman et al., 2011) conducted a study aimed to describe the healthcare utilization 
associated with IBD in an insured U.S. population 2003-2004 using the administrative databases 
of 87 health plans in 33 states to identify those with IBD using ICD-9 code 555.x for CD and 
556.x UC.  The mean number of office visits per 100 patients with CD was 167 primary care and 
179 GI-specialty, and for UC, 151 primary care and 128 GI-specialty. Overall, the results 
demonstrated that healthcare utilization was higher in the IBD population when compared to 
non-IBD controls. This is consistent with a paper by (Shi & Singh, 2012) which also reported 
healthcare utilization rates to be much higher in IBD than for other Americans who on average 
who make three visits a year to see a provider. A lack of healthcare utilization data in veterans 
with IBD supported analyzing this topic.  
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Similarly, (Ananthakrishnan, McGinley, Saeian, & Binion, 2010) conducted a study 
exploring the trends in outpatient and ER visits for IBD in the U.S. 1994-2005. While cohort 
generation for this study was the same as the (Kappleman et al., 2011) study, other differences in 
study design make comparison of investigational results difficult. The (Ananthakrishnan et al., 
2010) study data source originates from surveys within the National Health Care Survey that is 
used to inform the conceptual definitions for this study. The results demonstrated a 55% increase 
(95% CI, 1.4-2.2) in outpatient visits as well as a 165% increase (95% CI, 42,498-112,257) in 
ER visits in this population during the observation period. The authors advised further 
investigation into the influences on increased healthcare utilization in patients with IBD.  This 
study began to close this information gap by initiating exploration of the relationship between 
medication adherence and healthcare utilization in the VA population.  
A U.S. based study conducted by ((Mitra, Hodgkins, Yen, Davis, & Cohen, 2012)) 
examined the association between medication adherence and healthcare utilization in 1,693 
subjects using administrative data. Adherent subjects had 31% fewer hospitalizations (p = 
0.0025) as well as 34% fewer ER visits (p = 00016) when compared to non-adherent 
counterparts. 
Most recently, researchers in Australia (Sack et al., 2012) conducted a study using the 
CCM as a template for implementing a formal IBD Service in 100-200 patients with IBD to 
examine the effects of the Service on healthcare utilization. This is the first study in patients with 
IBD to use the CCM. While the authors did not declare the specific Model elements tested, 
application of the Model for this study is counterintuitive as the Model has origins in primary 
care, not specialty care as the authors present. Use of the Model in this manner is also 
asynchronous to knowledge building, as the descriptive work in this field is not accomplished.  
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However, the authors did note that 30% of subjects received IBD care from non-
gastroenterologists again, exploration of this relationship did not occur, a critical missing piece 
to the use of the Model. The intervention consisted of a team approach led by a 
gastroenterologist, an IBD nurse, surgical team, and radiology. Formal protocols tracked chronic 
illness care in this cohort. The results demonstrated a lower number of inpatient admissions in 
the treatment group (1.53) compared to controls (2.54, p < 0.0001). The costs of the admission 
were also lower in the treatment group ($12,857) versus controls ($30, 467, p = 0.005). The 
researchers concluded the intervention a success. 
Four studies in this review reported on healthcare utilization variables in relationship to 
medication adherence. None of the reviewed studies declared healthcare utilization as the 
primary outcome variable.  
The first study, conducted by (Horne et al., 2009) reported on the effects of outpatient IBD 
visits on medication adherence in 1,871 (63% female, 45% CD, 49% UC, mean age 50) 
members of the UK National Association for Colitis and Crohn's Disease (NACC) who were 
randomly chosen from the organization's database. This is the only IBD adherence study to 
catalog data on the annual number of IBD related visits to the patient's PCP, as well as the 
number of outpatient and inpatient IBD related visit in the previous year. Roughly, 33% of 
subjects had three or more IBD related PCP visits in the last year, and an equal percentage of 
subjects, had no PCP visits in the last year for IBD related illness. While another third, claimed 
three or more annual IBD specialty visits. Interestingly, the vast majority of subjects (80%) did 
not have any hospitalizations in the year for IBD related illness. This data is suggestive of 
quiescent disease in this cohort. Logistic regression showed that younger age, disease duration > 
5 years (OR 1.96, 95% CI 1.43-2.69, p = 0.000) and fewer outpatient visits were significantly 
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associated with rates of low adherence. The findings of this study support the need for 
forthcoming research to examine more fully the effects of healthcare follow-up on mediation 
adherence in this population.  
The second study in this review reporting an association between non-adherence and 
increased healthcare utilization was done by (Waters et al., 2005) who randomized 69 IBD 
patients to a nurse-lead education interventions and standard of care. Over the four- week 
observation period, the subjects had 44 outpatient visits, 16 for symptom control and 33 for 
follow-up. Patient diaries provided medication adherence information. Subjects also had four ER 
visits and five inpatient admissions. Although not statistically significant (t = 1.06, p = 0.294), 
the educational group had lower rates of healthcare use (M = 0.63) than the control group  
(M = 0.95). Those who reported missing medication in their diaries had significantly higher rates 
of outpatient visits (p = 0.01). 
(Sewitch et al., 2003) conducted the third study in this review to identify determinants of 
non-adherence in IBD. The outcome variable was medication adherence as measured by the 
validated MAS-4 showed total non-adherence to be (n = 63) 41%. Scheduling a follow-up 
appointment (OR = 0.30, p = 0.0059) and new patient status (OR 2.80, p = 0.0239) were 
significant predictors (p  < 0.05) of non-adherence. Interestingly, patients treated by the 
physician for < 1 year had an 84% higher risk of non-adherence than those treated by the same 
physician > 1 year.  
Data for the final study in this review to examine healthcare utilization and medication 
adherence originated from a community health insurance program database. This sample 
represents the largest retrospective cohort of patients with IBD year to date (n = 4,313) which 
assessed medication adherence using the MPR to determine the association between adherence 
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and healthcare costs from the payer's perspective (S. V. Kane, 2008). Overall, just over half 
(57.2%) of the subjects were adherent to treatment (i.e. MPR > 80%). Adherence was associated 
significantly (p < 0.05) with 62% lower costs for hospital admissions (p < 0.001), 13% fewer 
outpatient visits (p <0.05), 45% fewer ER visits (p < 0.001), and 49.8% lower total healthcare 
costs (p <0.001). The authors also controlled for comorbidity during multivariate analysis. A 
CCI was generated with ICD-9 codes from administrative data as posited by the (Deyo et al., 
1992) algorithm. Study results demonstrated that higher levels of comorbidity were associated 
with increased healthcare costs (p < 0.0001). 
Results of these studies demonstrate the impact of non-adherence on healthcare 
utilization in patients with IBD. However, a lack of information in this regard in VA represents a 
gap in the literature and endorsed auxiliary exploration into the effects of adherence on  
healthcare utilization in this cohort.  
Interventions to improve adherence in IBD 
Ultimately, the results of this study would support future generation of interventions to 
improve medication adherence in patients with IBD. Therefore, although this is a descriptive 
study, it was important to establish the state of interventional knowledge promulgated in the field 
to address adherence issues in this population as this data will apprise the generation of future 
endeavors.  
There was only one interventional study, conducted specifically to examine the effects of 
an intervention to improve medication adherence in patients with IBD.  Stable  patients (n = 81) 
from a specialty IBD clinics were randomized to either a 23 week independent ,community, 
nurse-delivered patient support program (n = 21) or standard of care (n = 60).   
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Patients with an MPR > 80% were deemed adherent to treatment as measured at 3 
months and 6 months in the Moss study. At three months, the rate of adherence was 39% for the 
control group and 44% for the experimental group. At six months, rates of adherence increased 
to 50% in the control group and 67% for those in the patient support group.  However, the 
differences in adherence for the two groups was not statistically significant (p = 0.3). 
Furthermore, there was no association between the community educated group and adherence at 
3 (OR 1.2, 95% CI 0.4-3.8) or 6 months (OR 2, 95% CI 0.6-7). The authors concluded that a 
nurse-delivered patient-support program did not significantly improve adherence when compared 
to standard of care.  
Condition Factors Affecting Adherence in IBD 
Several condition factors were identified as affecting adherence in IBD.  Condition 
related factors were disease recurrence, severity of disease, illness duration, disability, 
availability of effective treatment, pill burden, duration of treatment, and side effects are 
condition factors under consideration discussed as follows. 
Pill burden 
Pill burden refers to the total number of pills an individual takes in a day. Pill burden may 
also refer to the number of pills and doses required daily for each specific medication regime. 
Universally, higher pill burden is associated with decreased medication adherence. A systematic 
review done to examine the impact of regime factors on medication adherence in a variety of 
chronic illnesses confirmed this notion (Ingersoll & Cohen, 2008).  
Pill burden is of particular consequence in IBD as some of the medications used to treat 
the illness require two or more tablets to be taken up to four times daily with the worst case 
scenario of a total of 12 tablets to be taken daily for one medication to treat IBD. The impact of a 
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complex medication regime on adherence, not only because of the number of tablets taken per 
day, but also dosing frequency, is obvious. This study will provide insight into the impact of pill 
burden on veterans with IBD by using refill data to measure medication adherence, not only to 
collate the types of medications taken for this condition, but also to explore the number of tablets 
and dosing patterns prescribed and the effects of such on adherence.  
The literature produced mixed results regarding pill burden. Two studies did not include 
any information about the influence of pill burden on medication adherence in the results section 
of the papers (Bokemeyer et al., 2007; Lopez San Roman, Bermejo, Carrera, Perez-Abad, & 
Boixeda, 2005b).  Three studies found no relationship between the type of drug, number of 
drugs, and the number of pills administered and medication adherence (D'Inca et al., 2009; 
Ediger et al., 2007; S. Kane, Huo, Aikens, & Hanauer, 2003) .  
Two studies showed a relationship between pill burden and medication adherence. (Shale 
& Riley, 2003) examined adherence in 98 patients from a specialty practice in the UK and found 
that three-times-daily dosing was the only significant independent predictor of partial non-
adherence (p = < 0.01, OR 3.7, 95% CI 1.8-8.9). Similarly, (S. Kane, Huo, Aikens et al., 2003)  
conducted a study to determine adherence rates and predictors of non-adherence in 94 patients 
from a specialty IBD clinic. The overall rate of adherence was 40%. The results demonstrated 
that a history of taking more than four concomitant medications was associated with a two and a 
half times increased chance of non-adherence (OR 2.5, 95% CI 1.4-5.7).  
Disease Recurrence 
Disease recurrence in patients with IBD, as impacted by medication non-adherence, was 
the primary variable of interest in several studies published in the last decade   (S. V. Kane & 
Hanauer, 2000; S. Kane, Huo, Aikens et al., 2003; Khan, Abbas, Bazzano, Koleve, & Krousel-
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Wood, 2012; Robinson, Hankins, Wiseman, & Jones, 2013).  All investigations measured 
medication adherence using pharmacy refill data. The largest cohort was found in the (Khan et 
al., 2012) study that had 13,062 subjects, followed over a 10 year period and demonstrated a 1.17 
times increased risk of disease flares in non-adherent subjects.  
(S. V. Kane & Hanauer, 2000) documented adherence rates and disease recurrence at 6 
and 12 months. At 6 months, 12 patients (12%) had clinical recurrence all of which had 
medication compliance <75%. The median amount of medication consumed was statistically 
significant, 26% versus 83% for those still in remission (p = 0.001). At 12 months, an additional 
19 patients had recurrence, 68% (n = 15) of which were non-adherent. The median amount of 
medication taken was 80% for those in remission and 45%% with recurrence (p = 0.02).  
As well, in the (S. Kane, Huo, Aikens et al., 2003) study, at 6 months, 12 patients had 
recurrence of disease, all of which were non-compliance with medication. The median 
percentage of mesalamine refilled was 51% for those who were non-compliant compared to 77% 
for those still in remission. By 12 months, 19 additional patients had disease recurrence, 68% of 
which were non-compliant. Patients who were non-adherent had more than a fivefold greater risk 
of recurrence than patients who adhered (hazard ratio= 5.5, 95% CD 2.3-13, p = <0.001). 
Robinson used pharmacy data from the UK to examine the relationship between  
non-adherence, medication switches, and disease recurrence in 1,2000 subjects. The results of 
logistic regression revealed that patients who switched mesalamine maintenance preparations 
had a 3.5 fold greater risk of relapse than those who did not switch (95% CI = 1.16-10.62, p = 
0.008). Although not the primary outcome variable, patients with non-adherence were three 
times more likely to develop disease recurrence (OR 3.389, 95% CI 1.29-8.88, p = 0.012) in a 
study conducted with 127 patients with IBD (Bhatt et al., 2009). 
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Methods Used to Measure Adherence in IBD 
All of the studies in this review examining medication adherence in IBD occurred in the 
last decade. Table 5 contains a summary of tools used to measure medication adherence in this 
population. The majority of investigations (9) used non-validated, study specific instruments to 
collect adherence data. The method utilized to measure adherence was not transparent in three  
additional studies. Several studies contained less commonly used adherence measures such as 
drug serology (1), visual analog scale (VAS) (2), urine drug level (2), and patient diary (1). Five 
studies contained variations of the same self-report measure, the Medication Adherence Report 
Scale (MARS): MARS-4 (2) and the MARS-5 (1). The MARS eventually became the Morisky  
Medication Adherence Scale (MMAS-8). Five studies, all conducted by the same author (Kane) 
used pharmacy refill data to gather adherence information. Retrospective data analysis was the 
method of choice in three studies. Further discussion of adherence measurement in IBD will 
focus on the MMAS-8 as this is only validated self-report tool in IBD and assessment of 
adherence using pharmacy data as this is the method utilized for this study.  
MMAS-8 
 (Trindale, Ehrlich, Kornbluth, & Ullman, 2011)  conducted the first study to validate the 
MMAS-8 in IBD using gastroenterologists (n = 13) and 110 inpatient subjects on a specialized 
IBD service.  The study aim was to determine the level of agreement for adherence between the 
MMAS-8 and perceptions of the treating physician as well as agreement between the MMAS-8 
and pharmacy refill data. Although the cohort consisted of inpatients, the resulting assessment 
was of outpatient medication adherence.  
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Table 5 
 
Summary of Tools Used to Measure Medication Adherence in IBD 
 
 
Author 
 
Year 
 
Measurement Tool 
 
Baars 
 
2009 
 
Unclear, used cut off of > 80% = adherent 
 
Bermejo 2010 Medication Adherence Report Scale (MARS-4) 
 
Bernal 2006 Non-validated study specific self-report survey 
 
Bhatt 
 
2009 
 
Non-validated study specific self-report survey 
 
Bokemeyer 
 
2007 
 
Drug serology/Visual Analog Scale (VAS) 
 
Cerveny(a) 2007 Non-validated modified MARS-4 
 
Cerveny 
 
2007 
 
Non-validated modified MARS-4 
 
Ediger 
 
2007 
 
MARS-5 
 
Horne 
 
2009 
 
 
MARS-4 
Kane 2000 
 
Pharmacy Refill Data 
Kane 
 
2001 Pharmacy Refill Data: MED TOTAL 
Kane 
 
2003 Pharmacy Refill Data: MED TOTAL 
Kane  
  
Khan  
  
Lachaine 
 
2012  
  
2012  
  
2013 
Morisky Medication Adherence Scale (MMAS-8)/MPR  
  
Refill data: MPR, CSA, CMG  
  
Prescription and medical claims: MPR 
Lopez  
San-Roman 
2005 Non-validated study specific self-report survey 
 
Mantzaris 
 
Mitra 
 
2006 
 
2012 
 
Unclear, used cut off of > 80% = adherent 
 
Insurance Claims 
 
Moshkovska 
 
2009 
 
 
Non-validated study specific self-report survey/Urine drug level 
Nahon 2011 Unclear, used cut off of > 80% = adherent, VAS, patient diary 
 
Ngugen 
 
2009 
 
Modified Hill-Bone Compliance Scale (HBCS) 
 
Nigro 
 
2001 
 
Non-validated study specific self-report survey 
 
Robinson 
 
Robinson 
 
2001 
 
2013 
 
Non-validated study specific self-report survey 
 
Refill data: MPR 
 
Trindade 
 
2011 
 
MMAS-8/pharmacy refill data: CSA/MPR 
 
Shale 
 
2003 
 
One non-validated self-report question/Urine drug level  
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The foundation for the MMAS-8 stems from the MARS that views non-adherence in the 
context of forgetting, avoiding, stopping medication, or altering drug dosages. The MARS-4 
expanded into the MMAS-8 that includes dichotomous scoring of the following domains:  
forgetfulness, missing doses, decreasing medication without physician input, forgetting to take 
medications while traveling, decreasing medication when well, and the inconvenience of taking 
medications. One Likert scale question regarding remembering to take medications rounds out 
the questionnaire. A score of 8 on the Scale indicated perfect adherence; scores of 6-7 indicate 
medium adherence; and scores < 6 indicate low adherence.  The results of the MMAS-8 and 
calculated adherence using the CSA and MPR from refill data were compared. Non-adherence 
was denoted for subjects with CSA or MPR <0.8.  
Results identified 54 patients as low adherers and 56 as either medium or high adherers. 
Correlation between pharmacy refill data and scores on the MMAS-8 were found as 85% of low 
adherers had CSA and MPR scores <0.8. Meanwhile, only 11% of medium and high adherers 
had pharmacy refills scores suggestive of non-adherence. Furthermore, physician perception of 
adherence correlated with the MMAS-8 for medium and high adherers (95%) but was only 33% 
for low adherers. Physician overestimation of adherence was statistically significant (p = 
0.0001). 
(S. Kane et al., 2012) sought to build on Trindade's work by conducting a study aimed at 
determining if a correlation existed between a self-report measure, the MMAS-8, and pharmacy 
refill records in 150 (59% female) IBD patients from the Mayo Clinic. Unlike most of the 
adherence studies in IBD, this investigation used a power estimate to calculate sample size. 
Refill data collected retrospectively, 3 months before the study began as well as prospectively, 3 
months and 6 months after the study started, furnished information on medication adherence 
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using the MPR, recognized by the authors as the gold standard for measuring adherence in this 
population. Patients were given an allowable grace period between 80-120% of the expected  
time for a refill. For example, if a refilled date was 30 days, the grace period was between 24-36 
days. Procedures for handling patients falling outside the allowable grace period are unclear. 
Calculation of MPR occurred separately for each drug the patient took, up to three drugs per 
patient. Patients with MPR > 80% were considered adherent. A 5-ASA product was taken by 
47% of subjects, 54% on a thiopurine, 15% on Infliximab along with oral therapy, 8% on an 
injectable biologic, and 6% on budesonide. This was the first adherence study in IBD to provide 
adherence data on most of the agents used to treat the disease. 
Median MPR scores were as follows: 5-ASA 50%, thiopurines 60%, Infliximab 75%, 
injectable biologic 0, budesonide 33%.  Scores of < 6 on the MMAS-8 indicated non-adherence, 
while scores > 6 indicated adherence. The median score on the MMAS-8 was 7 indicating 
roughly two-thirds of the population fit the definition of adherence. The tool identified a third of 
patients classified as non-adherent by MPR. However, using a repeated-measures linear 
regression analysis, the authors demonstrated only one drug class, thiopurines, had an MMAS-8 
score significantly associated with refill data (p = 0.02, correlation 0.26). While the correlation 
between refill data and the MMAS-8 was not noteworthy, use of such a self-report tool in the 
outpatient gastrointestinal setting, may help clinicians identify those at greatest risk for non-
adherence so that generation of individualized patient education and counseling in this regard 
occurs.  
Pharmacy Refill Data 
Kane produced three U. S. based articles in the last decade using pharmacy refill 
information to measure medication adherence in patients with IBD. The first (S. V. Kane & 
  
 85 
Hanauer, 2000)  examined the effect of non-adherence on disease recurrence in patients with 
quiescent ulcerative colitis who take mesalamine.  A "valid calculation" provided information for 
medication adherence using pharmacy refill records. Adherence was defined as consumption of 
<75% of prescribed medication. Patients (n = 98) were interviewed at 6 and 12 months. At 6 
months, 12 patients (12%) had clinical recurrence all of which had medication compliance 
<75%. The median amount of medication consumed was significant, 26% versus 83% for those 
still in remission (p = 0.001). At 12 months, an additional 19 patients had recurrence, 68% (n = 
15) of which were non-adherent. The median amount of medication taken was 80% for those in 
remission and 45% with recurrence which was statistically significant (p = 0.02).  
The second study provided information regarding prevalence of medication adherence as 
well as risk factors for non-adherence in 94 IBD patients with inactive ulcerative colitis (S. Kane 
et al., 2001). Pharmacy refill data provided adherence information to calculate the MED 
TOTAL. Consumption of 80% of prescribed medication equated with adherence. The rate of 
non-adherence was 40%. Those who were male (67% versus 52%, p < 0.05, OR 2.06, 95% CI 
1.17-4.88), single (68% versus 53%, p = 0.04), and had left sided disease versus pancolitis (83% 
versus 51%, p < 0.01) had statistically significant higher rates of non-adherence.  Interestingly, 
two variables, which were statistically significant, were found to be protective against non-
adherence included colonoscopy within the last 2 years (p = 0.03, OR 0.96, 95% CI 0.93-0.99) 
and being married (p = 0.01 OR 0.46, 95% CI 0.39-0.57).    
The final study conducted by this author using administrative data to measure adherence 
assessed patient satisfaction with once daily dosing of mesalamine versus multiple dosing (S. 
Kane, Huo, & Magnanti, 2003). Stable UC patients (n = 22) were randomized to once daily 
dosing (n = 12) or conventional therapy (n = 12). The MED-TOTAL formula supplied 
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information on adherence at 3 and 6 months. Adherence again equated with consumption of  
>80%  of that prescribed. At 3 months, no patients experienced symptoms of relapse and the rate 
of adherence was 100% in the daily dosing group and 70% for those taking conventional therapy. 
At 6 months, one patient from each group experienced symptoms of disease relapse. Both were 
non-adherent to treatment. The average amount of medication taken in the once daily group was 
90% compared to 76% in the conventional group. Patient satisfaction was 83% for the once daily 
dose group at the end of the pilot compared to 60% for those taking multiple doses daily.  
2.6 Veterans Health Administration 
Providing benefits for veterans is unique in the world. The United States has done so in 
some fashion for centuries. The Veterans Health Administration (VHA) is a multifaceted agency, 
with origins in the 1600s, that governs the largest integrated benefits system in the world, 
providing services to honorably discharged members of the U.S. Armed Services. VHA’s 
primary mission is to enhance the health and wellbeing of those it cares for, emphasizing 
functionality of members with service connected injuries (conditions related to military service).   
Over time, as circumstances dictated, this country has evolved a complex organization within a 
politically charged environment, to meet the needs of those who served. Ever mindful of the 
changing demographics of veterans, the many stakeholders associated with veteran benefits, and 
the economic climate in which allocation of resources occurs, VA repeatedly transforms to 
emerge from these challenges. Investigators conducting research in such a unique atmosphere 
will need to be cognizant of how the characteristics of the system affect scientific inquiry.  
2.7 Veterans 
This study will use a systems model, the CCM, as a foundation for examining 
relationships within a closed healthcare system, the VA. While having a tangible appreciation of 
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the VA is crucial, equally important to this investigation, will be a working knowledge of the 
individuals who use the system under consideration. Veterans are a vulnerable population 
because of the presence of multiple disabilities, comorbid mental health diagnoses, substance 
abuse histories, and low incomes in substantive numbers (M. W. Smith & Joseph, 2003). 
2011 Survey of Veterans 
The characteristics of Veterans are ever changing. In an effort to meet the needs of this 
divergent population, the federal government has made it a priority to understand the individuals 
who utilize VA services and what influences their healthcare decision making and health status. 
To attain this objective, since 1999, an annual VHA Survey of Veteran Enrollees' Health and 
Reliance upon VA has been conducted by the Office of the Assistant Deputy Under Secretary for 
health for Policy and Planning (ADUSH/P&P).  Statistics from the survey generate a healthcare 
budget for VA. Additionally, this data informs health policy options that affect medical decision 
making for Veterans. The annual survey occurs in conjunction with OMB authority that 
determines the amount of funding apportioned for Veteran benefits. The survey results represent 
data only for Veterans enrolled in VA healthcare.  
The demographics discussed are from Fiscal Year 2011, the period of observation for this 
study. Therefore, the statistics presented here in should be representative of the population for 
this investigation. Data generation occurs by the Healthcare Analysis and Information Group and 
the Enrollment and Forecasting Service within ADAUSH/P&P. 
Data collection occurred via telephone survey. The observation period was inclusive of 
March 4, 2011 through May 27, 2011. Over 45,000 Veteran users of VA healthcare nationwide, 
chosen randomly, constituted the sample. Weighted results represent the entire population of 
enrollees of approximately 7.8 million Veterans. The survey included the following variables of 
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marital status, age, household income, priority level, period of service, combat status, ethnicity 
and race, employment status, public and private health insurance coverage. Additional variables 
included Medicare coverage, prescription drug benefit or coverage, number and costs of over-
the-counter and prescription medications, key drivers of enrollees' healthcare decision making, 
perceived health status, smoking status, and perceptions of VA healthcare, and planned future 
use of VA (Office of the Assistant Deputy Under Secretary for Health for Policy and Planning, 
2012).  A summary of key variables are below. Unless otherwise noted, all figures are from the 
Office of the Assistant Deputy Under secretary for Health Policy, 2012 report.  
Demographic Variables 
The average age of the patients was 62. The majority of enrollees were married (62%), 
white (80.8%), males (94%) with dependents.  Six percent of the population was Hispanic, 
11.7% African America, and 4.2% were Native American.  
Enrollees served in the military for an average 6.5 years with 43% reporting exposure to 
combat during their service. The greater part of veterans (41%) served during the Vietnam War 
Era.  
Most enrollees (60%) did not work outside the home. The reported median annual 
household income was $35,000. This figure is unchanged for the last five years.   
Health Status and Future Use of VA 
Enrollees under age 45 more often reported positive health status (excellent/very 
good/good).Veterans of OEF/OIF had annual incomes greater than $36,000, and were female. 
This statistic has remained steady in the last decade.  
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Of those enrolled to access VA services, 75% reported that they use VA for at least some 
of their healthcare needs. Veterans with annual household incomes of less than $36,000 were 
more likely to use VA to meet all of their healthcare needs.  
Consistently, for the last five years, at least 45% of enrollees plan to access VA for 
primary care only. Less than 5% plan to use VA for specialty care in the future. The reason for 
this is unclear. The overwhelming majority of patients who use VA services reported in a 
positive manner about their experiences. Predictors of future use of VA benefits were quality, 
cost, and availability and accessibility of services.  
Health Insurance Coverage 
The survey examined availability and use of health insurance by VA enrollees. Health 
insurance was defined as "any program that helps pay for medical expenses, whether through 
privately purchased insurance, social insurance, or non-insurance social welfare programs funded 
by the government" (p.59). Most enrollees (77%) reported some type of public or private health 
insurance coverage in addition to VA benefits. This number has been on a steady decline since 
2008.  Of those with healthcare coverage, 35% are accessing it through an employer.  
Younger Veterans, the unemployed, and those with lower incomes are more likely to be 
uninsured.  This number has grown steadily since 2008 from 34% to 41% in 2011. Medicare 
continues to be the most commonly (51%) reported health insurance coverage.  
Pharmaceutical Coverage 
VA provides both prescription and over the counter drug coverage for all enrollees with 
some paying a co-pay ($8/30day supply). Yet 40% of those in the cohort were unaware of the 
pharmacy benefit. Individuals with incomes above $36,000 a year and those who were under age 
45 were more likely not to have knowledge of these services.   
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On average, enrollees take 4.7 different medications in a month with 43% reporting to 
have taken five prescription medications in a 30-day timeframe. A comparison with non-veteran 
data showed only 11%, age 60 and older took 5 medications per month. This broad difference 
exists due to an older, comorbid Veteran population.  
Overall, 34% of enrollees do not use VA for prescriptions. The Execute Summary of this 
survey does not make clear if these individuals do not take any prescription medications at all, or 
if they are obtaining medications elsewhere. Of those who reported private insurance coverage 
(77%), only 39% had an associated prescription drug benefit with their health plan. However, it 
is not transparent if veterans access to private prescription services influences VA use of the 
same benefit. Knowledge of veteran access to pharmacy services outside VA is a recognized 
limitation of this study.  
In 2006, for the first time, Medicare patients could register for Medicare Part D, a 
prescription drug benefit.  As expected, VA enrollees with higher incomes who could afford the 
premiums were more likely participate. While 36% of VA enrollees have opted to purchase 
Medicare Part D, the survey analysis does not make clear the impact of this coverage on VA 
drug program usage. This is currently under further deliberation. Furthermore, the effects of the 
Patient Protection and Affordable Care Act (PPACA, 2010) on prescription drug coverage for all 
U. S. Citizens remains unknown.  
VA Reliance. 
VA reliance examined outpatient usage and was defined as "the number of visits or trips 
in a VA setting reported by an enrollee divided by the sum of all visits in both VA and non-VA 
settings" (p. 79). Nationwide, the average reliance on VA for outpatient care was 47%. Drivers 
of higher levels of reliance on VA services were: uninsured; reported poor health status; earned 
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less than $20,000 annually; 50-64 years of age; service during Vietnam Era; unemployed; single; 
and African American.  
2.8 Summary of Gaps in the Literature 
Significant support existed in the literature for the primary line of injury for this study. 
This study addressed several deficiencies in scientific knowledge discovered in this review.  
While a substantial amount of research subsists regarding medication adherence in IBD, small 
sample sizes and use of unreliable measurement, chiefly that of non-validated self-report 
measures, limit the interpretation of study findings. This study provided information on veterans 
with this disease, about which little data currently exists. Furthermore, this study assessed 
medication adherence using the prescribed "gold standard" for this cohort, pharmacy refill data.  
World experts have acknowledged the multifaceted nature of medication adherence, encouraging 
assessment of systematic influences on this construct in an effort to improve health outcomes. 
However, adherence research in IBD is in early development, with the majority of studies 
conducted in the last five years that are descriptive in nature, providing information regarding 
adherence rates and predictors of the most common demographic variables. The results of this 
review demonstrated persistence in adherence science in IBD in examination of individual 
behaviors with very few if any researchers casting a wider net to explore systematic impacts. 
Therefore, this study was the first of its kind to assess medication adherence in this cohort using 
a systems Model as a guiding framework to explore coordination of care and its relationship to 
medication adherence and healthcare utilization in veterans with IBD.  
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Chapter 3 
METHODS 
This chapter includes a description of the study research design.  This chapter also 
includes a discussion of the population used for this study as well as how the investigational 
cohort generation occurs. Additionally, this chapter contains information regarding protection of 
study subjects. Furthermore, this chapter incorporates information regarding the databases from 
which study variable retrieval occurs, knowledge of data quality housed within these 
infrastructures, as well as how study data points are measured.  This chapter closes with the 
details of data handling procedures, planned statistical analysis, and sample considerations. 
3.1 Research Design 
The design for this study was a descriptive retrospective data analysis. Medical records of 
veterans with IBD provided the information for analysis. Retrospective analysis has been used to 
assess medication adherence in patients with IBD using pharmacy refill data retrieved from large 
healthcare databases (S. V. Kane & Hanauer, 2000; S. Kane et al., 2001; S. Kane, Huo, & 
Magnanti, 2003; S. Kane et al., 2012; Khan et al., 2012; Lachaine et al., 2013; Mitra et al., 2012; 
Trindade et al., 2011).(S. V. Kane & Hanauer, 2000; S. Kane et al., 2001; S. Kane, Huo, Aikens 
et al., 2003; S. Kane et al., 2012; Trindale et al., 2011)However, few frameworks are available to 
guide methodologic decision making in retrospective studies using administrative data (A. K. 
Smith et al., 2011; Worster & Haines, 2004) . For this reason, ISPOR generated a consensus 
document outlining a systematic approach to designing retrospective database studies of 
medication adherence that informed study methodology as well as final manuscript publication 
(Peterson et al., 2007).  
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3.2 Population 
The population for this investigation was enrollees in one northeast Department of 
Veterans Affairs Medical Center (VAMC) who sought care for IBD between October 1, 2010 
and September 30, 2011 for IBD, FY 2011.  
3.3  Procedures for Protection of Human Subjects 
Conducting research entails protection of human subjects participating in such an 
endeavor, the guidelines for which exist in the Research Act of 1974 (Zucker, 2007). However, it 
was not until the passage of Public Law 104-191, the Health Insurance Portability and 
Accountability Act (HIPAA) of 1996, that protection of health information (PHI) came to the 
forefront. Because PHI access occurred in this study, the implications of HIPAA on study 
protocols are reported. Table 6 contains a summary of the procedures used to protect human 
subjects for this investigation.  
The intent of HIPPA was to improve portability and continuity of health insurance 
coverage by allowing chronically ill individuals to change jobs without losing healthcare 
coverage (Watts et al., 2003). However, the law also contains a provision mandating health 
systems maintaining healthcare information to implement safeguards ensuring the integrity and 
confidentiality of PHI that has had consequences for research conducted using administrative 
data (Nosowsky & Giordano, 2006). Although not specifically directed at research, HIPPA, also 
known as the Privacy Rule, significantly restricts situations in which PHI are used and disclosed. 
PHI includes any information collected from an individual, including demographics, related to 
the person's past, present, or future mental or health condition as well as payment for such, and 
applies to all healthcare plans and providers transmitting this information in an electronic form 
  
 94 
(U.S. Department of Health and Human Services, 2003). This description of PHI applies to all 
data used in this study.  
Typically, in research, data collection occurs after patients have given informed  
consent. However, there is no direct permission obtained in retrospective studies (VonKoss 
Krowchuk, More, & Richardson, 1995). The Privacy Rule does allow disclosure of PHI without 
permission under limited circumstances, such as when using de-identified and limited datasets, 
contingent upon completion of a Waiver of  HIPAA Authorization  (Watts et al., 2003). 
Congruent with 45 CFR 164.512(i)(2), a HIPPAA Waiver is appropriate because this study could  
not have been conducted without the waiver or without access to the requested PHI (Department 
of Veteran Affairs, 2012). Furthermore, in accordance with the Privacy Rule, patient 
authorization is not required for studies using PHI in existence at the time of IRB submission, in 
this case, FY 2011 (VA Pittsburgh Healthcare System Research and Development, 2010) . Table 
7 contains PHI elements omitted from a dataset considered de-identified or limited (Department 
of Veteran Affairs, 2012).  
Because this study is examining the relationship between coordination of care, 
medication adherence, and healthcare utilization, dates, month and day, of the following 
variables are required for data analysis: prescription refills, outpatient visits to primary and 
specialty care, ER visits, as well as inpatient admissions for all services related to IBD as 
outlined in the measurement section below. While exclusion of all other PHI elements from 
study datasets occurs, knowledge of the month and day when service rendering occurs, because it 
is necessary to achieve research aims. As a result, this study protocol included a request to the 
local VA IRB as well University IRB to obtain a limited dataset through an expedited IRB 
process. VA Policy 002, VHA Handbook 1605.1, and VHA Handbook 1605.2 outline  
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Table 6 
Summary of Procedures for Protection of Human Subjects 
1. Use of a Limited Dataset  
 
2. No effort was made to re-identify de-identified data 
 
3. Dataset access occurred only through a password protected VA machine or CAG   
    through an access restricted SharePoint site 
 
4. All research records were maintained in accordance with the Veterans Health   
    Administration (VHA) Records Control Schedule.  Paper records were disposed of   
    using methods deemed appropriate by the VAPHS Privacy Officer, and all electronic   
    data was sanitized using methods rendered appropriate by the VAPHS ISO. 
 
5. Data was only reported in the aggregate 
 
6. The dataset will be retained indefinitely according to policy by the Institution of   
    Record  
 
7. All research records, as defined by VHA Handbook 1200.05, were stored under lock   
    and key in the researcher's VA office with the VA PI having the only access 
 
8. The requested dataset was not reused or disclosed to any other person or entity, except  
    as required by law, for authorized oversight of the research study, or for other research  
    for which the use or disclosure of the requested information would be permitted by the  
    Privacy Rule (VHA Handbook 1200.05, p. 66). 
 
9. Any loss or compromise of any VA sensitive information (including research data),   
    VA equipment or device, or any non-VA equipment or device that is used to transport,  
     access, or store VA information was reported in accordance with the reporting   
    requirements outlined in VA Handbook 6500.  
 
10. In accordance with VHA Handbook 1200.05(63)(a), the study was conducted with  
      a Co-PI 
 
11. Completion of a Waiver of HIPAA Authorization. 
 
12. The PHI requested was the minimum necessary for the stated purposes 
 
13. Data acquisition occurred only for research purposes and future dissemination of   
      findings 
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steps in requesting a limited dataset (Department of Veterans Affairs, 2006b; Department of 
Veterans Affairs, 2013).  
This study protocol included a VA IRB request to access the limited dataset for use 
through remote access provided by the VA, known as Citrix Access Gateway (CAG), that 
permitted password protected access to VA information from a personal computer. This study 
protocol also included an application submitted to the VA for statistical support through the local 
VA Research Office. The dataset was returned to the statistician according to current VA policy 
upon final manuscript publication.  
A data safety monitoring plan was implemented to ensure that there were no changes in 
the benefit/risk ratio during the study and that confidentiality of research data was maintained. 
Study personnel met weekly to discuss any issues or concerns. Any instances of adverse events, 
protocol deviations, or other problems identified during the meeting were to be reported within 
the required timeframes using the standard forms and/or procedures set forth by the IRB. There 
was no data compromise during this investigation.  
Additional data safeguards included reporting of data in aggregate form to ensure patient 
confidentiality and anonymity, as well as storage of all research records, as defined in VHA 
Handbook 1200.05, in a locked VA office that only the co-PI had access to. The risks associated 
with this study were minimal. Data acquisition occurred only for research purposes and 
dissemination of findings.  
3.4 Measurement 
The following passages contain information regarding measurement of study variables. 
The variables included medication adherence, demographic variables, and healthcare utilization.  
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Table 7 
 
PHI Data Elements Excluded from De-identified and Limited Datasets 
 
Identifiers Excluded in 
De-identified Datasets  
 
Identifiers Excluded in 
Limited Datasets 
Names Names 
All geographic subdivisions smaller than a 
state, except for the initial three digits of the 
zip code of the geographic unit formed by 
combining all zip codes with the same three 
initial digits contains more than 20,000 people 
 
Street Address 
All elements of dates except year and all ages 
over 89 
 
 
Telephone Numbers Telephone Numbers 
 
Fax Numbers Fax Numbers 
 
E-mail Addresses E-mail Addresses 
 
Social Security Numbers (SSN) Social Security Numbers (SSN) 
 
Medical Record Numbers Medical Record Numbers 
 
Health Plan Beneficiary Numbers Health Plan Beneficiary Numbers 
 
Account Numbers Account Numbers 
 
Certificate or License Numbers Certificate or License Numbers 
 
Vehicle Identifiers/License Plate Numbers Vehicle Identifiers/License Plate Numbers 
 
Device Identifiers and Serial Numbers Device Identifiers and Serial Numbers 
 
Uniform Resource Locator (URLs) Uniform Resource Locator (URLs) 
 
Internet Protocol (IP) Addresses Internet Protocol (IP) Addresses 
 
Biometric Identifiers Biometric Identifiers 
 
Full-face Photographs/Comparable Images Full-face Photographs/Comparable Images 
 
Any other unique, identifying characteristic or 
code, except as permitted for re-identification 
in the Privacy Rule 
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Medication Adherence 
 Medication adherence was measured using the MPR that was operationalized as: “the 
sum of the days’ supply of medication divided by the number of days between the first fill 
and the last refill plus the days’ supply of the last refill” Figure 3.1 (Sikka et al., 2005). 
Corroboration between dosing instructions and days’ supply of medication did not occur because 
this information was not available in the databases accessed for this study. 
All individuals had a uniform follow-up period to prevent biases upward in calculating 
MPR for individuals with shorter follow up times, for this study, FY 2011 served as the uniform 
observation period (Sikka et al., 2005). Adjustment in the denominator of this equation occurred 
for subjects with inpatient admissions. Therefore, the observation period for patients with an 
inpatient admission, reflected the omission of hospitalized days from the total days in the 
observation period (Gellad, 2012). 
In the descriptive analysis, MPR was a continuous variable. As found throughout the 
adherence literature in a variety of chronic diseases where retrospective analysis of pharmacy 
refill data is employed, (Kreyenbuhl et al., 2010; Krousel-Wood et al., 2009; Siegel, Lopez, & 
Meier, 2007) further analysis was conducted with the MPR dichotomized so that those with 
MPR of  >.80 or above were adherent and those with an MPR < .80 were non-adherent. The 
origins of these cut off points are based on the principal that loss of >20% of a patient population  
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Figure 3.1 Calculation of MPR. “Reprinted from The American Journal of Managed Care,11(7), 
Sikka, R., Xia, F., Aubert, R. E., Estimating medication persistency using administrative claims 
data, 449-457, 2005, with permission from Managed Care & Healthcare Communications” 
 
in a clinical trial makes the results suspect (Guyan, Sackett, & Cook, D. J. for the Evidenced 
Based Medicine Working Group, 1993). 
Essentially, an MPR of .80 equates to taking a medication 80% of the time. This means 
that 20% of the time, the patient is not taking any medication. Use of this cutoff implicitly 
assumes that no change in health outcome occurs as result of this “allowable gap” in treatment. 
As reported in this paper, the 80% cut off is used widely throughout the adherence literature for 
many chronic disease states, although not supported by any documentation of the clinical validity 
of this measure (Ho et al., 2009; Peterson et al., 2007) this includes IBD  (Regueiro, 2012c). 
Thereby, adding further to the limitations of measuring medication adherence using pharmacy 
refill data.  
The literature supports the use of adherence cutoffs  in IBD as  >.80 as adherent and < .80 
as non-adherent (Bhatt et al., 2009; S. V. Kane, 2008; S. Kane et al., 2001; S. Kane, Huo, & 
Magnanti, 2003; S. Kane, Huo, Aikens et al., 2003; S. Kane et al., 2012; Lachaine et al., 2013; 
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Mantzaris et al., 2007; Moss et al., 2010; Nahon et al., 2011; Robinson et al., 2013; Trindale et 
al., 2011) . Additionally, the MPR with these cutoffs appears previously in retrospective 
adherence studies using a sample of veterans (Khan et al., 2012; Kreyenbuhl et al., 2010). 
Therefore, these cutoffs were also employed for this investigation. However, to improve the 
robustness of the evaluation, the analysis was repeated using .90 as a cutoff to assess if the 
results changed in a statistically significant manner.  
MPR calculation occurred for each of the applicable medications in this study for each 
patient, because it was conceivable that patients could be taking more than one drug for IBD 
simultaneously. Combination of MPR calculations did not occur across patients due to different 
denominators for each drug. Therefore, a mean MPR was calculated for each patient taking more 
than one medication (Hess et al., 2006; Peterson et al., 2007). 
It was acknowledged that the MPR will miss those with primary non-adherence i.e. those 
who are prescribed a medication but never pick it up from pharmacy. Additionally, because the 
MPR requires at least two medication refills during the observation period, those who filled only 
one prescription and never fill again were not included. Therefore, the sample for this study was  
limited to subjects who were relatively more adherent than others in the cohort.  
While administrative pharmacy data represents a valuable research tool, there are several 
confounding elements of this measurement to address such as, over- supply of medication, 
persistence, and switching.  
Over-Supply of Medication 
Over-supply of medication is a consideration when using refill data to measure 
adherence. MPR scores typically run 0 to 1.00 with higher values indicating higher levels of 
medication adherence (Kim, Agostini, & Justice, 2010). The literature demonstrates a variety of 
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procedures regarding MPR values > 1, indicating oversupply of medication. There were no cases 
of medication over-supply in this sample.  
 Persistence 
The literature recognizes retrospective measure of persistence as a concept distinguished 
from adherence and defined as the length of time from initiation to discontinuation of therapy, 
measured in units of time (Burrell et al., 2005). Such that, individuals who are persistent with 
therapy, have medication taking behavior that is continuous, filling medications frequently, and 
regularly, during a specified period (Sikka et al., 2005). Whereas retrospective measure of 
adherence is the total number of days of medication availability for a defined observation period 
which does not take into account the consistency with which individuals refill medication   
(Burrell et al., 2005).   
The mostly widely used measure of persistency is measurement based on gaps between 
refills (Sikka et al., 2005). The literature lacks consensus regarding the appropriate length of the 
permissible gap (Sikka et al., 2005). Furthermore, there are no allowable gaps in treatment for 
IBD (Regueiro, 2012b). Therefore, to contribute to adherence science in a meaningful way, 
persistency was not measured for this study.  
Switching            
Subjects switching between drugs within the same therapeutic class or between a 
different therapeutic class were deemed adherent with an MPR of > .80 (Andrade, 2006). 
Demographic Variables 
The analysis included covariate demographic characteristics that have demonstrated, 
although not consistently, an association with medication adherence in IBD. Demographic 
variables included age, gender, race, and ethnicity. Age was reported as a continuous variable. 
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Gender was a categorical variable, male or female. For regression models, females were 
excluded due to low counts in this group.    
Race was also a categorical variable with seven levels. The nationally approved race 
standardization in VHA originates in Handbook 1601A.01 and Directive 2009-21 and included 
the following standardized race values American Indian or Alaska Native, Asian, Black or 
African American, Native Hawaiian or Pacific Islander, and White, Unknown by Patient, and 
Declined to Answer (Veterans Health Administration, 2012). VA categories for ethnicity 
included Hispanic or Latino, not Hispanic, don't know/refused (VA Information Resource Center 
(VIReC), 2011) . As such, data collection for race and ethnicity reflected these groups. Report of 
descriptive statistics, including frequencies, took place for all races and ethnicities. However, due 
to low frequencies in many of the above categories, for further evaluation, race and ethnicity 
were collapsed as appropriate. Despite categorical collapse, race and ethnicity were excluded as 
variables in multivariate analysis due to minimal occurrences for many categories.  
Additionally, IBD diagnosis, CD versus UC, as well as, IBD medication, categorized as 5-ASA, 
immunomodulator, were both included.  
Healthcare Utilization 
 Healthcare utilization was the “use of healthcare resources” (Bernstein et al., 2003). The 
services chosen for examination in this study were derived from the National Health Care 
Survey, a collection of surveys, done to assess how the U. S. healthcare delivery system is being 
used and by whom. While the main outcome variable for this study was medication adherence, 
research demonstrates a relationship exists between adherence and consumption of healthcare 
resources (World Health Organization, 2003). Additionally, while healthcare utilization in IBD 
has been studied (Ananthakrishnan et al., 2010; Gibson et al., 2008; Longobardi & Bernstein, 
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2006; Mitra et al., 2012; Nguyen et al., 2007), no information regarding the healthcare utilization 
of veterans with this disease exists. Therefore, this study began to explore these relationships in 
the VA for which a gap in science exists.  
Data on healthcare utilization originated from FY 2011 VistA datasets. For this 
investigation, the following healthcare services represented healthcare utilization: ER visits, 
outpatient department visits that included both primary and specialty GI care clinic visits, as well 
as inpatient admissions. The frequencies of each visit type for each patient were included in the 
analysis. For further multivariate evaluation, three logistic regression models were created. In 
each model, the dependent variable was dichotomous, yes/no. Analysis details of healthcare 
utilization are contained in subsequent passages. 
Comorbidity 
Measurement of comorbidity in research occurs to correct for confounding, to establish 
use as a predictor of a study outcome, and for statistical efficacy (de Groot, V., Beckerman, 
Lankhorst, & Bouter, 2003). As is established in the literature, healthcare utilization 
investigations typically include consideration of comorbidities in the population of interest and 
control for this variable during multivariate analysis (Valderas et al., 2009; Vogeli, Shields, & 
Lee, 2007) . In turn, this variable was included in this exploratory analysis of healthcare 
utilization.  
There are over 75 million Americans with two or more chronic conditions (Parekh & 
Barton, 2010).  Level of comorbidity is of particular concern in the veteran population because 
veterans who receive care in the VA are more likely to have multiple chronic health conditions  
and higher rates of mortality when compared to the general population or veterans who do not 
use the VA for healthcare (Agha, Lofgren, VanRuiswyk, & Layde, 2000; Lee et al., 2007).  Of 
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further concern, are the results of studies that suggest patients with multiple medical conditions 
have poor outcomes and increased healthcare resource utilization (Vogeli et al., 2007).  
Similar to medication adherence, no consensus exists in the literature regarding how best to 
define and measure comorbidity (Fortin, 2007). As a result, a review article (Valderas et al., 
2009) generated explicit definitions for the nomenclature surrounding comorbidity as well as 
measurement considerations of this construct, with the aim of consistent usage of these 
definitions and measures in future research to allow for comparison of results across reports and 
improve generalizability of study findings. To this end, the recommended definition and measure 
emanating from this paper informed the measurement of this construct for this study.  Hence, the 
definition of comorbidity for this study was the "presence of additional diseases in relation to an 
index disease in one individual” (Valderas et al., 2009).  
(Valderas et al., 2009) encouraged use of measuring comorbidity with established disease 
classification systems such as the one chosen for this study, ICD-9. Choice of the (Deyo et al., 
1992) comorbidity measure took place based on this recommendation. The Deyo algorithm 
originates from work completed by (Charlson et al., 1987), who identified 19 medical conditions 
associated with increased rates of mortality within 12 months and created a tool to measure this 
risk, the Charlson Comorbidity Index (CCI) which has become the most widely used measure to 
characterize the risk of death from comorbid disease (Valderas et al., 2009).  A comorbidity 
index reduces the coexistence of illnesses to a single score that allows for comparison with other 
patients in a study as well as subjects across studies. 
The CCI assigns a weighted score to each medical condition that ranges between 1-6. 
Patients receive a score for each of the medical conditions in the CCI that combined for a total 
comorbidity score, with higher values, up to 37, indicating more severe levels of comorbidity. To 
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place the scores in context, in the (Charlson et al., 1987) study, a patient  in the first cohort (559 
patients) with a score of 0 had a 12% 1year mortality rate,  scores of 1-2 with a 26% risk, 3-4 
with a 52% risk, and those with a score >5 had an 85% risk of mortality at 1 year.  The authors 
then followed a second cohort (685 patients) for 10 years. The morality risk for the various CCI 
scores was similar in that those with a score of 0 had a 12% risk of mortality, scores of 1 a 25% 
risk, 2 a 48% risk, and scores >  3 had 59% risk of death. Thereby demonstrating that as CCI 
scores increased, so did the cumulative affective of comorbid disease (p < 0.0001).  In the second 
cohort, age was also a predictor of mortality (p < 0.001).  
The CCI was included in a critical review of the measures of comorbidity conducted to 
evaluate the validity and reliability of a total of 13 such methods (de Groot et al., 2003).  A 
correlation coefficient (ICC) exceeding 0.40 supports the concurrent validity of the CCI.  The 
predictive validity or ability of the CCI to predict future events on an outcome measure of 
interest, has been established by the presences of significant relationship of the Index with 
various criterion measures such as mortality, disability, hospital readmission rates, and length of 
stay (Chalson, Szatrowski, Peterson, & Gold, 1994; Librero, Peiro, & Ordinana, 1999; Rochon et 
al., 1996). Data also exists that the CCI has good test-retest as well as interrater reliability 
(Extermann, Overcash, Lyman, Parr, & Balducci, 1998; Liu, Domen, & Chino, 1997). Of the 13 
comorbidity measures in this review, the authors concluded that only 4 of the 13 are valid, 
reliable measures of comorbidity, CCI being one of these measures. More recently, (S. F. Hall, 
2006) published a paper in a similar vein producing comparable results.  
Building on Charlson’s work, (Deyo et al., 1992) created a method for calculating the 
CCI, specifically using administrative data, based on the ICD-9 codes of the 19 medical 
conditions in the original Index, see Table 8 (permission located in Appendix D) . The Deyo 
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method has 17 chronic diseases in its algorithm. The only difference between the CCI and the 
Deyo algorithm is in the category for malignancy. The CCI has three categories for malignancy, 
classified as any malignancy, leukemia, and lymphoma. However, the Deyo algorithm places all 
three classifications into one category resulting in the creation of 17 medical condition categories 
instead of 19.  Multivariate analysis in the Deyo (1992) study demonstrated significant 
association with outcomes post lumbar spine surgery as well as resource utilization in this cohort 
(p <0.0005).  
(Quan, Parsons, & Ghali, 2004) sought to validate the Deyo algorithm by examining the 
administrative data of 1,200 subjects by comparing algorithm scores using administrative data to 
scores generated using the same tool calculated from manual chart review.  The authors 
calculated a kappa score to determine the extent of agreement between the two sources above 
chance.  Overwhelmingly, the kappa scores showed moderate (0.41 to 0.60) to substantial 
agreement (0.61 to 0.80) between the scores calculated using administrative data and the scores 
calculated from manual chart review. Logistic regression models were used to predict in-hospital 
mortality using both data sources.  While some differences between administrative data and 
manually retrieved data occurred, overall the ability to predict in-hospital mortality was the same 
for both groups (OR 1.4; 955 CI 1.3-1.5).  Recognizing the limitations of administrative data, the 
authors concluded that calculation of a comorbidity score using administrative data may 
adequately characterize the burden of comorbidity.  
Use of the Deyo algorithm in the population of interest provided additional support for its 
use in this study.  As reported previously, the investigations conducted by (S. V. Kane, 2008) 
and (Nguyen et al., 2007) both described in detail previously, are included in this substantiation.  
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For example, (Anathakrishnan, McGinley, & Binion, 2008) used the Deyo algorithm to estimate 
mortality in a group of hospitalized IBD patients with Clostridium difficile. The results of study 
showed that after controlling for comorbidity using the Deyo algorithm during regression 
analysis, patients with C. difficile had higher odds of death than those admitted for IBD alone 
(OR = 5.7, 95% CI 2.9-11.3), longer lengths of stay (95% CI 0.8-3.2),  and were more likely to 
undergo bowel surgery (OR = 4.8, 95% CI 2.2-8.1).  
 (Ananthakrishnan, McGinley, & Binion, 2009) and colleagues again used the Deyo 
algorithm in a national sample of hospitalized IBD patients examining the frequency of 
complications, requirements for surgery, and outcomes of hospitalization comparing older 
patients (>65) to younger patients (<65). Age was recognized as an independent risk factor for 
IBD related death. After controlling for comorbidity using the Deyo algorithm in regression 
models, older patients persistently had greater mortality than younger comparisons (OR 3.91, 
95% CI 2.50-6.11).  Regression models also demonstrated that rates of surgery were not 
significantly different between the two groups (OR 1.03, 95% CI 0.90-1.18).  Additionally, post-
operative complication rates were similar in both groups (OR 1.12, 95% CI 0.88-1.43).  
Finally, the Deyo algorithm provided information regarding the impact of in-hospital 
malnutrition on mortality in a national sample of IBD patients (Nguyen et al., 2009). Predicator 
variables in logistic regression models included age, race, sex, IBD diagnosis, primary health 
insurance carrier, a comorbidity score calculated using the Deyo algorithm, surgery done during 
admission, and hospital characteristics. The risk of mortality in IBD patients with malnutrition 
was three times higher than for those who were not malnourished after controlling for 
comorbidity, age, sex, health insurance, and hospital factors (95% CI 2.89-23). 
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Calculation of Comorbidity 
Comorbidity for this study was measured using the following procedures. The statistician 
retrieved the ICD-9 codes associated with the CCI located in Table 8 for each patient in the 
cohort. The researcher then used the (W. H. Hall, Ramachandran, Narayan, Jani, & Vijayakumar, 
2004) age adjusted comorbidity calculator to obtain a comorbidity score that was used in 
regression analysis for Specific Aim 3.  
(W. H. Hall et al., 2004)  developed an online CCI calculator using Microsoft Excel 
Macro that rapidly calculates a comorbidity score that originates from Charlson’s original work 
(1987) and is downloadable onto a desktop through the following link, 
(http://www.biomedcentral.com/content/supplementary/1471-2407-4-94-S1.xls). The scoring 
using the Hall calculator as identical to scoring found in the CCI, see Table 8, with a range of 0-
37.  Like the CCI, the Hall calculator also makes a provision for an age adjusted comorbidity 
which was applied in this study.  
Of the comorbidity calculators that have documented reliability and validity (de Groot et 
al., 2003), the Index of Coexistent Disease (ICED), Kaplan Index, the Cumulative Illness Rating 
Scale (CIRS), and the CCI, only the ICED and CCI have easy to use electronic calculators 
available for clinical use. The ICED has not been used in the population of interest. Whereas the 
CCI, translated by the Deyo algorithm has been applied in IBD (S. Kane & Shaya, 2008). 
Therefore, the comorbidity calculator developed by (W. H. Hall et al., 2004) was the chosen 
calculator for this study. Because the majority of subjects had no comorbidity, this variable was 
dichotomized yes/no for regression models.  
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Table 8 
Translation of Charlson Comorbidity Index (CCI) elements into ICD-9 codes 
 
Diagnostic Category 
 
ICD-9 Codes Assigned 
weights for 
diseases 
Condition Description 
Myocardial infarction 410-410.9 
412 
1 
 
Acute myocardial infarction 
Old myocardial infarction 
Congestive heart failure 
 
428-428.9 1 Heart failure 
Peripheral vascular 
disease 
 
443.9 
441.441.9 
785.4 
V43.4 
procedure 
38.48 
 
1 Peripheral vascular disease, includes intermittent claudication 
Aortic aneurysm 
Gangrene 
Blood vessel replaced by prosthesis 
Resection and replacement of lower limb arteries 
Cerebrovascular disease 430-438 1 Cerebrovascular disease 
Dementia 
 
290-290.9 1 Senile and presenile dementia 
Chronic pulmonary 
disease 
 
490-496 
500-505 
506.4 
 
1 Chronic obstructive pulmonary disease 
Pneumoconioses 
Chronic respiratory conditions due to fumes and vapors 
Rheumatolgic disease 710.0 
710.1 
710.4 
714.0-714.2 
714.81 
725 
1 Systemic lupus erythematosus 
Systemic sclerosis 
Polymyositis 
adult rheumatoid arthritis 
Rheumatoid lung 
Polymyalgia rheumatic 
 
Peptic ulcer disease 
 
 
 
 
 
 
 
531-534.9 
531.4-531.7 
532.4-532.7 
533.4-533.7 
534.4-534.7 
1 Gastric, duodenal and gastrojejunal ulcers 
Chronic forms of peptic ulcer disease 
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Table 8 (continued) 
Diagnostic 
Category 
ICD-9 
Codes 
Assigned 
weights for 
diseases 
Condition Description 
Mild liver disease 571.2 
571.5 
571.6 
571.4-
571.49 
 
1 Alcoholic cirrhosis 
Cirrhosis without mention of alcohol 
Biliary cirrhosis 
Chronic hepatitis 
Diabetes 250-250.3 
250.7 
 
1 Diabetes with or without acute metabolic disturbances 
Diabetes with peripheral circulatory disorders 
Diabetes with 
chronic 
complications 
 
250.4-250.6 1 Diabetes with renal, ophthalmic, or neurological manifestations 
Hemiplegia or 
paraplegia 
344.1 
342-342.9 
 
2 Paraplegia 
Hemiplegia 
Renal disease 582-582.9 
582-583.7 
585 
586 
588-588.9 
2 Chronic glomerulonephritis 
Nephritis and nephropathy 
Chronic renal failure 
Renal failure, unspecified 
Disorders resulting from impaired renal function 
 
Any malignancy, 
including 
leukemia and 
lymphoma 
140-172.9 
174-195.8 
200-208.9 
 
2 Malignant neoplasms 
Malignant neoplasms 
Leukemia and lymphoma 
Moderate or 
severe liver 
disease 
572.2-572.8 3 Hepatic coma, portal hypertension, other sequelae of chronic liver disease 
 
Metastatic solid 
tumor 
196-199.1 6 secondary malignant neoplasm of lymph nodes and other organs 
 
AIDS 042-044.9 6 HIV infection with related specific conditions 
 
“Reprinted from Journal of Clinical Epidemiology, 45(6), Deyo, R. A., Cherkin, D. C., Ciol, M. A., Adapting a clinical comorbidity 
index for use with ICD-9-CM administrative databases, 613-619, 1992, with permission from Elsevier” 
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Emergency Department Visit 
For this study, the number of all ED visits, with any diagnosis code, represented by clinic 
stop code 77, during FY 2011, represented healthcare utilization of ED services as represented in 
the literature in this population (Gibson et al., 2008; Motheral et al., 2003). 
Outpatient Department Visit 
OPD visit measurement consisted of clinic stop codes for primary (323, 301, 322, 348, 
350, 170, 634, and 172) and specialty (Gastroenterology, 151) care. OPD visits did not require a 
corroborating ICD-9 code for IBD. All OPD visits for the above primary care stop codes and 151 
for GI in this cohort, were included for analysis because it is conceivable that IBD patients are 
seen in either venue for IBD related issues and the diagnosis code for IBD not be rendered 
(Motheral et al., 2003; Regueiro, 2012a). 
Inpatient Admission 
Inpatient hospital admissions for any illness, during FY 2011, afforded inpatient 
admission information (Ananthakrishnan et al., 2010; Kappleman et al., 2011; Motheral et al., 
2003; Nguyen et al., 2007; Regueiro, 2012a; Sewell et al., 2009; Sonneberg, Richardson, & 
Abraham, 2009). 
Care Coordination  
Care coordination was the “deliberate organization of patient care activities between two 
or more participants (including the patient) involved in a patient’s care to facilitate the 
appropriate delivery of healthcare services. Organizing care involves the marshaling of personnel 
and other resources needed to carry out all required patient care activities, and is often managed 
by the exchange of information among participants responsible different aspects of care” 
(McDonald et al., 2007).  
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The literature characterizes the term “shared care” as tantamount with coordination of 
care, as was the case for this study (Starfield, 2003). Identification of coordination of care 
occurred with use of “a clinic stop code, a required field in the VA OPC Hospital Location file 
that assigns a number representing a type of care or Service/treating Specialty” (Zivin et al., 
2010). For this study, stop codes for primary care (323, 301, 322, 348, 350, 170, 634, 172) and 
gastroenterology (specialty care, 151) represented coordination of care (Regueiro, 2012a). Care 
coordination was assumed when the patient had clinic stop codes for both primary and specialty 
care. Care coordination was a critical element of this study, originating from the theoretical 
model for such, the CCM, that posits improved outcomes when use of healthcare resources are 
coordinated between primary and specialty care, in this case, gastroenterology.  
In VA, primary care serves as the gatekeeper for specialty care access (Kizer, 1996). As a 
result, patients should be unable to make appointments with a specialist without a consultation 
placed into the electronic medical record by the PCP for said specialty. However, it is 
conceivable, due to systematic influences, that patients will access specialty care without 
intersession by primary care. For example, the institution under investigation serves as a regional 
GI referral center for four other VAMCs.  Therefore, patients seen at the VAMC of interest for 
GI specialty care will have no records regarding primary care use because this care delivery 
occurs elsewhere. Additionally, patients may receive a referral for specialty care services through 
the ER.   
3.5 Data Handling Procedures 
None of the IBD adherence studies in this review, contained information regarding data 
handling. To address this issue, a discussion of data handling procedures for this study follows 
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which included assessment of missing data, normality, linearity, homoscedasticity, 
multicollinearity, and outliers.  
Missing Data 
Frequency evaluation yielded eight cases with missing race/ethnicity data that was 
confirm by the statistician who pulled the data from the local VA database. Eight missing cases 
corresponds to 5% of the sample, which is an allowable amount of missing data (D. F. Polit, 
2010b; Tabachnick & Fidell, 2007). Therefore, no attempt was made to correct this missingness. 
No other variables had missing data.  
Normality, Linearity, Homoscedasticity, and Multicollinearity 
Evaluation of univariate normality was assessed using histograms, stem and leaf plots, 
box plots, as well as skewness and kurtosis. While the outcome variables for this study, 
medication adherence and healthcare utilization, were not normally distributed, all were 
dichotomized for logistic regression analysis.  
Linearity and Homoscedasticity 
Linearity and homoscedasticity between two variables was evaluated using bivariate 
scatterplots (Tabachnick & Fidell, 2007). Generation of an oval shaped scatter takes place with 
normally distributed data. Otherwise, data transformation addressed problems with heterogeneity 
of variance (univariate) and heterogeneity of variance-covariance (multivariate) (Tabachnick & 
Fidell, 2007). 
Multicollinearity 
Bivariate and multivariate correlation took place to assess Multicollinearity. Variance 
inflation factor (VIF) greater 10 and the tolerance values <.10 were considered representative of 
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Multicollinearity (Bowerman & O'Connell, 1990) . No variables met this statistical definition of 
collinearity.  
Univariate and Multivariate Outliers 
Univariate outliers were assessed via visual screening through histograms and boxplots. 
If the value remained a true outlier after screening, standardized z scores were generated for each 
group and those with scores greater than 3.29 (p<.001, two tailed) were considered potential 
outliers (Tabachnick & Fidell, 2007).  Multivariate outliers were detected through Mahalanobis 
distance at p<.001 (X2  df  =  to the number of variables) as this is currently the best method for 
multivariate outlier detection (Tabachnick & Fidell, 2007).   
Expected outliers for healthcare utilization variables were present. However, all 
healthcare utilization variables were dichotomized yes/no for regression models. Therefore, no 
additional treatment occurred to these variables.  
3.6 Analysis 
The Statistical Package for the Social Sciences (SPSS) version 21.0 (Chicago, IL, 2012) 
was used for data analysis. To control for Type I error, a two-tailed test of significance was used 
with an alpha set at .05. 
Descriptive Statistics 
Variable relationship exploration began with descriptive statistics. Frequencies were 
provided for the categorical variables of comorbidity, IBD diagnosis, care coordination and IBD 
medication.  
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Primary Study Aim 
Described medication adherence, healthcare utilization, and care coordination of 
veterans with inflammatory bowel disease (IBD) who employ Veterans Affairs (VA) 
healthcare at one Veterans Affairs Medication Center (VAMC).  
Measures of central tendency characterized medication adherence rates of veterans with 
IBD as measured by the MPR. An MPR for each drug was calculated as a continuous variable. 
However, based on the literature, MPR was dichotomized into non-adherent (<.80) and adherent 
(> .80) for further analysis. Frequencies and percentages for adherent and non-adherent patients 
were computed. The total number of occurrences for the healthcare utilization variables of ER 
visits and inpatient admissions during the one year observation period were collected. Care 
coordination measured by total number of occurrences for both primary and GI specialty care 
during the one year observation period were also collected.  
Secondary Study Aim 1 
Examined the association between medication adherence adjusted for care 
coordination, age, IBD diagnosis, comorbidity, and IBD medication in veterans with IBD 
who employ VA healthcare. 
Bivariate Analysis. 
Bivariate analysis was assessed using Chi-square test of independence to make inferences 
about the existence of a relationship between the dependent variable, medication adherence and 
independent study variables. Phi coefficient and Cramer’s V were examined as appropriate. The 
continuous variable of age was examined through an independent samples t-test. Additionally, in 
an effort to facilitate future meta-analysis, the odds ratio (OR), 95% confidence intervals (CI) 
were reported (D. F. Polit, 2010a).  
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Multivariate Analysis.  
Logistic regression yielded information about the probability of an IBD patient being 
adherent or non-adherent to a medication regime for said disease based on a subscribed set of 
factors: age, IBD diagnosis, IBD medication, as well as care coordination and comorbidity. 
Inclusion of all independent variables for regression analysis occurred owing to parsimony in 
choosing predictors based on study framework, literature, and data availability (Norusis, 2012). 
The variables of gender, race, as well as ethnicity were not included in the final analysis due to 
homogeneity of the sample. Main effects were determined by simultaneously entering all of the 
variables into the model to determine the predictive ability of the overall model. The odds ratio, 
95% CI were reported. The Nagelkerke R2 portrayed effect size of the analysis.  
Specific Aim 2 
Began to explore the relationship between healthcare utilization adjusted for medication 
adherence, care coordination, age, IBD diagnosis, IBD medication, and comorbidities in 
veterans with IBD who employ VA for healthcare. 
To examine the relationship between variables in preparation for further regression 
analysis, similar bivariate analysis occurred as described above.  Logistic regression yielded 
information about the probability of an IBD patient having healthcare utilization measured by 
ER or inpatient admissions based on the following predictors: medication adherence, age, IBD 
diagnosis, IBD medication, care coordination, as well as comorbidity.   
The dependent variable for the two healthcare utilization regression models was 
dichotomized (yes/no). The variables of gender, race, and ethnicity were not included in final 
models due to homogeneity of the sample. Main effects of each model were determined by 
simultaneously entering all of the variables into the model to determine the predictive ability of 
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the overall model. As explained previously, all variables from the bivariate analysis were 
included in this model regardless of the relationship with the dependent variable. The odds ratio 
and 95% CI were reported. Generation of interaction terms for subsequent models was based on 
the significance of predictors. The Nagelkerke R2 portrays effect size of the analysis.  
3.7  Sample Considerations 
Many studies have been conducting examining medication adherence in IBD using 
logistic regression. However, little information exists regarding formal sample size consequences 
that could provide a benchmark for this investigation (S. Kane et al., 2012). Therefore, sample 
size deliberation took place using statistical text references.  
Sample size calculations for logistic regression require consideration based on the 
number of predictors in the models (Bartlett, Kotrlik, & Higgins, 2001) . One simple 
recommendation exists regarding sample size that advised the use of at least 10-20 subjects for 
each predictor to reduce the risk of a Type II error (D. F. Polit, 2010c).  (D. E. Miller & Kunce, 
1973)  as well as  (Halinski & Feldt, 1970), provided additional support for the use of ten 
observations per independent variable. One source cited the use of not less than five observations 
per independent variable to ensure generalizability of study findings (Hair, Anderson, Tatham, & 
Black, 1995).  
 Therefore, based on 10-20 patients per predictor, an appropriate sample size for Specific 
Aim 2 that included five predictors would be in the range of 50-100. The study sample met this 
requirement. Using the above metric, a sample size of the same caliber was required for the 
regression analysis of Specific Aim 3 that also included five predictors.  
However, to test that the regression model was significant overall, the researcher also 
needed to contemplate the size of the effect of the independent variables to predict the outcome. 
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(Cohen, 1988) established as a benchmark, an effect size of .80 to achieve a high level of power. 
Cohen further suggests "standard effect sizes" for regression: .02 (small), .13 (medium), and .26 
(large). Applying this rubric, using G Power, a sample size of 77 is appropriate, with up to 20 
predictors, to achieve a large effect (Field, 2013) . Whereas, a sample of 160 patients, using up to 
20 predictors, is required for a medium effect, and the minimum number of subjects of 100 is 
required with six or fewer predictors for medium effect size (Field, 2013). As noted above, the 
study sample met these sampling requirements.  
3.8 Study Limitations 
Overall, compared to primary data collection, secondary data analysis is less time 
consuming, labor intensive, and cost producing. Furthermore, patient non-response or recall bias 
does not occur with administrative data because data collection is independent of patient 
participation (Schneewiss & Avorn, 2005).  
However, while secondary data analysis is recognized as a valid investigational 
methodology for assessing medication adherence (Andrade, 2006), nearly three decades have 
lapsed since researchers began assessing healthcare practice using retrospective analysis. Yet, the 
fundamental issues of using administrative data for research remain. Matching study 
conceptualizations with data element definition is challenging since the collection of database 
information did not occur for research purposes (Waltz, Strickland, & Lenz, 2010).   
 Knowledge of the quality of many data elements housed in a variety of administrative 
databases infrequently exist, inclusive of VA, creating concern about the reliability and validity 
of this methodology (Waltz et al., 2010). Rarely, can researchers comment on the reliability of 
original data (Worster & Haines, 2004) . However, by Congressional mandate in 2002, through 
Section 515 of the Treasury and General Government Appropriations Act, VA is bound to 
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maximize the quality of the information it disseminates (U. S. Department of Veterans Affairs, 
2003) . 
VA researchers have been major contributors to the methodological literature in the area 
of administrative data use during the last 20 years. Nevertheless, VistA, the chosen database for 
this study, has more than 1,940 files and 44,960 data fields, generating massive amounts of 
information available for systematic inquiry, which has limited the science, as few are expert in 
translating this data into usable information for investigation (Hynes, 2012) .  However, 
investigators who do make use of automated databases, facilitate the translation of data into 
information, thereby influencing clinical practice and health policy.  
VA informatics and analytics professionals at VA Central Office in Washington, D.C. 
share concerns about the quality of VA data because the ability to capture clinical concepts using 
standardized data elements found in VA databases remains limited (Francis, 2012) . As a result, 
VA pays more than $12 million a year to have national manual chart abstractions done instead of 
electronic data pulls to estimate performance on Healthcare Effectiveness Data and Information 
Set (HEDIS) measures (Francis, 2012). 
Clearly, the impact of poor data quality can have widespread deleterious effects on patient 
care. To address data quality concerns, the VHA Data Quality Program exists within the Health 
Information Governance Office of VHA's Office of Informatics and Analytics, whose mission it 
is to ensure data accuracy for all VHA stakeholders (U. S. Department of Veterans Affairs, 
2007).  Additionally, each VAMC also has a Clinical Application Coordinator (CAC) who is an 
authority on the meaning and utility of local VA data (VA Information Resource Center 
(VIReC), 2012) .  
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Concerns regarding quality of VA data, lent further support for the goals of this study 
using local VA data only, to begin examination of coordination of care, medication adherence, 
and healthcare utilization in a population in which little data currently exists. Some of the largest 
contributions VA researchers are making currently using administrative data is to provide 
documentation of the limitations of many widely used variables, as was the case with this study    
(Atkins, 2012) .       
Completeness of data commands attention. Not all variables in VA datasets are of equal 
quality, as measured by completeness and accuracy of information entered into the system. 
Missing or erroneous values are possible.  
The information about data quality presented below represents information on data 
quality from a national VA database perspective. To this researcher’s knowledge, no data quality 
information exists on the elements housed in the local VistA modules used for this study.  
Systematic evaluation that occurs through the research process strengthens database 
quality. The passages that follow contain information about processes used for this study to 
maintain methodologic rigor and include database source for research in VA, cohort generation, 
clinic stop code quality, pharmacy data, measuring medication adherence and race data quality.  
Database Sources for Research in VA 
VA represents one of the largest self-contained healthcare systems in the world. For 
decades, systems data captured and storage has occurred in a variety of administrative databases 
utilized in health services research. Although VA databases do not exist specifically for research 
purposes, informational access ensues to measure patient outcomes particularly when chart 
review would prove too labor intensive and cost prohibitive.  
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It is important to note, that in accordance with VHA Handbook Policy 1605.1, only VA 
employees conduct VA research (Department of Veterans Affairs, 2006a). Furthermore, access 
to any VA data for research purposes, requires prior IRB authorization from the investigator's 
VA facility, where scrutiny of the application takes place for protocols that address privacy and 
security concerns.  
VA Databases 
While many VA databases exist, for this study, only databases that contained variables 
under examination were accessed which included local VistA and CPRS, as well as local and 
VISN level pharmacy databases. Data collection for a VA fiscal year (FY) runs October 1-
September 30. When retrieving data for a FY, it is advised to wait until January 1st of the 
following calendar year to ensure that a complete FY dataset can be obtained (Hynes, 2012).  
Additionally, from a systems perspective, because VA datasets are under constant amendment, it 
is imperative for growth in database research, to review the most current VA dataset, as 
interfacing with databases even just a year ago, could provide vastly different information when 
compared to current database configuration (Mark, Dirani, Slade, & Russo, 2002). 
VistA 
VistA is an integrated system of software applications that directly supports patient care 
at VHA healthcare facilities by tying together workstations and personal computers (Hynes, 
George, & Pfeil, 2002) .VistA provides system management tools that provide uniformity of data 
across the VA system and yet permit customization of each software package to meet local VA 
requirements (Brown, Lincoln, Groen, & Kolodner, ). The majority of data found in VistA exists 
due to manual entry of information (VA Information Resource Center (VIReC), 2012) . 
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Each VistA application generates clinical and administrative data that support the day-to-
day operations of VA facilities and contain patients' medical and healthcare utilization histories 
(Hynes, Perrin, Rappaport, Stevens, & Demakis, 2004). VistA contains the most clinical detail of 
any VA database and as such, captures many data points that are not currently available in any 
other national VA data source (VA Information Resource Center (VIReC), 2012).  Specifically, 
information on patient demographics (age, race, ethnicity, and gender), coordination of care, 
pharmacy refill records, and service utilization (ER visits, inpatient admissions) are examples of 
some of the variables housed within VistA's powerful applications (Department of Veterans 
Affairs: Office of Enterprise Development, 2008). 
Additionally, located within VistA, are International Classification of Diseases (ICD-9) 
and Current Procedural Terminology (CPT) codes that are required for use by all VHA sites to 
map local data, facilitating the origination of patient cohorts for use in health services research 
(Hynes et al., 2004). VistA contains several mechanisms that allow data analysts to identify 
unique individuals and subsequently link the identifier to ICD-9 codes during cohort generation. 
Such was the case for this study.  
A saying is proliferated in VA, that “when you have seen one VA, you have seen one 
VA”.  Opponents of comparing patient care across hospitals profess that it is not possible to 
control adequately for the way patient care varies from hospital to hospital, let alone across an 
entire healthcare system (Temple, 1990). Variations in clinical care among individual VAMCs 
was of particular concern since a systems framework provides the investigational foundation.   
VistA is a good example of the individualized character perpetuated by each VAMC. All 
VA data housed in VistA originates at the local level of each individual VA site of operation 
(Justice et al., 2006). Local data is subsequently stored at the VISN (regional) level by 
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combining information from multiple facilities into a data warehouse. Finally, consolidated data 
from local and VISN levels, processed through the National Patient Care Database System 
(NPCD), is made available for research in a central location in Texas, the Austin Information 
Technology Center (AITC) (Hynes et al., 2004). Therefore, VistA provides the foundation for all 
VA databases and is the best source of clinical data (M. W. Smith & Joseph, 2003). 
However, while each VAMC has VistA, not all modules are available at each facility 
creating differences in data fields varying across medical centers (VA Information Resource 
Center (VIReC), 2012). Additionally, because of the large amounts of information generated by 
VistA, facilities regularly purge data, further adding to the hazard of heterogeneous data pulls.  
Furthermore, local VA procedures may differ in the manner data collection and 
recordings occur, causing data elements to have slightly different meanings at various VA sites 
(VA Information Resource Center (VIReC), 2012) . This is true of the outcome variable for this 
study, medication adherence, as variations exist across facilities in processing pharmacy data (M. 
W. Smith & Joseph, 2003). Therefore, knowledge of a local VistA system is required to ensure 
the information obtained is what is requested (Maynard & Chapko, 2004). As a result, this study 
provided preliminary information regarding systematic VA influences of one VAMC on 
coordination of care, medication adherence, and healthcare utilization that segway into regional 
and national investigations examining the relationship of these variables.   
CPRS 
VistA is comprised of more than 100 applications under constant revision. A keystone 
VistA application is the Computerized Patient Record System (CPRS), part of the revolution in 
patient care within VHA in the 1990s and remains the software package most often accessed by 
clinical personnel throughout the VA healthcare system today (Kizer, 1996). As such, CPRS 
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generates a large portion of data found in VistA and can provide longitudinal statistics for an 
individual patient (VA Information Resource Center (VIReC), 2012). Information culminating 
from CPRS provided foundational elements for the dataset used in this study.   
Pharmacy Databases 
VA pharmacy data is an important resource for understanding medication adherence 
because refill data can stratified prescription drug use by patient characteristics, such as age, 
gender, or race. While inpatient and outpatient pharmacy information exists, this study only 
captured outpatient pharmacy data as previously outlined.  
There are three sources for VA pharmacy data: VistA, the Pharmacy Benefits 
Management (PBM) package, and DSS NDE Pharmacy SAS datasets. Because this study used 
local and VISN level VA data only, this discussion will focus on the database used for local as 
well as VISN level data capture, VistA. An important aspect of VA pharmacies is that they only 
fill prescriptions promulgated by VA providers with prescriptive privileges. Customarily, the 
provider enters medication orders into CPRS.  
VistA Pharmacy 
The VistA pharmacy package is comprised of 13 elements that function synergistically to 
assemble all pharmacy data at the local level relative to prescriptions filled in the VA 
(Department of Veterans Affairs: Office of Enterprise Development, 2008). VistA contains both 
inpatient and outpatient prescription data from 1997 onward and features information on the 
prescribing origin of the prescription such as primary or specialty care, National Drug Code 
(NDC), VA product name, VA drug class, prescription fill date, total quantity of medication 
dispensed, dispensing units (mg, ml, etc.), and days’ supply of medication given (M. W. Smith & 
Joseph, 2003).  
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To improve the quality of pharmacy data capture, ideally, the days’ supply is corroborated with 
the actual dosing instruction as well as the price per unit of drug. However, dosing instructions 
are only available in national data warehouses that were not accessed for this study. Due to 
resource constraints, the price per unit of medication was not retrieved.  
Cohort Generation 
The literature acknowledges that administrative data is usually of unknown validity. Due 
to feasibility and cost, validity in secondary data analysis occurs by a diagnosis code (ICD-9 
code) and a particular strategy (Harris, Reeder, Ellerbe, & Bowe, 2010). In the case of this study, 
corroboration between an ICD-9 code and refill of a precise list of medications used to treat IBD, 
equated as a reliable method for identifying care of interest (Quan et al., 2004). The International 
Classification of Diseases, ninth revision (ICD-9) codes represent a nosology, an official system 
of assigning codes to diagnoses and procedures associated with healthcare in the U.S.   
ICD-9 codes are frequently used to identify patients for administrative database studies in 
a variety of chronic illnesses including IBD (Motheral et al., 2003).  The inherent limitations of 
this measure, including the possibility of coding errors that pose a challenge to the credibility of 
data accuracy, due to institutional variations in data input, are appreciated (Baker, 2007; Waltz et 
al., 2010). To minimize the threat of institutional variation, this study only retrieved data from 
one VA facility because local VA data managers possess detailed knowledge of the clinical and 
administrative processes used to produce various data elements (VA Information Resource 
Center (VIReC), 2012) .  
 While VHA uses ICD codes to set resource allocation for its beneficiaries, the validity of 
using ICD-9 codes as a measure of patient status continues to be widely debated (VA 
Information Resource Center (VIReC), 2012). Suggestions exist that clinician payment for 
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services drives the assignment of a diagnosis code (Sarrazin & Rosenthal, 2012). However, in 
VA, direct reimbursement for care to the provider does not occur, making this a less influential 
factor. Another argument against using ICD-9 codes in research is the evolution of diagnoses 
codes overtime (Sarrazin & Rosenthal, 2012). This study controls for this impact by examining 
only one FY, 2011.  
To improve the accuracy of patient selection, a technique validated previously in the 
study population is used. The study sample consisted of all veterans enrolled in one northeast 
VAMC between October 1, 2010 and September 30, 2011 with an ICD-9 code of 555.x for CD  
and 556.x for UC, validated previously in the VA IBD population (Khan et al., 2012; Lachaine et 
al., 2013; Mitra et al., 2012; Thirumurthi et al., 2010).  See Figure 3.2 for study variable 
extraction. The possibility of selection bias exists in administrative database studies due to lack 
of randomization. To account for this, all factors utilized in the selection of subjects for this 
study were clearly delineating as described below.   
Inclusion Criteria 
Individuals with at least one of the above outpatient ICD-9 codes at any time during FY 
2011, with at least one outpatient prescription of the following oral medications used to treat 
IBD, and who refilled the medication at least twice during the observation period, were included 
for final analysis: medication (mesalamine 250mg (NDC: 54092-0189-81), mesalamine 375mg 
(NDC: 65649-0103-02), mesalamine 400mg (NDC: 00149-0752-15) mesalamine 1,200mg 
(NDC: 54092-0476-12), olsalazine (NDC: 68220-0160-10), balsalazide (NDC:, 00054-0079-28), 
sulfasalazine (NDC: 43353-0495-80) , azathioprine (NDC: 00054-4084-25), mercaptopurine 
(6MP) (NDC:  00054-4581-27).  
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At least two refills of medication were required to calculate the adherence measure for 
this study, the MPR. Any patient with a 555.x for CD and 556.x for UC, on any occasion in FY 
2011, as well as a prescription for any of the above medications confirmed the diagnosis of IBD 
(Kappleman et al., 2008; Kappleman et al., 2011; Waltz et al., 2010).  For patients with ICD-9 
codes for both UC and CD, disease assignment occurred according to the majority of codes 
presented (Kappleman et al., 2011).  
Exclusion Criteria 
Because of a whole host of treatment specific confounders with oral steroids, biologic 
medications, rectal preparations, and injectable methotrexate, these drugs were excluded from 
analysis (Cooper, Hall, Penland, Krueger, & May, 2009; Kappleman et al., 2008). Moreover, 
exclusions included prescriptions filled prior to October 1, 2010, thereby limiting "carry in" 
prescriptions filled prior to the measurement period (Cooper et al., 2009).   Patients with ICD-9 
codes for IBD but who were note prescribed medications for said disorder were also 
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Figure 3.2  Extraction of Study Variables 
 
excluded from analysis, as the aim of this study was to describe the medication adherence rates 
in this population (Gellad, 2012).  
Additional exclusions are the above IBD medications administered while the veteran was 
an inpatient, since the aim of this study was to describe adherence to long-term therapy in IBD 
and not adherence to acute medication needs dictated by an inpatient admission. Therefore, 
adjustment of the denominator in the MPR calculation occurred to reflect the number of days 
between the first fill and the last refill plus the days’ supply of the last refill minus the days of 
inpatient admission. 
Furthermore, patients seen in Gastroenterology not seen by primary care were also 
excluded from analysis because a critical component of this study was to examine the 
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relationship between medication adherence and healthcare utilization among subjects cared for in 
the primary care setting in isolation, versus subjects who received coordination of care. Further 
discussion of these excluded patient follows. Information on patients receiving GI care alone was 
included in the final report. 
Clinic Stop Code Quality 
The study used clinic stop codes, 323, 301, 322, 348, 350, 170, 634, and 172 for Primary 
Care, 151 for Gastroenterology, and 77 for ER. The literature contained only one study that 
examined the accuracy of a VA clinic stop code. While the clinic stop code under investigation 
was not the one used in this study it is the only data that exists that speaks to the validity of using 
this method to identify points of care. Because the quality of data in VistA is largely uncharted, 
reviewing a study containing pertinent variables of interest may be the best place to discover 
information on data quality (VA Information Resource Center (VIReC), 2012) . As a result, the 
details of this study follow.  
  (Harris et al., 2010) conducted a study that included over 2,600 subjects, to validate the 
substantiation with specialty clinic stop codes used to designate treatment for a substance use 
disorder (SUD) and receipt of SUD care as documented in clinical progress notes. Two raters 
independently reviewed records and classified them as either documenting or not documenting 
SUD. The results demonstrated that 14.1% of the progress notes reviewed did not contain a note 
supporting the diagnosis SUD the day of code entry. Approximately 92% of progress notes 
contained evidence of SUD treatment when both a clinic stop code and CPT code for such 
accompanied the medical record. However, the VISN ranges of concordance were variable 
between 57-100%, which are exacerbation at the local facility level as has been supported in the 
literature previously (Tarlov & Stroupe, 2010).   
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The results of this study demonstrate the inability to ascertain data quality in national VA 
datasets with discordance found between national and local information. National level VA data 
discrepancies provided further support for the use of local VA data for this investigation.  
Additionally, as the above study demonstrated, diligence in the actual process of data 
mining is required. For example, the use of two independent raters to review data results is 
suggested to improve the accuracy of data pulls. While resources for this study did not allow for 
a second data reviewer, concretely defining study variables by creating a coding index served to 
improve data retrieval accuracy as well as internal validity  (Gearing, Mian, Barber, & Ickowics, 
2006) and inter-rater reliability (VonKoss Krowchuk et al., 1995) as displayed in Table 9. 
While VA databases provide the most comprehensive patient-level clinical data in VHA, 
the size and complexity of these databases requires in depth understanding to ensure accurate 
data extraction (VA Information Resource Center (VIReC), 2012). Therefore, VA researchers 
who wish to use retrospective data for research are strongly encouraged to work closely with a 
local VA data manager who has expert knowledge of the information contained in each database 
because extracting data in a structure that can be analyzed using statistical software can be 
arduous (Maynard & Chapko, 2004). The statistician for this study was the in residence local 
data expert. 
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Table 9 
Coding Index 
 
Dependent Variables Definition Level of Measure 
 
MedAdhere1 
 
Medication Adherence 
 
0 = Non-adherence (MPR < 0.80) 
1 = Adherence        (MPR > 0.80) 
 
Dichotomous 
MedAdhere2 Medication Adherence 
 
0 = Non-adherence (MPR < 0.90) 
1 = Adherence        (MPR > 0.90) 
 
Dichotomous 
HealthCareU1 Utilization primary + GI    
                                      
0 =  no GI outpatient, primary care only 
1 =  yes primary care  +  GI outpatient  
 
Dichotomous 
HealthCareU2 Utilization primary + ER 
 
0 =  no ER visits, has primary care only 
1 =  yes primary care  +  ER visits 
Dichotomous 
HealthCareU3 Utilization primary + inpatient admission  
 
              
0 =  no inpatient, primary care only 
1 =  yes primary care  +  inpatient  
Dichotomous 
Independent Variables Definition Level of Measure 
 
Demographic 
Age Age Continuous 
Gender Gender 
0 = Male 
1= Female 
Dichotomous 
RaceEth 
 
 
 
 
0 = White 
1 = Non-White: Black, American Indian or 
Alaska Native, Asian, Native Hawaiian or 
Pacific Islander, Hispanic or Latino, not 
Hispanic 
 
 
Dichotomous 
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Table 9 (continued) 
Coding Index 
 
Independent Variables Definition Level of Measure 
 
Medication 
MPR Medication Possession Ratio (MPR) 
 
Pharmacy refill records to calculate the 
MPR: the sum of days’ supply of 
medication divided by the number of days 
between the first fill and the last refill plus 
the days’ supply of the last fill 
 
 
Continuous 
Fill Date 
 
Date of fill, date Date 
Days’ Supply 
 
Day Supply of medication (30, 90) Continuous 
Tablets Dispensed 
 
Number of tablets dispensed Continuous 
IBD 
 
IBD Diagnosis Diagnosis: 555x. CD, 556.x UC                                                                                   
 
0 = UC 
1 = CD 
 
 
Categorical  
IBDMED IBD Medication 
 
0 = 5-ASA 
1 = Immunomodulator 
2 = Both 
 
Categorical 
 
IBD Medication: 5-ASA 
 
Balsalazide 
 
 
Balsalazide 
0 = no 
1 = yes 
 
Dichotomous 
Mesalamine 
 
 
 
 
Mesalamine 
0 = no 
1 = yes 
 
Dichotomous 
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Table 9 (continued) 
Coding Index 
 
Independent Variables Definition Level of Measure 
 
IBD Medication: 5-ASA 
 
Olsalazine Olsalazine 
0 = no 
1 = yes 
 
Dichotomous 
Sulfasalazine Sulfasalazine 
0 = no 
1 = yes 
 
Dichotomous 
 
 
IBD Medication: Immunomodulator 
 
Azathioprine Azathioprine 
0 = no 
1 = yes 
 
Dichotomous 
Mercaptopurine (6MP) Mercaptopurine 
0 = no 
1 = yes 
 
Dichotomous 
Comorbidity 
 
Comorbidity Comorbidity 
 
Deyo (1992) with Hall (2004) Calculator 
 
Continuous 
ComorbidityII Comorbidity 
 
0 = no 
1 = yes 
 
Dichotomous 
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Table 9 (continued) 
Coding Index 
 
Independent Variable Definition 
 
Diagnostic Category 
(All comorbidities are dichotomous coded yes/no for each diagnostic category by ICD-9) 
 
MI 
 
Myocardial Infarction:  410-410.9, 412 
 
CHF 
 
Congestive Heart Failure:  428-428.9 
 
PVD 
 
Peripheral Vascular Disease:443.9, 441, 441.9, 785.4, V43.4, 38.48 
 
Cerebro 
 
Cerebrovascular Disease:  430-438  
 
Dementia 
 
Dementia: 290-290.9 
 
Lung 
 
Chronic Pulmonary Disease: 490-496, 500-505, 506.4 
 
Rheum 
 
Rheumatologic Disease: 710.0, 710.1, 710.4, 714.0-714.2, 714, 81, 725 
 
Peptic 
 
Peptic Ulcer Disease: 531-534.9, 531.4-531.7, 532.4-532.7, 533.4-
533.7, 534.4-534.7 
 
LiverMild 
 
Mild Liver Disease: 571.2, 571.5, 571.6, 571.4, 571.49 
 
Diabetes 
 
Diabetes: 250-250.3, 250.7 
 
DiabetesCom 
 
Diabetes with Chronic Complications: 250.4-250.6 
 
Paralysis 
 
Hemiplegia/Paraplegia: 344.1, 342-342.9 
 
Renal 
 
Renal Disease: 582-582.9, 582-583.7, 585, 586, 588-588.9 
 
Malignancy 
 
Any Malignancy: 140-172.9, 174-195.8, 200-208.9 
 
LiverMoSev 
 
Moderate/Severe Liver Disease: 572.2-572.8 
 
MalignancyMets 
 
Metastatic Solid Tumor: 196-199.1 
 
AIDS HIV Infection: 042-044.9 
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Table 9 (continued) 
Coding Index 
 
Independent Variable 
 
Definition Level of Measure 
Healthcare Utilization 
 
CoordinationCare 
 
Coordination of care, FY 2011  
0 = Primary Care only 
1 = Primary Care + GI Specialty Care 
 
Dichotomous 
PrimeCare 
 
Total primary care visits, FY 2011 
  
stop codes 323, 301, 322, 348, 350, 170, 
634, and 172 
 
Continuous 
GIOutpt 
 
Total GI specialty visits, FY 2011 
 
stop code 151 
 
Continuous 
ERVisit 
 
Total ER visits, FY 2011: stop code 77 Continuous 
InPt 
 
Total inpatient admissions, FY 2011  Continuous 
LOS Length of Stay Continuous 
 
 
Pharmacy Data  
Data quality is a limitation when using pharmacy refill information in research. While a 
large body of literature has been generated using VA pharmacy data, a gap in the literature exists  
regarding the exactness of this material (M. W. Smith & Joseph, 2003) . VistA is the primary 
source for clinical data in VA for which no record is available against which to validate 
information because all data entry occurs directly into the system through CPRS  (M. W. Smith 
& Joseph, 2003).Pharmacy administrative database have a high specificity, if medications are 
obtained from a closed pharmacy system such as in VA and patients are not obtaining 
medications from other sources as is assumed for this study (Hynes, 2012).  Moreover, pharmacy 
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datasets support analysis of population based prescribing habits, drug utilization trends,  
unwarranted variations in clinical practice, and estimate drug usage at local, regional, or national 
levels (Cunningham, Sales, & Valentino, 2001). 
Accuracy of medication identification using VA pharmacy databases was the focus of a 
national VA study of 268,774 individuals (Schutte, Hu, Schmitt, & Phibbs, 2011). Subjects with 
at least one outpatient or inpatient diagnosis for bipolar disorder between FY02 and FY09 based 
upon ICD-9 codes for this mental illness. Eligible patients were then paired with descript list of 
medications (26) used to treat this condition. Similar to how cohort generation will take place in 
this study.  
Subsequently, a systematic review of patient’s medication compared the presence of one or 
more of the identifiers noted below in a national VA database using such combinations as: IEN 
only, NDC only, IEN + NDC, and IEN + NDC + IPNUM/IPNO.  There are four variables in VA 
national databases that provide medication name and strength: Internal Entry Number (IEN), 
National Drug Code (NDC), Intermediate Product Number (IPNUM/IPNO), Drug Description 
(DRUGDESC) (Schutte et al., 2011), the first three of which were used in this study. Omission 
of the DRUGDESC identifier occurred since an unknown quantity of misspellings and 
abbreviated drug names exist in this file (Schutte et al., 2011) . 
Overall, the results established with 99.3% accuracy that the assigned IEN, NDC, and 
IPUNUM/IPNO identifying codes were in full agreement about whether a prescription for 
bipolar medication existed. Results for all identifiers were statistically significant (p. <0.05) with 
higher levels of significance found with multiple identifies (p.<0.001). The authors 
recommended the use of multiple-drug identifiers for completeness. To enhance the accuracy of 
pharmacy data in this study, the use multiple medication identifiers was deployed when possible.  
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Measuring Medication Adherence 
Medication adherence is a multifaceted construct, such that any measurement used in 
isolation for measurement is a recognized study limitation. Pharmacy data is not a proxy for 
adherence it represents just one part of this complex construct.  
For example, in this study, the use of pharmacy refill data did not take into account the 
additional activities that may influence medication adherence in this regard, such as a visit to the 
clinician to obtain said prescription, filling the prescription, taking the medication as prescribed, 
as well as refilling the medication. Therefore, this study examined just one of the many aspects 
of medication adherence.   
Lack of a consensual definition of medication adherence in the literature is another 
limitation of this study. Significant enhancement to external validity or reproducibility occurs 
with the standardization of data (Jansen et al., 2005).   A critical component of secondary data 
analysis will be to establish operationalized definitions of chosen measurements to aid in 
reclamation of data from databases. To add to the current adherence literature in a meaningful 
way, the definition of medication adherence advised by ISPOR (Cramer et al., 2008) in a 
consensus document served as the definition of adherence for this study.  Additionally, during 
methodologic decision-making, every attempt to utilize standard measures as outlined by the 
international retrospective adherence experts of ISPOR occurred (Peterson et al., 2007) . 
The outcome variable for this study was medication adherence, assessed using VA 
pharmacy refill data, measured for one year, FY 2011, for several reasons. One, the theoretical 
foundation for this investigation, the CCM, is a systems model. The system under consideration, 
the VA, is constantly changing how it organizes care delivery, assigns clinical priorities, and 
allocates funding appropriated by Congress. Therefore, examination of recent FY data to 
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describe current systematic influences on all variables, specifically the relationship between 
coordination of care, medication adherence, and healthcare utilization was consistent with the 
CCM. Additionally, to ensure completeness of information, use of FY datasets that are closed is 
advised (Hynes, 2012) . At the time of this publication, FY 2011 is the most recent complete 
dataset available. Two, VA databases are under constant revision. Therefore, how data 
compilation takes place, using current databases, may not be how data aggregation occurred even 
a year ago (Hynes, 2012). Additionally, database attributes can vary widely depending on the 
research question(s) and analysis performed (Motheral et al., 2003). 
Moreover, this study  examined only 1 year of medication adherence because medication 
adherence changes over time and this study was meant to describe the medication adherence 
patterns of a group about which little is known. While the greatest decline in adherence for many 
chronic medications occurs over the first year of therapy (Deizii, 2000), it was not the intent of 
this study to explore adherence rates of new users versus those with longer disease durations.  
The following were assumptions when using pharmacy refill data to measure medication 
adherence: medications prescribed were appropriate, pharmacy records were accurate, 
medication acquisition from another person or venue did not occur, lack of a refill equated with 
medication not consumed during that period, and no healthcare provider treatment interruptions 
occurred during the refill period (Williams, Amico, Bova, & Womack, 2012).  An additional 
assumption was that patients refilling medication were unlikely to pick up medications with no 
intentions of taking them (S. Kane et al., 2001).  
Local VA databases did not contain any information regarding private insurance 
coverage outside of VA. Therefore, it was conceivable that a patient may fill a prescription for 
IBD medications outside the VA. This was a study limitation. 
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Race Data Quality 
All race data originates at the local VA level in VistA and is then compiled into national 
VA datasets. Heterogeneity in defining race exists in VA national level race data. For example, 
the VHA Office of Informatics and Analytics compared data extraction for race from two 
national VA databases, Corporate Data Warehouse (CDW) and the Administrative Data 
Repository Reporting Production (ADRRP) that demonstrated a lack of consistency in defining 
race across the VA system. Review of four million unique patient records housed in CDW, 
revealed 31 non-standard race values with different race values for the same individual across 
facilities. A patient may have up to seven race assignments in CDW. Whereas ADRRP, provides 
only standardized race values contained in a single demographic record for each patient. 
However, race data was missing for 171,000 individual demographic records. These 
inconsistencies provided further support for the use of local VA data only to improve the 
accuracy of data capture. An additional race limitation of this study was homogeneity in this 
cohort that limits generalizability of study findings beyond VHA.  
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Chapter 4 
Manuscript: Results and Discussion 
The results for study aims are below which included the primary study aim: described 
medication adherence rates, healthcare utilization, and care coordination of veterans with 
inflammatory bowel disease (IBD) who employ Veterans Affairs (VA) healthcare at one 
Veterans Affairs Medication Center (VAMC). Secondary study aims included: examination of 
the association between medication adherence adjusted for care coordination, age, IBD 
diagnosis, comorbidity, and IBD medication in veterans with IBD who employ VA healthcare; 
and exploration of the relationship between healthcare utilization adjusted for medication 
adherence, age, IBD diagnosis, IBD medication, care coordination and comorbidities in veterans 
with IBD who employ VA for healthcare. The manuscript was prepared for submission to a 
journal with a GI focus entitled, Inflammatory Bowel Diseases. The title for this manuscript is 
“A retrospective data analysis: Using Wagner’s Chronic Care Model to explore predictors of 
medication adherence in veterans with inflammatory bowel disease”.  ISPOR retrospective 
database publishing recommendations informed final manuscript construction.1   
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Abstract 
Background 
Medication adherence in inflammatory bowel disease (IBD) ranges between  
7-72%. Increased healthcare utilization has been associated with non-adherence in IBD. 
Wagner’s Chronic Care Model (CCM) posits that care coordination between primary and 
gastroenterology (GI) specialty care could improve adherence and healthcare utilization.  
Methods 
Guided by the CCM, a retrospective analysis was conducted in veterans with IBD to: 
describe medication adherence rates; describe healthcare utilization measured by ER visits and 
inpatient admissions; and describe care coordination measured by primary care and GI specialty 
care use.  A secondary study aim was to explore the relationships between those key outcome 
variables and select demographic/health history characteristics. 
A local Veteran’s Affairs database was used to extract a cohort of individuals with 
Crohn’s disease and ulcerative colitis for fiscal year (FY) 2011. Medical utilization and IBD 
medication refills were collected. A dichotomized medication possession ratio (MPR .80) was 
used in logistic regression to identify factors affecting medication adherence.  Logistic regression 
was also used to examine factors affecting ER visits, inpatient utilization, and care coordination. 
Results 
The cohort consisted of 165 White male veterans 75 with Crohn’s disease and 89 with 
ulcerative colitis. The overall rate of adherence was 50.9% with a median MPR of .82. 
Regression models did not render any statistically significant predictors of adherence.  ER 
utilization was significantly associated with adherence (OR=.314, 95%CI=.111-.886, p=.029) 
and care coordination (OR=45.73,95%CI=9.053-231,p=.001) in multivariate analysis. Inpatient 
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admission was associated with: younger age (OR=.108,95%CI:.019-.609,p=.012), adherence 
(OR=.113,95%CI=.014-.939,p=.044), IBD diagnosis (OR=.117,95%CI=.017-.784,p=.027), and 
care coordination (OR=11.89,95%CI=1.228-115,p=.033). Logistic regression identified 
statistically significance associations with care coordinated between primary and GI specialty 
care and the following factors: taking both a 5-ASA and immunomodulating medication 
(OR=5.122,95%CI=1.874-14.00, p=.001), younger age (OR=.905,95%CI=.871-.940,p=.001), 
and having a comorbidity (OR=2.643,95%=1.171-5.965,p=.027).   
Conclusions  
No predictors of medication adherence emerged. However, the CCM element of care 
coordination provided additional insight into the healthcare utilization of veterans with IBD as 
statistically significant associations between ER visits and hospitalization were identified. 
Further inquiry into the influences of medication adherence and healthcare utilization in this 
population is warranted.  
 
 
 
 
 
 
 
 
key words: adherence to medication, Wagner’s chronic care model, coordination of care,    
                  veterans, inflammatory bowel disease  
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Introduction 
Ulcerative colitis (UC) and Crohn’s disease (CD) comprise inflammatory bowel disease 
(IBD), a set of chronic inflammatory diseases of the GI tract. The financial burden of IBD in the 
United States (U.S.) is considerable, in the range of 3-8 billion dollars annually.1 Nearly 1.5 
million Americans suffer with IBD.2  However, little is known about the 45,000 veterans with 
this disease who access the world’s largest integrated healthcare system, the Veterans Health 
Administration (VHA).  
Life-long medication administration is required in IBD to control this often tenuous 
condition.  However, medication adherence for those who are diagnosed is problematic, in the 
range of 7-72%.3  Modifying factors affecting medication adherence in IBD are not distinctive, 
existing in many chronic diseases and include age, lack of knowledge regarding illness and 
treatment, discordance in the physician-patient relationship, low health literacy, pill burden, 
employment, and depression.4  Several noteworthy, unique, condition specific factors found to 
affect adherence include remission status, disease type (CD versus UC), new patient status, 
timing of last colonoscopy, and taking immunosuppressants.4  No consistent variables that could 
be used to direct interventions have emerged as predictors of adherence in this population. 
Furthermore, there have been no studies conducted to date that have explored predictors 
of medication adherence in veterans with IBD. While two studies have been published 
examining medication adherence in this cohort, the studies focused on disease recurrence. The 
authors found the adherence rate of veterans to be between 37-48%, with non-adherent patients 
at increased risk for a disease flare.49,50 
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Evidence indicates that when chronic illness is sub optimally treated, complications may 
worsen leading to increased consumption of healthcare resources such as ER services, inpatient 
admissions, as well as office visits,4 suggesting that higher levels of medication adherence may 
reduce healthcare costs.5 Repeatedly, research has demonstrated that those with IBD who do not 
follow prescribed medication regimes have higher rates of healthcare utilization.6-8 World 
adherence experts provide support for examination of healthcare utilization concurrently with 
medication adherence as this data works synergistically to accurately inform health outcomes 
and future interventions. 9 
Often IBD care is multidisciplinary requiring input from other specialty services and 
departments such as the emergency room (ER), inpatient medicine, surgery, radiology, 
pathology, dermatology, rheumatology, and ophthalmology.10  Contributions from primary care, 
the gatekeeper to specialty healthcare in the United States, are rarely considered.16   Inquiry into 
the effects of a closed system such as VHA, using Wagner’s Chronic Care Model (CCM) may 
provide insight into the associations of both primary and specialty care with medication 
adherence and healthcare utilization of veterans with IBD. 11  VHA adopted the CCM in the late 
1990s as a vehicle for transformation. 12 The CCM element of care coordination became integral 
to delivery of chronic illness care of veterans orchestrated by primary care with consultation to 
specialists as warranted.  Intuitively, coordination of primary and specialty care should equate 
with improved health outcomes. However, results from a Cochrane review revealed conflicting 
results.13  Medication adherence was the only clinical outcome that demonstrated improvement 
with care coordination. The effects of the VHA system on medication and healthcare utilization 
in this population are unknown supporting the primary line of inquiry to describe medication 
adherence and healthcare utilization in veterans.  
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Study Purpose 
 Guided by the CCM, a retrospective analysis was conducted in veterans with IBD to: 
describe medication adherence rates; describe healthcare utilization measured by ER visits and 
inpatient admissions; and describe care coordination measured by primary care and/or GI 
specialty care use. A secondary study aim was to explore the relationships between those key 
outcome variables and select demographic/health history characteristics. 
Ethical Considerations 
Approval was obtained from the appropriate institutional review boards.  
Methods 
Design & Data Source 
A descriptive, retrospective data analysis was conducted by extracting information from a 
local VA data warehouse, Veterans Health Information Systems and Technology Architecture 
(VistA), containing information about patients treated in the VA Healthcare System which is 
updated nightly. VistA is an integrated system of software applications that directly supports 
patient care at VA healthcare facilities by tying together workstations and personal computers, 
providing a system of management tools that create uniformity of data across the VA system. 15 
Each VistA application generates clinical and administrative data that support the day-to-day 
operations of VA facilities and contain patients' medical and healthcare utilization histories. 16  
VistA contains the most clinical detail of any VA database and as such, captures many data 
points that are not currently available in any other national VA data source 10 and was used to 
collect the following study measures: International Classification of Diseases, Ninth Revision 
(ICD-9) codes, outpatient pharmacy, patient demographics, and healthcare utilization.  VistA  
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and Veterans Integrated Service Network (VISN) data were collected for outpatient medication 
refills only to ensure completeness of  pharmacy data capture.   
Study Population 
The population for this investigation consisted of enrollees in one northeast VA who 
sought care for IBD between October 1, 2010 and September 30, 2011 for IBD, fiscal year FY 
2011.  Cohort inclusion and exclusion criteria are located in Table 1.  
Study Measures 
 Medication adherence was measured using the medication possession ratio (MPR).17 
 The MPR was the sum of the days’ supply of medication divided by the number of days 
between the first fill and last fill including the days’ supply of the last fill.16  MPR was calculated 
for each medication for each patient and a mean MPR was calculated for each patient taking 
more than one medication. 18  As is widely used in the literature, the MPR was a continuous 
variable for descriptive analysis, dichotomized for logistic regression models so that those with 
an MPR >.80 were adherent and those with an MPR < .80 were non-adherent. 19-30  MPR was an 
examined both as a dependent variable in a logistic regression model and was then an 
independent variable in the regression models for ER utilization and inpatient admission. The 
MPR would not include those with primary non-adherence such as those who were prescribed a 
medication but had not picked it up from the pharmacy. Additionally, because the MPR requires 
at least two medication refills during the observation period, those filling only one prescription 
were not included in the final analysis.  
Healthcare utilization variables included ER visits and inpatient admissions, represented 
by respective clinic stop codes. For descriptive purposes, the total number of occurrences over 
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the one year observation period for each visit type for each patient was collected. However, for 
logistic regression, all healthcare utilization variables were dichotomized, yes/no.  
Care coordination was measured using clinic stop codes for primary care and 
gastroenterology (GI) specialty care. For descriptive purposes, the total number of occurrences 
over the one year observation period for each visit type for each patient was also collected. 
Veterans with IBD were assumed to have care coordination if both primary and specialty GI 
clinic stop codes were present.  
Demographic variables included age, gender, race, ethnicity, IBD diagnosis (CD versus 
UC) and IBD medication (5-aminosalycilate (5-ASA), immunomodulator, or both) were used to 
describe the population under study. 
The Deyo adaptation 31 of the Charlson Comorbidity Index (CCI) 32 was used to calculate 
comorbidity. Deyo identified 17 categories of medical conditions using ICD-9 codes and 
assigned a weighted score for each condition that was summed (Table 1). Higher values 
indicated more severe levels of comorbidity.   
Statistical Analysis 
Data analysis was performed using the Statistical Package for the Social Sciences (SPSS) 
version 21.0. 33  A two-tailed test of significance was used with alpha set at .05.   
Variable analysis began with descriptive statistics for all study variables including 
distribution of continuous variables. Chi-squared tests for categorical variables and t-test 
(normally distributed) or Mann-Whitney U tests (non-normally distributed) for continuous 
variables were conducted to examine bivariate associations between the primary outcomes of 
medication adherence and healthcare utilization and remaining study variables. Similar 
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procedures were used to explore care coordination as an outcome. All variables were entered into 
logistic regression models regardless of bivariate analysis results.34 
Simultaneous logistic regression was used to examine the effect of age, IBD diagnosis, 
IBD medication, comorbidity, and care coordination on adherence, dichotomized (yes (MPR 
>.80)/no MPR <.80). Medication adherence was then entered as an independent predictor in ER 
and inpatient regression models. 
Similar logistic regression model construction was used to explore the impact of age, IBD 
diagnosis, IBD medication, comorbidity, medication adherence, and care coordination on ER 
utilization and inpatient admission (both dichotomized yes/no). Because IBD diagnosis was not a 
significant bivariate predictor, the interaction terms: IBD diagnosis * coordination of care; IBD 
diagnosis*age; and IBD diagnosis*medication adherence were created and entered separately 
into the inpatient regression model. Odds ratio, 95% CI, and P-values were reported for all three 
regression models.  
Results 
A cohort of 247 (Figure 1) patients extracted from a local VA database with at least one 
ICD-9 code for 555.x (CD) and 556.x (UC) were identified between October 1, 2010 and 
September 30, 2011.  Females (n=11) and non-Whites (n=14) were excluded because of minute 
representation. Patients receiving GI specialty care alone (n=36) were also excluded because a 
critical study component was to examine relationships between patients cared for in the primary 
care setting in isolation, versus patients who received care coordination through primary and GI 
specialty care. The final study sample consisted of 165 patients who met all inclusion and 
exclusion criteria (Table 2).  
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Study Population 
The final study sample was homogenous, consisting of White males. The mean age was 
69.2 years (SD+ 13.4) with 81% of the sample falling between 60 and 89 years.  In the study 
cohort, 75 had CD (46%) and 89 had UC (53.9%). A 5-ASA product was prescribed for 76% of 
patients while 24% of the sample refilled an immunomodulating medication.  Comorbidity was 
not present in 44.8% of the sample. The median comorbidity score was 3, SD + 2.9. The top 
three comorbidities were COPD (23%), malignancy (15.2%), and cerebrovascular disease 
(9.1%).   
Medication Adherence Descriptive Results 
The adherence rate for the entire sample was 50.9%. The median MPR was .82.  As 
Table 3 demonstrates, the range of adherence for all IBD medications was as high as 78% for 
mesalamine 375mg and as low as 60% for those taking both a 5-ASA and an immunomodulator. 
Table 4 presents a summary comparison of study variables by adherence in bivariate analysis 
which did not reveal any statistically significant factors associated with adherence.  
Healthcare Utilization Descriptive Results 
ER Utilization 
The mean number of ER visits was .37. The median was 0 .00; 83.1% of patients did not 
utilize ER services. Seventeen of the 28 patients who used the ER had 1 ER visit. Bivariate 
analysis revealed a statistically significant relationship between ER utilization and patients with 
care coordinated between primary and GI specialty care indicating that patients with care 
coordination were more likely to engage ER services (OR=29, 95%CI=6.67-129.6, p<.001).  
Bivariate analysis also identified medication adherence as a predictor of ER utilization 
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suggesting that adherent patients were less likely to use the ER (OR=.321, 95%CI=.132-.779, 
p=.009).  
Inpatient Admission 
Only 10 patients (6%) had an inpatient admission, the mean length of which was .71 
days, SD +   3.9. The median number of inpatient admissions was zero as most patients were not 
hospitalized. Bivariate analysis revealed a statistically significant relationship between inpatient 
utilization and care coordination suggesting that patients with care coordination are more likely 
to have an inpatient admission (OR=14.64, 95%CI=1.809-118.547, p=.001). Medication 
adherence was also a statistically significant bivariate predictor of inpatient admission 
demonstrating that adherent subjects were less likely to experience an inpatient admission 
(OR=.223, 95%CI=.046-1.082, p=.044). Bivariate analysis likewise revealed a statistically 
significant difference in age between patients with an inpatient admission and patients without an 
inpatient admission (t (163)=2.654, 95%CI=2.982-19.943, p =.009).  Those with an inpatient 
admission were younger (M = 57.3) versus those who without (M = 70.6). 
Care Coordination Descriptive Results 
The final primary study aim was to describe care coordination of veterans with IBD 
measured by primary care and GI specialty care visits. Care presumed to be coordinated between 
primary and GI specialty care was found in 41% of the sample. A statistically significant 
percentage of patients who had care coordination were prescribed both a 5-ASA and an  
immunomodulating medication (30%) compared to those managed by primary care alone 
(13.2%)   X2(14.182, p=.001).   
Independent samples t-test demonstrated a statistically significant difference in age 
between those cared for in primary care alone and those who received care coordination 
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(t (163)=4.829, 95%CI=.166-.396, p<.001). Those who received care coordination were younger, 
(M=62.9, SD +14.1) than those seen in primary care alone (M=74.4, SD+10.3). More patients 
with CD (24.2%) than UC (17.1%) had chronic illness care coordinated between primary and GI 
specialty care which was statistically significant (OR=2.421, 95%CI=1.283-4.567, p =.006).  
The mean number of primary care visits for patients with care coordinated between 
primary and GI specialty care was 2.21 (SD + 1.073)  compared to 1.40 (SD+ .623)  visits for 
those seen in primary care alone, which was statistically significant (t(163)= 6.066,95%CI=.542-
1.066, p=.001). Comparatively, 46% of patients with care coordination had 3 (SD+ 2.76) or more 
visits to GI which was also statistically significant (t(163) = 10.724, 95%CI =.2.472-3.587, 
p=.001).  Interestingly, 58.8% of those with a diagnosis of IBD were never seen in a GI specialty 
clinic.  
Multivariate Results 
Medication Adherence 
A secondary aim of this study was to explore predictors of medication adherence and 
healthcare utilization. Multivariate analysis showed no statistically significant relationships 
between medication adherence and the variables of age, IBD diagnosis, IBD medication, 
comorbidity, and care coordination (Table 5). 
ER Utilization 
The logistic regression model with ER utilization dichotomized (yes = ER and no = no 
ER) containing all predictors was statistically significant,  X (7, n=165) = 50.218, p<.001.  The 
model revealed a statistically significant association between ER utilization and care coordinated 
between primary care and GI specialty care (p=.001) and medication adherence ( p=.029)  
(Table 5).  
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Inpatient Admission 
 The full model with all predictors was able to distinguish between patients who did and 
did not have an inpatient admission (X (7, N=165) = 23.681, p<.001).  Table 5 shows that four of 
the six independent variables had a statistically significant relationship with inpatient healthcare 
utilization.  Care coordination was the strongest multivariate predictor of inpatient admission 
(p=.033).  Addition of interaction terms did not produce any statistically significant results.   
Discussion 
This is the first study known that critically appraised chronic illness care in veterans with 
IBD through the CCM lens of care coordination between primary care and GI specialty care 
relative to medication adherence and healthcare utilization. Study strengths included: use of a 
theoretical framework recognized by IBD experts as a mechanism to improve outcomes in 
patients with IBD; 35-37 generation of a cohort using an administrative definition validated in this 
population; 38  use of the gold standard for measuring medication adherence in IBD, the MPR; 19 
and use of the consensus definition and measure for adherence  propagated by the International 
Society for Pharmacoeconomics and Outcomes Research (ISPOR). 18,39 
The overall level of adherence in this study (50.9%) is congruent with previous 
investigations that included other closed government sponsored healthcare systems and continues 
to demonstrate adherence levels well below the accepted value of 80%. 3,47  This study used local 
and VISN level VA pharmacy data only. Although slightly higher in this study, the level of 
adherence was comparable with recent adherence studies that revealed overall levels of 
adherence in this population to be between 37-48%.41,42  as evidenced in large national samples of 
veterans that used the same administrative definition for IBD and similar MPR calculations.  
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However, this is the first study to examine adherence in the IBD population that was not 
able to identify predictors. Regression model construction was parsimonious, guided by the 
literature. One possible reason for the lack of significance in our adherence model could be 
characteristics unique to our sample. Only two studies have been published that examined 
medication adherence rates in veterans with IBD, neither had the goal of identifying predictors of 
adherence in this population. 48-50  The samples of both studies consisted primarily of White 
males with UC, prescribed oral mesalamine. Our study included patients with both CD and UC 
who were prescribed a variety of oral 5-ASA products and/or an immunomodulator.  
Additionally, a recent systematic review conducted to examine factors associated with non-
adherence in IBD demonstrated that patients in IBD adherence studies are younger than the 
patients in our study and are an equal mix of males and females.3   
An additional consideration for these results is the power of the study. It is plausible that 
these analyses could have been underpowered, even though steps were taken to address this issue 
a priori. The only published data that exists related to medication adherence in veterans with IBD 
utilized considerably large samples (n=13,062)50 and (n=4,452)49..  However, these same data had 
been shown to demonstrate significance using other statistical tests. This provides evidence that 
the current sample size provided adequate power. For example, medication adherence 
dichotomized as the MPR (.80) was a significant predictor of ER and inpatient utilization which 
speaks to adequate power of the study.  Nonetheless, our adherence regression model was only 
able to explain 2% (Cox and Snell) to 3% (Nagelkerke) of the variance of those who were 
adherent versus those who were non-adherent. Future adherence studies in veterans with IBD 
should include larger sample sizes and explore additional variables for clinical relevance to 
medication adherence. 
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There is a lack of scientific agreement regarding measurement and definition of 
medication adherence using administrative data in the literature. Measuring adherence using 
pharmacy refill data has been deliberated for decades. 40 Notwithstanding, even consensus 
documents promulgated by ISPOR contain discrepancies in advised definition and measure of 
adherence 18,39. Most recently, Raebel 41 and colleagues, which included Steiner whose sentinel 
paper in 1988 42 started the evolution of electronic database measurement, developed a 
conceptual model for standardization of adherence measurement using an algorithmic approach. 
The model introduces new concepts into the adherence lexicon. Terms such as adequate 
secondary adherence, inadequate secondary adherence, later-stage persistence, later-stage non-
persistence are presented. A new measure of adherence based on medication gaps, new 
prescription medication gap (NPMG), is also offered. In an attempt to provide a comprehensive 
approach to adherence measurement, new layers of complexity appear. One issue that was 
beyond the scope of the paper was the acceptance of an MPR of .80 as representative of 
adherence. Although the MPR is the most frequently used administrative measure, it too has its 
limitations.  43 An MPR of .80 equates to taking a medication 80% of the time. This means that 
20% of the time, the patient is not taking any medication. Use of this cutoff implicitly assumes 
that no change in health outcome occurs as result of this “allowable gap” in treatment. The 80% 
cut off is used widely throughout adherence literature for many chronic disease states, although 
not supported by any documentation of the clinical validity of this measure. 44,45 The origins of 
these cut off points are based on the principal that loss of >20% of a patient population in a 
clinical trial makes the results suspect. 46  In the interim, the .80 value is the acceptable cut off for 
measuring adherence in patients with IBD using administrative data.  
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As an independent predictor, medication adherence emerged in our study as having a 
strong association with both ER visits and inpatient admissions, suggesting that patients more 
adherent to their medications were less likely to engage these services. Our findings were 
consistent with a recent study (n=1,693) that also used the MPR to measure adherence and 
controlled for comorbidity using the Deyo adaptation method, which demonstrated 34% fewer 
ER visits (p=.0016) and 31% fewer hospitalizations (p=.0025) in adherent IBD patients.8 Our 
findings also corroborate previous work that demonstrated 45% lower ER (p<.001) and 62% 
lower inpatient (p<.001) resource utilization in adherent IBD patients. 7  
The percentages of patients who utilized the ER (16.9%) and had an inpatient admission 
(6%) in our cohort were small. One explanation for these healthcare utilization figures may be 
the limited one year observation period used in this study because many researchers have 
investigated utilization in the IBD population over multiple years. 7,8,51-57,,58 However, healthcare 
utilization data in this study was part of an exploratory analysis as the influences on healthcare 
utilization in veterans with IBD has not been  researched. 8,59 Therefore, further inquiry into the 
healthcare utilization patterns of veterans with IBD is warranted.  
Care was coordinated in 41% of the sample. Our data demonstrated that the CCM 
element of care coordination was found to have several statistically significant bivariate 
associations between study variables. Patients with care coordinated between primary care and 
GI specialty care were less healthy than patients who were not, as represented by the statistically 
significant bivariate characteristics found among patients with care coordination that included: 
younger age; more likely to have CD compared to UC; had been prescribed a 5-ASA + 
immunomodulating medication; had comorbidities; and had an increased propensity for both ER 
and inpatient utilization. One explanation for the characteristics of patients cared for in the GI 
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specialty setting may be that primary care providers do not feel comfortable providing care for 
patients with IBD more affected by their illness which prompts consultation to the specialist. 62 
While it is accepted that a majority of patients with IBD are followed on a long-term basis in an 
outpatient GI specialty clinic,63 58.8% of patients  in our study were never seen in the GI clinic 
which may be due to a more quiescent course of illness in patients with IBD seen in primary 
care. This corroborates the comorbid characteristics of our patients with coordinated care 
suggesting PCP willingness to treat less complicated patients with IBD by referring them to the 
GI specialist as necessary.  An alternative explanation for the increased propensity of patients 
with care coordination to consume ER and inpatient services could be that these services were 
accessed for patient comorbid conditions. However, without specific ICD-9 codes for each type 
of healthcare utilization, this is unfeasible to discern.  
Limitations 
A main study limitation is the definition of care coordination. No consensus in the 
literature exists regarding how best to define and measure this variable. Often, research reports 
do not include information regarding the definition of this variable.61 Therefore, to contribute to 
science in a meaningful way, the definition of care coordination in our study was derived from 
the CCM which adopted the definition from the Agency for Healthcare Research and Quality 
(AHRQ) Technical Review and was as follows:  “the deliberate organization of patient care 
activities between two or more participants (including the patient) involved in a patient’s care to 
facilitate the appropriate delivery of healthcare services. Organizing care involves the marshaling 
of personnel and other resources needed to carry out all required patient care activities, and is 
often managed by the exchange of information among patients responsible different aspects of 
care” (p.41). 61  Care coordination in our study was assumed when the patient had clinic stop 
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codes for both primary and specialty care. Further exploration of the influences of care 
coordination on medication adherence and healthcare utilization in veterans with IBD is 
warranted.   
An additional limitation of our study is lack of consideration of veteran access to 
healthcare outside the VA system. An assumption of our study was that veterans did not access 
health services outside the VA for IBD chronic illness care. However, a survey of veterans 
conducted during the observation for this study, FY 2011, reported that 45% of enrollees have 
access to prescription drug coverage outside the VA, the details of which were unavailable for 
this study, and may influence many key study variables. 65  More than 65% of our study sample 
was age 65 and over qualifying them for Medicare. The use of Medicare services in veterans was 
the focus of a 2012 study conducted by Trivedi that reviewed over 1 million records and 
confirmed that 50% of veterans used both Medicare and VA for a variety of healthcare services. 
All of this said, access to healthcare outside the VA represents a serious confounder that will 
need to be addressed in future veteran research.  
Finally, there are several study limitations precluding generalizability of study findings. 
Our cohort consisted of White males over the age of 65. However, a recent national survey of  
veterans suggested these characteristics are representative of the veteran population.65 Our study 
relied on administrative data that were not verified by comparison with health records due to 
resource constraints.  Furthermore, these data may reflect the specific practice patterns of the 
local VA facility and may not be representative of IBD care delivery across VA.  Data used in 
this study were not originally generated for research purposes and are subject to coding errors 
both during data entry phase by hospital staff and during the data extraction process. We created 
a coding index containing detailed definitions of each study variable that was used to retrieve 
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data elements to ensure accuracy of data capture.  Another study limitation is the fact that a 
medication refill does not equate with consumption of medication. A prescription may have been 
filled but the patient may not have ingested the medication.  
Conclusions 
The overall adherence rate in this study, which was consistent with the literature, 
demonstrates the need for interventions to improve medication use among patients with IBD. 
No predictors of medication adherence emerged, yet medication adherence was an independent 
predictor of both ER and inpatient utilization which indicated that adherent patients were less 
likely to access these services. The CCM element of care coordinated care was significantly 
associated with all healthcare utilization variables suggesting those with care coordinated 
between primary care and GI specialty care were overall more likely to access health services 
compared to patients cared for in primary care in isolation. The solution to non-adherence and 
consumption of healthcare resources in patients with IBD will likely be as complex and 
individualized as the treatments they receive. To advance knowledge in this area, this study 
suggests that Wagner’s Chronic Care Model can provide a solid foundation for further inquiry.  
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Table 1 
Translation of Charlson Comorbidity Index (CCI) elements into ICD-9 codes 
 
Diagnostic Category 
 
ICD-9 
Codes 
Assigned 
weights for 
diseases 
Condition Description 
Myocardial infarction 410-410.9 
412 
1 
 
Acute myocardial infarction 
Old myocardial infarction 
Congestive heart failure 
 
428-428.9 1 Heart failure 
Peripheral vascular disease 
 
443.9 
441.441.9 
785.4 
V43.4 
procedure 
38.48 
 
1 Peripheral vascular disease, includes intermittent claudication 
Aortic aneurysm 
Gangrene 
Blood vessel replaced by prosthesis 
Resection and replacement of lower limb arteries 
Cerebrovascular disease 430-438 1 Cerebrovascular disease 
Dementia 
 
290-290.9 1 Senile and presenile dementia 
Chronic pulmonary disease 
 
490-496 
500-505 
506.4 
 
1 Chronic obstructive pulmonary disease 
Pneumoconioses 
Chronic respiratory conditions due to fumes and vapors 
Rheumatolgic disease 710.0 
710.1 
710.4 
714.0-714.2 
714.81 
725 
1 Systemic lupus erythematosus 
Systemic sclerosis 
Polymyositis 
adult rheumatoid arthritis 
Rheumatoid lung 
Polymyalgia rheumatic 
 
Peptic ulcer disease 
 
 
 
 
531-534.9 
531.4-531.7 
532.4-532.7 
533.4-533.7 
534.4-534.7 
1 Gastric, duodenal and gastrojejunal ulcers 
Chronic forms of peptic ulcer disease 
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Table 1 (continued) 
Diagnostic Category ICD-9 
Codes 
Assigned 
weights for 
diseases 
Condition Description 
Mild liver disease 571.2 
571.5 
571.6 
571.4-
571.49 
 
1 Alcoholic cirrhosis 
Cirrhosis without mention of alcohol 
Biliary cirrhosis 
Chronic hepatitis 
Diabetes 250-250.3 
250.7 
 
1 Diabetes with or without acute metabolic disturbances 
Diabetes with peripheral circulatory disorders 
Diabetes with 
chronic 
complications 
 
250.4-
250.6 
1 Diabetes with renal, ophthalmic, or neurological manifestations 
Hemiplegia or 
paraplegia 
344.1 
342-342.9 
 
2 Paraplegia 
Hemiplegia 
Renal disease 582-582.9 
582-583.7 
585 
586 
588-588.9 
2 Chronic glomerulonephritis 
Nephritis and nephropathy 
Chronic renal failure 
Renal failure, unspecified 
Disorders resulting from impaired renal function 
 
Any malignancy, 
including leukemia 
and lymphoma 
140-172.9 
174-195.8 
200-208.9 
 
2 Malignant neoplasms 
Malignant neoplasms 
Leukemia and lymphoma 
Moderate or severe 
liver disease 
572.2-
572.8 
3 Hepatic coma, portal hypertension, other sequelae of chronic liver disease 
 
Metastatic solid 
tumor 
196-199.1 6 secondary malignant neoplasm of lymph nodes and other organs 
 
AIDS 042-044.9 6 HIV infection with related specific conditions 
“Reprinted from Journal of Clinical Epidemiology, 45(6), Deyo, R. A., Cherkin, D. C., Ciol, M. A., Adapting a clinical comorbidity 
index for use with ICD-9-CM administrative databases, 613-619, 1992, with permission from Elsevier”
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Table 2 
 
Inclusion Criteria 
At least one outpatient ICD-9 code  
 
CD (555.x) 
UC (556.x) 
 
At least two refills of any oral IBD medication 
 
Mesalamine 250mg 
Mesalamine 375mg 
Mesalamine 400mg 
Mesalamine 1,200mg 
Olsalazine 
Balsalazide 
Sulfasalazine 
Azathioprine 
Mercaptopurine 
Exclusion Criteria 
 Oral steroids, biologic medications, rectal preparations, injectable 
methotrexate 
 Inpatient IBD medications 
 Patients treated in GI specialty care in isolation with no follow up to primary 
care 
 Patients with only one refill of outpatient IBD medication(s) 
CD=Crohn’s disease; UC=ulcerative colitis; IBD: inflammatory bowel disease; GI=gastrointestinal;  
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       Figure 1        Cohort Generation 
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                   Table 3.  Mean MPR by drug 
 
Drug Class: 5-ASA 
Drug Class: 5-ASA Frequency 
(n=165) 
Mean MPR 
Balsalazide 2(1.2) .74 
Olsalazine 1(.6) .99 
Mesalamine 250mg 11(6.7) .71 
Mesalamine 375mg 74(44.8) .78 
Mesalamine 400mg 48(29.1) .73 
Mesalamine 1,200mg 7(4.2) .66 
Sulfasalazine 
 
24(14.5) .74 
Drug Class: Immunomodulator 
 
  
Azathioprine 21(12.7) .65 
Mercaptopurine 18(10.9) .77 
Aza + 5-ASA 16(9.7) .60 
Mercaptopurine + 5-ASA 16(9.7) .83 
                         MPR=medication possession ratio;5-ASA=5-aminosalicylate; Aza=azathioprine 
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Table 4. Bivariate analysis of study variables in adherent and non-adherent patients (n=165) 
 
Variable 
 
Adherent 
>.80 
 
Non-
Adherent<.80 
 
P 
         
        Odds Ratio 
                                             n     %      n     %      OR          95%CI 
Coordination of Care          30     18 38     23               .144           .629       .337-1.17 
IBD Diagnosis 
CD                                      38     23     38    23                .829          .935  .507-1.725 
UC                                      46     28     43    26                .829          .935  .507-1.725 
IBD Medication 
5-ASA                                 65     39     61    37                .739            ----     ----- 
Immunomodulator                   3       2       5      3                .739            ----     ----- 
Both                                     16     10     15      9                .739            ----     ----- 
Comorbidity                        44     27     47    28                .466            .796    .430-1.472 
Age                                      84     51     81    49                .158            ----    -.164-.077 
CD=Crohn’s disease; UC=ulcerative colitis: 5-ASA=5-aminosalicylate; IBD=inflammatory bowel disease 
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Table 5.  Logistic Regression Summary  
 
  
Adherence 
 
 
ER Visits 
 
Inpatient Admit 
Variable  OR P 95%CI OR P 95%CI OR P 95%CI 
 
Age 
 
 
1.014 
 
.322 
 
.986-1.042 
 
1.009 
 
.641 
 
 
.971-1.049 
 
 
.108 
 
 
.012* 
 
 
.971-1.004 
 
MPR >.80 
 
----- ----- ----- .314 .029* .111-.886 .113 .044* .014-.939 
IBDDx 
 
.837 1.070 .564-2.029 .478 .166 .168-1.360 .117 .027* .017-.784 
IBDMed 
 
.666 1.202 .520-2.778 .537 .305 .164-1.762 1.111 .907 .190-6.490 
Comorbid 
 
.343 .727 .377-1.404 1.494 .457 519-4.298 3.222 .166 .616-16.839 
CareCoor 
 
.372 .713 .339-1.499 45.73 .001* 9.053-231.035 14.862 .022* 1.463-150.245 
*statistically significant .05 
ER=emergency room; MPR=medication possession ratio; IBD=inflammatory bowel disease; IBDMed=inflammatory bowel 
disease medication;  IBDDx=IBD diagnosis; Cormorbid=comorbidity; CareCoor=care coordinationOR=odds ratio; 95%CI=95% 
confidence interval 
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